Rank,Current/Most Recent Study,Status,Study Results,Interventions,Outcome Measures,Age,Phases,Enrollment,Study Type,Study Designs,Completion Date,Locations,URL,Other Locations,Latitude,Longitude,Hospital Name,Temp Locations 2,Principal Investigator,County,ICU Beds in the County,Composite Score,Total Successful Trials,State,ICU Beds true,Normalized Composite Scores
1,Retrospective Postoperative ARDS Study at Vanderbilt University,Completed,No Results Available,,ARDS,"11 Years and older   (Child, Adult, Older Adult)",,89,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,8-Aug,"Vanderbilt University Medical Center, Nashville, Tennessee, United States",https://ClinicalTrials.gov/show/NCT00656071,,36.14092375,-86.80163418,"Vanderbilt University Medical Center, Nashville",Vanderbilt University Medical Center,"Christopher G Hughes, M.D.",Davidson,614,0.384689218,2,Tennessee,614,69.00921291
2,The Relationship Between Positive End Expiratory Pressure and Cardiac Index in Patients With Acute Respiratory Distress Syndrome (ARDS) Managed on a Fluid Protocol,Completed,No Results Available,,Cardiac Index,"18 Years and older   (Adult, Older Adult)",,367,Observational,Time Perspective: Retrospective,12-Sep,"Yale University, School of Medicine, Department of Internal Medicine, Section of Pulmonary and Critical Care Medicine, New Haven, Connecticut, United States",https://ClinicalTrials.gov/show/NCT01714583,,41.25713055,-72.9896696,"Yale University, School of Medicine",Yale University,"Wassim H Fares, MD MSc",South Central Connecticut Planning Region,,,1,Connecticut,,
3,"Associations Between COVID-19 ARDS Treatment, Clinical Trajectories and Liberation From Mechanical Ventilator - an Analysis of the NorthCARDS Dataset",Completed,No Results Available,Other: ARDS and COVID19 treatments,Index Hospital Survival|Time to Mechanical Ventilator Liberation|Hospital Readmission,"Child, Adult, Older Adult",,1800,Observational,Observational Model: Cohort|Time Perspective: Other,19-Jan-21,"Feinstein Institutes for Medical Research, Manhasset, New York, United States",https://ClinicalTrials.gov/show/NCT04729075,,40.7756285,-73.7023206,"Feinstein Institutes for Medical Research, Manhasset",Feinstein Institutes for Medical Research,"Negin Hajizadeh, MD, MPH",Nassau,461,0.313666411,1,New York,461,47.05255711
4,Assessing the Role of Inclined Positioning in Acute Respiratory Distress Syndrome Patients Recovery,Completed,No Results Available,Procedure: upright bed,highest value per day of mechanical ventilation of total respiratory system compliance,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,5,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1-Jan-22,"University of Kentucky, Lexington, Kentucky, United States",https://ClinicalTrials.gov/show/NCT04612608,,38.027038,-84.50483742,"University of Kentucky, Lexington",University of Kentucky,,Fayette,3,0.479679108,2,Kentucky,260,98.37527725
5,Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2),Completed,Has Results,Drug: Dornase Alfa Inhalation Solution,Change in Arterial Blood Oxygen Content to Fraction of Inspired Oxygen Ratio (PaO2/FiO2)|Change in Static Lung Compliance|Duration of Mechanical Ventilation|Length of ICU Stay|Length of Hospitalization|Secondary Bacterial Infections|Mortality,"18 Years and older   (Adult, Older Adult)",Phase 3,30,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,31-Dec-20,"University of Missouri Hospital and Clinics, Columbia, Missouri, United States",https://ClinicalTrials.gov/show/NCT04402970,,38.9385546,-92.3274421,"University of Missouri Hospital and Clinics, Columbia",University of Missouri Hospital and Clinics,"Zachary M Holliday, MD",Boone,0,0.368950589,2,Missouri,110,64.14362573
6,A Prospective Clinical Study to Explore Response to Prone Positioning in ARDS Patients,Completed,No Results Available,Other: Lung Ultrasound (LUS),Oxygenation and Lung Ultrasound Score (LUS)|COVID-19 ARDS vs non-COVID-19 ARDS,"18 Years and older   (Adult, Older Adult)",,60,Observational,Observational Model: Cohort|Time Perspective: Prospective,31-Jan-22,"Rush University Medical Center, Chicago, Illinois, United States",https://ClinicalTrials.gov/show/NCT04692779,,41.87352605,-87.66910151,"Rush University Medical Center, Chicago",Rush University Medical Center,"Tyler Weiss, MS",Cook,0,0.319824519,3,Illinois,1606,48.9563323
7,Treprostinil Sodium Inhalation for Patients At High Risk for ARDS,Terminated,Has Results,Drug: Treprostinil Inhalation Solution|Drug: Placebo,Change in the Ratio of the Partial Pressure of Arterial Oxygen to the Fraction of Inspired Oxygen (PaO2/FiO2 Ratio)|Change in the Ratio of Peripheral Oxygen Saturation to Fraction of Inspired Oxygen (SaO2/FiO2)|Number of Days Not on a Ventilator|Number of Subjects Who Required Bi-level Positive Airway Pressure (BiPAP) or Continuous Positive Airway Pressure (CPAP) Via Face Mask|Acute Respiratory Distress Syndrome (ARDS) Associated Biomarkers|Change in the Central Venous Oxygen Saturation (SCVO2).|Change in Central Venous Pressure (CVP).|Change in Mean Arterial Pressure (MAP).|All-cause Mortality|Number of Subjects Requiring Intubation and Mechanical Ventilation|Number of Deaths During Hospitalization|Peak Plasma Concentration Determined 15 Min After Inhalation and Trough Determined 4 Hours Following the Drug/Placebo Administration|Number of Days From Study Enrollment Until Mechanical Ventilation is Required,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,14,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",7-Nov-17,"University of North Carolina Hospitals, Chapel Hill, North Carolina, United States",https://ClinicalTrials.gov/show/NCT02370095,,35.9049367,-79.0506255,"University of North Carolina Hospitals, Chapel Hill",University of North Carolina Hospitals,"Hubert J Ford, MD",Orange,0,0.178217076,0,North Carolina,13,5.178480972
8,Electrical Impedance Tomography (EIT) Monitoring in Adults With ALI or ARDS,Completed,Has Results,Device: Electrical Impedance Tomography monitoring,Feasibility of EIT Monitoring in This Population of ARDS/ALI Patients,"18 Years and older   (Adult, Older Adult)",Not Applicable,13,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,11-Mar,"Christiana Hospital, Newark, Delaware, United States",https://ClinicalTrials.gov/show/NCT01272882,,39.68753175,-75.67103927,"Christiana Hospital, Newark",Christiana Hospital,"John S Emberger, BS",New Castle,119,0.26237067,1,Delaware,119,31.19451126
9,Viral-Related Neutrophil Response and Condition Severity in People With ARDS,Completed,No Results Available,,Primary outcome measure of subject mortality.,"18 Years and older   (Adult, Older Adult)",,132,Observational,Observational Model: Cohort|Time Perspective: Prospective,12-Jul,"University of Colorado Health Sciences Center, Aurora, Colorado, United States",https://ClinicalTrials.gov/show/NCT00548795,,39.74519125,-104.8375871,"University of Colorado Health Sciences Center, Aurora",University of Colorado Health Sciences Center,"Jerry A. Nick, MD",Adams,0,0.223048163,2,Colorado,168,19.03798313
10,The Effect of Intravenous Lipids on Lung Function in Acute Respiratory Distress Syndrome (ARDS),Terminated,Has Results,Drug: ClinOleic 20%|Drug: Intralipid 20%,Bronchoalveolar Lavage Fluid Interleukin-8 Concentrations|Ventilator Days|PaO2:FiO2 Ratio|30 Day Mortality|New Infection|Organ Failures|Biomarkers (C-reactive Protein)|Hospital Length of Stay|Allergic Reactions|Hypertriglyceridemia,"18 Years to 90 Years   (Adult, Older Adult)",Phase 2,14,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",12-Nov,"Methodist Hospital, Indianapolis, Indiana, United States",https://ClinicalTrials.gov/show/NCT01096771,,39.79124045,-86.16317582,"Methodist Hospital, Indianapolis",Methodist Hospital,"Chris Naum, MD",Marion,14,0.370007758,0,Indiana,526,64.47044885
11,Stress Index to Individualize Mechanical Ventilation in ARDS,Terminated,No Results Available,Procedure: Recruitment Maneuver with PEEP and Tidal Volume Optimization,Comparison of ARDSnet-optimized and protocol-optimized tidal volume|Comparison of ARDSnet-optimized and protocol-optimized driving pressure|Comparison of ARDSnet-optimized and protocol-optimized PEEP|Comparison of ARDSnet-optimized and protocol-optimized elastance,"18 Years and older   (Adult, Older Adult)",Not Applicable,4,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,17-Dec,"Vanderbilt University Medical Center, Nashville, Tennessee, United States",https://ClinicalTrials.gov/show/NCT02871102,,36.14092375,-86.80163418,"Vanderbilt University Medical Center, Nashville",Vanderbilt University Medical Center,,Davidson,614,0.384689218,2,Tennessee,614,69.00921291
12,ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND),Recruiting,No Results Available,Device: ECMO support|Other: PROSpect protocolized therapies,Change in functional status|Change in health-related quality of life|The proportion of children with a new morbidity|All-cause mortality at hospital discharge or 90-days|Comparative change in one-year functional status|Comparative change in one-year health-related quality of life|Change in pediatric overall performance category|Change in pediatric cerebral performance category|Change in breathing support|Change in the psychosocial component of health-related quality of life|Change in the physical component of health-related quality of life|Change in child fatigue|Change in family impact of the child's health|Change in one-year functional status of children suffering a neurologic injury|Difference between groups in intracranial bleeding or ischemic stroke|Difference between groups in pneumothorax|Difference in the organ dysfunction score at 28 days|Comparative difference in the change in child fatigue|Comparative difference in the change in family impact of the child's health|Comparative difference in the change in the psychosocial component of health-related quality of life|Comparative difference in the in change in the physical component of health-related quality of life|Comparative change in respiratory support|Comparative difference in new morbidity,14 Days to 17 Years   (Child),,550,Observational,Observational Model: Cohort|Time Perspective: Prospective,26-Jun,"University of Michigan - Mott Children's Hospital, Ann Arbor, Michigan, United States",https://ClinicalTrials.gov/show/NCT05388708,,42.281891,-83.7271714,"University of Michigan - Mott Children's Hospital, Ann Arbor",University of Michigan - Mott Children's Hospital,"Ryan Barbaro, MD",Washtenaw,92,0.349973993,2,Michigan,92,58.27702309
13,Mild Hypothermia for COVID-19 ARDS,Withdrawn,No Results Available,Other: Hypothermia Via Cooling Machine- Arctic Sun 5000,Changes in metabolic requirement during and after hypothermia|Changes in oxygen requirements and levels during and after hypothermia|length of intubation|Changes in carbon dioxide levels during and after hypothermia|does application of hypothermia reduce pro inflammatory response,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,0,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,31-Dec-20,"North Shore University Hospital, Manhasset, New York, United States",https://ClinicalTrials.gov/show/NCT04570462,,40.7752137,-73.70102797,"North Shore University Hospital, Manhasset",North Shore University Hospital,,Nassau,461,0.313666411,0,New York,461,47.05255711
14,Trial of Steroids in Pediatric Acute Lung Injury/ARDS,Unknown status,No Results Available,Drug: methylprednisolone|Drug: Normal Saline (0.9%),Duration of mechanical ventilation|Improvement in oxygenation|Incidence of nosocomial infections|Incidence of hyperglycemia,"1 Month to 18 Years   (Child, Adult)",Phase 2,100,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",14-Dec,"Le Bonheur Children's Hospital, Memphis, Tennessee, United States",https://ClinicalTrials.gov/show/NCT01274260,,35.14437035,-90.0313146,"Le Bonheur Children's Hospital, Memphis",Le Bonheur Children's Hospital,,Shelby,0,0.391387252,0,Tennessee,277,71.07990588
15,Electrical Impedance Tomography for Optimization of Positive End-Expiratory Pressure: Acute Respiratory Distress Syndrome,Completed,No Results Available,Other: Usual care|Device: PEEP titration by EIT,Change in lung inflammation as measured by physiologic parameter: Mechanical Power|Change in lung inflammation as measured by physiologic parameter: Partial pressure of arterial oxygen (PaO2)|Change in lung inflammation as measured by physiologic parameter: Partial pressure of arterial oxygen/Fraction of Inspired Oxygen (P/F ratio)|Change in lung inflammation as measured by physiologic parameter: Plateau pressure|Lung inflammation as measured by physiologic parameter: Driving Pressure|Change in lung inflammation as measured by physiologic parameter: Static compliance,"18 Years and older   (Adult, Older Adult)",Not Applicable,16,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,24-Jun-22,"The University of Michigan, Ann Arbor, Michigan, United States",https://ClinicalTrials.gov/show/NCT03793842,,42.277145,-83.7382071,"The University of Michigan, Ann Arbor",The University of Michigan,"Robert Hyzy, MD",Washtenaw,92,0.349973993,3,Michigan,92,58.27702309
16,Pilot RCT of Therapeutic Hypothermia Plus Neuromuscular Blockade in COVID-19 Patients With ARDS,Withdrawn,No Results Available,Device: Hypothermia|Drug: Neuromuscular Blocking Agents|Device: Standard of Care,Targeted temperature compliance|Adverse event|28-day ICU-free days|Survival|non neurologic Sequential Organ Failure (SOFA) scores|Oxygen saturation (SpO2)|Plateau airway pressure|Mean airway pressure|Airway driving pressure|Oxygen saturation index|Core temperature|Urine output|comprehensive metabolic panel|Complete blood count with differential count and platelet count|Biomarkers|Serum electrolytes|Blood glucose|28-day ventilator-free days,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,0,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,27-Apr-21,"University of Maryland Medical Center, Baltimore, Maryland, United States",https://ClinicalTrials.gov/show/NCT03376854,,39.28827365,-76.62439437,"University of Maryland Medical Center, Baltimore",University of Maryland Medical Center,"Jeffrey D Hasday, MD",,,,2,Maryland,,
17,Prolonged Prone Positioning for COVID-19-induced Acute Respiratory Distress Syndrome (ARDS),Completed,Has Results,Other: Prolonged Proned Positioning|Other: Traditional Proning Arm,Duration in Prone Position|Change in P:F Ratio|Change in Drive Pressure|Unplanned Extubations|Pressure Ulcers|Line Displacement|Vent Free Days|Mortality|Rescue Interventions|Tracheostomy|ICU Free Days|S:F Ratio,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,52,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20-Mar-21,"University of Alabama at Birmingham, Birmingham, Alabama, United States",https://ClinicalTrials.gov/show/NCT04581811,,33.5016153,-86.80604756,"University of Alabama at Birmingham, Birmingham",University of Alabama at Birmingham,,Jefferson,471,0.48493457,6,Alabama,471,100
18,A Study of GEn-1124 in Subjects With Acute Respiratory Distress Syndrome (ARDS),Recruiting,No Results Available,Drug: GEn-1124|Drug: Placebo,To assess the safety and tolerability (SAEs and TEAEs) of GEn-1124,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,52,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",24-Jul,"Ocean Springs Hospital, Ocean Springs, Mississippi, United States",https://ClinicalTrials.gov/show/NCT05795465,,30.4138542,-88.78126903,"Ocean Springs Hospital, Ocean Springs",Ocean Springs Hospital,"Ritu Lal, PhD, MS",Jackson,0,0.368181424,0,Mississippi,48,63.90583885
19,Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19),Completed,No Results Available,Drug: vadadustat|Drug: placebo,"Number of participants who are classified 8 (dead), 7 (hospitalized, on invasive mechanical ventilation or ECMO), or 6 (hospitalized, on non-invasive ventilation or high flow oxygen devices) on the NIAID ordinal scale|Number of participants with a total score of 0 on the Modified Sequential Organ Failure Assessment (MSOFA) scale","18 Years and older   (Adult, Older Adult)",Phase 2,449,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",7-Mar-22,"The University of Texas Health Science Center at Houston, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04478071,,29.7029537,-95.4031995,"The University of Texas Health Science Center at Houston, Houston",The University of Texas Health Science Center at Houston,"Bentley J. Bobrow, MD",Harris,918,0.290090595,2,Texas,918,39.76410852
20,ARDSnet Protocol vs. Open Lung Approach in ARDS,Completed,No Results Available,Other: Different Mechanical Ventilation Protocols,60 day mortality|ICU mortality|Hospital mortality|28 day mortality|180 day mortality|365 day mortality|Ventilator free days|Length of ICU stay|Development of extra-pulmonary organ failures|Duration of hospitalization|Incidence of barotrauma|Systemic inflammatory mediator levels|Lung function 6 months after discharge|Lung function 12 months after discharge|Need for rescue therapy|Ventilation associated pneumonia rate,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,224,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,13-Mar,"Massachusetts General Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT00431158,,42.36286045,-71.06875297,"Massachusetts General Hospital, Boston",Massachusetts General Hospital,"Robert M Kacmarek, Ph.D., R.R.T",Suffolk,281,0.317766372,2,Massachusetts,447,48.32005745
21,Diaphragm Ultrasound Vs Transpulmonary Pressure To Set PEEP in ARDS,Completed,Has Results,Device: Ultrasound,Feasibility,"18 Years and older   (Adult, Older Adult)",Not Applicable,14,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,16-Jul,"Hennepin County Medical Center, Minneapolis, Minnesota, United States",https://ClinicalTrials.gov/show/NCT02463773,,44.97208635,-93.26218936,"Hennepin County Medical Center, Minneapolis",Hennepin County Medical Center,"Matthew Prekker, MD",Hennepin,311,0.214906439,2,Minnesota,311,16.52097431
22,Provider Perceptions of Neuromuscular Blockade in ARDS,Completed,No Results Available,Behavioral: Interview,Barriers to adoption of NMB|Contextual factors that influence the effectiveness of NMB,"18 Years and older   (Adult, Older Adult)",,35,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,18-Mar-18,"University of Pittburgh Medical Center, Pittsburgh, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT03179709,,40.4414655,-79.9948277,"University of Pittburgh Medical Center, Pittsburgh",University of Pittburgh Medical Center,"Jeremy M Kahn, MD, MS",Allegheny,580,0.350498218,1,Pennsylvania,580,58.43908692
23,Role of Vascular Endothelial Growth Factor (VEGF) in Acute Lung Injury/Adult Respiratory Distress Syndrome (ARDS),Withdrawn,No Results Available,,,"18 Years and older   (Adult, Older Adult)",,0,Observational,Observational Model: Case-Only|Time Perspective: Prospective,17-Jan,"Weill Medical College of Cornell University, New York City, New York, United States",https://ClinicalTrials.gov/show/NCT00319631,,40.76484285,-73.95476247,"Weill Medical College of Cornell University, New York City",Weill Medical College of Cornell University,"Robert J. Kaner, M.D.",New York,761,,0,New York,761,
24,Clinical Decision Support for Mechanical Ventilation of Patients With ARDS,Recruiting,No Results Available,Procedure: Implementation of Processes,LTVV Compliance|PEEP FI02 Compliance (continuous variable)|Utilization of Ventilation Protocol (continuous)|Utilization of Oxygenation Protocol (continuous)|LTVV Compliance >90% (binary)|PEEP FI02 Compliance >70% (binary)|Ventilator-Free Days (VFD) to Day 28|% of Patients who do not survive to day 28,"18 Years and older   (Adult, Older Adult)",Not Applicable,350,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,23-Dec-22,"Intermountain Medical Center, Murray, Utah, United States",https://ClinicalTrials.gov/show/NCT03984175,,40.65952605,-111.8911944,"Intermountain Medical Center, Murray",Intermountain Medical Center,,Salt Lake,282,0.192021026,0,Utah,282,9.445963373
25,Safety and Effectiveness of Placental Derived Exosomes and Umbilical Cord Mesenchymal Stem Cells in Moderate to Severe Acute Respiratory Distress Syndrome (ARDS) Associated With the Novel Corona Virus Infection (COVID-19),Recruiting,No Results Available,Drug: EV-Pure™ and WJ-Pure™|Drug: Placebo,"To Assess the safety of EV-Pure™ and WJ-Pure™ administration in patients exhibiting moderate to severe ARDS associated with COVID-19, compared to placebo.|To assess the efficacy of EV-Pure™ and WJ-Pure™ compared to placebo, in patients with moderate to severe ARDS assoociated with COVID-19|Time to clinical improvement|Overall Survival|COVID-19 polymerase chain reaction (PCR) test result as negative","18 Years to 75 Years   (Adult, Older Adult)",Phase 1,20,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",23-Dec,"Kit Bartalos, Liberty, Missouri, United States",https://ClinicalTrials.gov/show/NCT05387278,,38.9420831,-94.3812761,"Kit Bartalos, Liberty",Kit Bartalos,,Jackson,0,0.368181424,0,Missouri,274,63.90583885
26,Effect of Randomization to Neuromuscular Blockade on Physical Functional Impairment and Recovery in ARDS,Unknown status,No Results Available,,Neuromyopathy|Muscle Function and Strength|Physical Recovery and Healthcare Utilization,"18 Years and older   (Adult, Older Adult)",,290,Observational,Observational Model: Cohort|Time Perspective: Prospective,20-Sep,"University of Washington, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT03038906,,47.6543466,-122.3080606,"University of Washington, Seattle",University of Washington,"Catherine Hough, MD",King,450,0.211214428,2,Washington,450,15.37959145
29,Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS),Completed,No Results Available,Procedure: Stellate Ganglion Block,Adverse events related to SGB|All Adverse events|Death|Assessment of respiratory/ pulmonary function|Radiographic criteria|Cardiac function,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,5,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,31-Dec-20,"West Virginia University Rockefeller Neuroscience Institute, Morgantown, West Virginia, United States",https://ClinicalTrials.gov/show/NCT04402840,,39.6533542,-79.9600751,"West Virginia University Rockefeller Neuroscience Institute, Morgantown",West Virginia University Rockefeller Neuroscience Institute,"Ali R Rezai, MD",Monongalia,119,0.454995261,1,West Virginia,119,90.74428158
30,ARDS Esophageal Balloon Pressure Changes With Positioning Study,Terminated,No Results Available,Device: Esophageal balloon catheter,Change in Esophageal pressure measurements from upright to prone position|Change in Esophageal pressure measurements from upright to supine position|Change in Transmural pressure measurements from upright to prone position|Change in Transmural pressure measurements from upright to supine position|Change in Airway pressure measurements from upright to prone position|Change in Airway pressure measurements from upright to supine position,"18 Years and older   (Adult, Older Adult)",,2,Observational,Observational Model: Cohort|Time Perspective: Prospective,1-Mar-20,"University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, United States",https://ClinicalTrials.gov/show/NCT03120793,,35.90503535,-79.04775327,"University of North Carolina, Chapel Hill",University of North Carolina,"Thomas Bice, MD, MS",Orange,0,0.178217076,0,North Carolina,13,5.178480972
31,Alveolar Macrophage Programming Following Endotoxin Exposure,Recruiting,No Results Available,Other: bronchoscopy with intrabronchial administration of lipopolysaccharide,"Resident alveolar macrophages and recruited macrophages will be distinguished from one another using multi-parameter flow cytometry, and the relative proportions enumerated",18 Years to 50 Years   (Adult),Not Applicable,25,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,24-Mar,"National Jewish Health, Denver, Colorado, United States",https://ClinicalTrials.gov/show/NCT03859050,,39.7392061,-104.9423725,"National Jewish Health, Denver",National Jewish Health,,,,,0,Colorado,,
32,A Strategy to Improve Implementation of LTVV for Patients w/ ARDS,Withdrawn,No Results Available,Behavioral: Multi-component LTVV implementation strategy,"LTVV rate|Difference in proportions of patients receiving LTVV between intervention and usual care groups during pre-trial period|Difference in proportions of patients receiving LTVV between intervention and usual care groups during trial period|LTVV rate in individual ICUs|Difference in overall LTVV rate between pre-trial and trial periods|Percentage of time receiving LTVV|Time from ARDS onset to LTVV initiation|Percentage of ventilator settings adherent to LTVV|ARDS duration|Proportion of clinicians using LTVV|Plateau pressure|ICU and hospital length of stay|ICU, hospital, 30-, 60-, 90-, 180-day and one year mortality|Discharge status|Ventilator duration|Intervention delivered as intended|Subgroup analyses of primary and secondary endpoints based on ARDS severity|Subgroup analyses of primary and secondary endpoints based on FiO2|Subgroup analyses of primary and secondary endpoints based on plateau pressure","18 Years and older   (Adult, Older Adult)",Not Applicable,0,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,31-Aug-17,"Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States",https://ClinicalTrials.gov/show/NCT03051139,,41.89624,-87.6195677,"Northwestern University Feinberg School of Medicine, Chicago",Northwestern University Feinberg School of Medicine,"Curtis H Weiss, MD, MS",Cook,0,0.319824519,0,Illinois,1606,48.9563323
33,Efficacy of Bevacizumab in Preventing Acute Respiratory Distress Syndrome (ARDS),Withdrawn,No Results Available,Drug: Bevacizumab|Drug: Placebo,Proportion of individuals progressing to meet RDS criteria as defined by the American- European ARDS consensus conference and as used by ARDSnet.|Ventilator-free days to Day 28|28 day all-cause mortality|Proportion of subjects progressing to acute lung injury (who do not meet the definition at randomization)|Worst PaO2/FiO2 ratio recorded following enrollment|Change in PaO2/FiO2 ratio between Day 0 to Day 3|Change from baseline in number of non-lung organ failures using the Multi-Organ Dysfunction (MOD) score and Sepsis Organ Failure Assessment (SOFA) score|Proportion of subjects surviving to hospital discharge|Vasopressor-free days|Reversal of shock if present at randomization.,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,0,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",16-Feb,"Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York, United States",https://ClinicalTrials.gov/show/NCT01314066,,40.7664886,-73.9555127,"Weill Cornell Medical College-New York Presbyterian Hospital, New York",Weill Cornell Medical College-New York Presbyterian Hospital,"Robert Kaner, MD",New York,761,,0,New York,761,
34,Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 Acute Respiratory Distress Syndrome,"Active, not recruiting",No Results Available,Drug: Instilled T3|Other: Placebo Therapy,Change Extravascular Lung Water Index|Length of ICU Stay|Number of Ventilator-Free Days|30-day Survival|Creatinine Concentration|Glomerular Filtration Rate|New York Heart Association (NYHA) Functional Classification,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,250,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",24-Jul,"University of Minnesota, Minneapolis, Minnesota, United States",https://ClinicalTrials.gov/show/NCT04725110,,44.9863392,-93.1794558,"University of Minnesota, Minneapolis",University of Minnesota,"Timothy P Rich, MD",Hennepin,311,0.214906439,0,Minnesota,311,16.52097431
35,"Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection",No longer available,No Results Available,Drug: Remestemcel-L,,"18 Years and older   (Adult, Older Adult)",,,Expanded Access:Intermediate-size Population|Treatment IND/Protocol,,,"Mount Sinai Hospital, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04366830,,40.78996445,-73.95322824,"Mount Sinai Hospital, New York",Mount Sinai Hospital,"Elizabeth Burke, ANP-C",New York,761,,1,New York,761,
36,Nitric Oxide Administration for Acute Respiratory Distress Syndrome,Completed,Has Results,Drug: Nitric Oxide|Other: No Intervention,Mean PaO2/FiO2 Ratio,"1 Month to 18 Years   (Child, Adult)",Phase 3,52,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,8-Sep,"The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT00240487,,39.9487346,-75.193924,"The Children's Hospital of Philadelphia, Philadelphia",The Children's Hospital of Philadelphia,"Rodolfo I Godinez, MD, PhD",Philadelphia,528,0.359212402,2,Pennsylvania,528,61.13307138
37,Comparison of Curosurf and Infasurf in the Treatment of Preterm Infants With Respiratory Distress Syndrome,Completed,Has Results,Drug: Poractant alfa|Drug: calfactant,Change From Baseline in Blood C-reactive (CRP) Protein|Presence of Pulmonary Hemorrhage|Change in Number of Tracheal Macrophages,22 Weeks to 35 Weeks   (Child),Not Applicable,30,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",15-Jul,"University of Missouri, Women's and Children's Hospital, Columbia, Missouri, United States",https://ClinicalTrials.gov/show/NCT02834624,,38.93641465,-92.32970302,"University of Missouri, Women's and Children's Hospital",University of Missouri,"Naomi Lauriello, MD",Boone,0,0.368950589,1,Missouri,110,64.14362573
38,The ASTERS Study: Assessing the Role of Sphingolipids in AcuTE Respiratory Distress Syndrome (ARDS),Completed,No Results Available,,Ceramide levels in exhaled breath condensate,"18 Years and older   (Adult, Older Adult)",,8,Observational,Observational Model: Case-Control|Time Perspective: Prospective,12-Mar-21,"University of Kentucky Chandler Medical Center, Lexington, Kentucky, United States",https://ClinicalTrials.gov/show/NCT03654352,,38.031102,-84.5076352,"University of Kentucky Chandler Medical Center, Lexington",University of Kentucky Chandler Medical Center,,Fayette,3,0.479679108,3,Kentucky,260,98.37527725
39,Relationship of Pulmonary Contusion to Pulmonary Inflammation and Incidence of Acute Respiratory Distress Syndrome,Completed,No Results Available,,Volume of Pulmonary Contusion on CT scan|Volume of serum inflammatory mediator levels in BAL fluid|Presence of Tregs in BAL fluid|Presence of activated neutrophils in BAL fluid|Appearance of M2 macrophage phenotypes in BAL fluid,"16 Years and older   (Child, Adult, Older Adult)",,10,Observational,Observational Model: Case-Control|Time Perspective: Prospective,15-Mar,"Wake Forest Baptist Health, Winston-Salem, North Carolina, United States",https://ClinicalTrials.gov/show/NCT02265198,,36.0783207,-80.3336044,"Wake Forest Baptist Health, Winston-Salem",Wake Forest Baptist Health,"Jason Hoth, MD",Forsyth,259,0.361796043,2,North Carolina,259,61.93180236
40,Adaptive Support Ventilation in Acute Respiratory Distress Syndrome,Completed,No Results Available,Other: ASV|Other: Lung Protective Ventilation,Tidal Volume|Driving Pressure (cmH20)|Respiratory rate (BPM)|Oxygenation (SpO2%)|CO2 clearance|Blood Gas pH|Blood Gas Partial Pressure of Oxygen|Blood Gas Partial Pressure of Carbon Dioxide (PaCO2) (mm Hg)|Composite measure (lung protectiveness) - Asynchrony index|Composite measure (lung protectiveness) - Number of Adjustments|Composite measure (lung protectiveness) - Time with tidal volumes under 6cc/kg|Composite measure (lung protectiveness) - Driving pressures less than 15|Composite measure (lung protectiveness) - Plateau Pressure <30|Composite measure (lung protectiveness) - Oxygen saturation by pulse Oximetry (SpO2) >88%|Time to extubation|ICU length of stay,"18 Years and older   (Adult, Older Adult)",Not Applicable,20,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,31-Jan-21,"Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT03715751,,42.33837185,-71.10970568,"Beth Israel Deaconess Medical Center, Boston",Beth Israel Deaconess Medical Center,"Daniel Talmor, MD, MPH",Suffolk,281,0.317766372,4,Massachusetts,447,48.32005745
41,Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS,Completed,Has Results,Device: high flow nasal cannula (HFNC)|Procedure: Prone positioning (PP),Treatment Failure (Intubation or Death)|Number of Participants With Intubation|Mortality|Number of Participants With Adverse Events,"18 Years and older   (Adult, Older Adult)",Not Applicable,224,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,21-Feb-21,"Rush University Medical Center, Chicago, Illinois, United States",https://ClinicalTrials.gov/show/NCT04325906,,41.87352605,-87.66910151,"Rush University Medical Center, Chicago",Rush University Medical Center,"Jie Li, PhD",Cook,0,0.319824519,3,Illinois,1606,48.9563323
42,Tregs for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Associated With COVID-19 (regARDS),Terminated,No Results Available,Biological: Cryopreserved Ex Vivo Expanded Polyclonal CD4+CD127lo/-CD25+ T Regulatory Cells,Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs),"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,4,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2-Mar-22,"University of North Carolina, Chapel Hill, North Carolina, United States",https://ClinicalTrials.gov/show/NCT05027815,,35.90503535,-79.04775327,"University of North Carolina, Chapel Hill",University of North Carolina,"Maor Sauler, MD",Orange,0,0.178217076,0,North Carolina,13,5.178480972
43,"Open Lung Strategy, Gas Distribution and Right Heart Function in ARDS Patients",Recruiting,No Results Available,Procedure: PEEP ARDSnet|Procedure: PEEP LRM,Driving Pressure (cmH2O),"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,50,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,24-Aug,"Massachussets General Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT03202641,,42.3625677,-71.0687661,"Massachussets General Hospital, Boston",Massachussets General Hospital,"Robert Kacmarek, RRT, PhD",Suffolk,281,0.317766372,0,Massachusetts,447,48.32005745
44,Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS),Completed,Has Results,Drug: Defibrotide,Number of Major Hemorrhagic Complications Within 14 Days of Initiation of Treatment|Overall Survival|Ventilator-free Survival|Number of Ventilator Free Days Within 14 Days of Study Entry|The Time to Improvement in Oxygenation|Mean Change in the WHO COVID-19 Ordinal Scale During Therapy,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,13,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,9-Apr-21,"University of Michigan, Ann Arbor, Michigan, United States",https://ClinicalTrials.gov/show/NCT04530604,,42.2942142,-83.71003894,"University of Michigan, Ann Arbor",University of Michigan,"Gregory Yanik, MD",Washtenaw,92,0.349973993,2,Michigan,92,58.27702309
45,Inhaled Steroids for the Treatment of Early Pediatric Acute Respiratory Distress Syndrome,Terminated,Has Results,Drug: Budesonide|Drug: Placebo|Device: Nebulizer,Number of Ventilator-free Days (VFD)|Oxygenation Index (OI)|Oxygen Saturation Index (OSI)|Number of Days Participant Stayed in Pediatric Intensive Care Unit (PICU)|Number of Days Participant Stayed in Hospital|TNF Alpha Levels as Assessed by the Enzyme-linked Immunosorbent Assay (ELISA) Test|Interleukin (IL) -6 Levels as Assessed by the Enzyme-linked Immunosorbent Assay (ELISA) Test|IL-6 Levels as Assessed by the Enzyme-linked Immunosorbent Assay (ELISA) Test|IL-8 Levels as Assessed by the Enzyme-linked Immunosorbent Assay (ELISA) Test|MMP-8 Levels as Assessed by the Enzyme-linked Immunosorbent Assay (ELISA) Test|MMP-9 Levels as Assessed by the Enzyme-linked Immunosorbent Assay (ELISA) Test|Neutrophil Count|FEV1|Forced Expiratory Volume at One Second FEV1/FVC|Forced Vital Capacity (FVC)|Forced Expiratory Flow FEF 25-75%|Respiratory Resistance by Impulse Oscillometry (IOS)|Respiratory Impedance by Impulse Oscillometry (IOS)|Respiratory Reactance by Impulse Oscillometry (IOS),"30 Days to 18 Years   (Child, Adult)",Phase 2,2,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",30-Mar-20,"The University of Texas Health Science Center at Houston, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04064684,,29.7029537,-95.4031995,"The University of Texas Health Science Center at Houston, Houston",The University of Texas Health Science Center at Houston,"Alvaro J Coronado Munoz, MD",Harris,918,0.290090595,2,Texas,918,39.76410852
46,High Flow Nasal Cannula in Comparison With Nasal Continuous Positive Airway Pressure in the Management of Respiratory Distress Syndrome,Completed,No Results Available,Device: HHHFNC|Device: NCPAP,"the need for re-intubation|Duration of respiratory support using HHHFNC /NCPAP.|Incidence of nasal breakdown|sepsis|intraventricular hemorrhage (IVH),|retinopathy of prematurity (ROP)","Child, Adult, Older Adult",Not Applicable,60,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,12-Apr,"Akron Children's Hospital, Akron, Ohio, United States",https://ClinicalTrials.gov/show/NCT02587832,,41.0792309,-81.5257958,"Akron Children's Hospital, Akron",Akron Children's Hospital,"Mohammed Elkhwad, MD",Summit,4,0.376737295,1,Ohio,170,66.55088095
48,Early Insulin and Development of ARDS,Completed,Has Results,Drug: Insulin,"Plasma Levels of Free Fatty Acids, Tumor Necrosis Factor-α, Interleukin-6, and Von Willebrand Factor Antigen|Murray Lung Injury Score","18 Years and older   (Adult, Older Adult)",Phase 2,18,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,13-Sep,"Montefiore Medical Center, Bronx, New York, United States",https://ClinicalTrials.gov/show/NCT00605696,,40.8800853,-73.8798439,"Montefiore Medical Center, Bronx",Montefiore Medical Center,"Michelle Ng Gong, MD, MS",,,,1,New York,893,
49,Comparison in Pulmonary Compliance Between Curosurf and Survanta in Preterm Infants With Respiratory Distress Syndrome,Withdrawn,No Results Available,Drug: Curosurf®|Drug: Survanta®,Change in dynamic compliance,15 Minutes to 12 Hours   (Child),Not Applicable,0,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,"University of Michigan C & W Mott Children's Hospital, Ann Arbor, Michigan, United States",https://ClinicalTrials.gov/show/NCT01537354,,42.281891,-83.7271714,"University of Michigan C & W Mott Children's Hospital, Ann Arbor",University of Michigan C & W Mott Children's Hospital,"Steven Donn, M.D.",Washtenaw,92,0.349973993,2,Michigan,92,58.27702309
50,Molecular Epidemiology of ARDS,"Active, not recruiting",No Results Available,,Risk of ARDS|Mortality,"18 Years to 80 Years   (Adult, Older Adult)",,4000,Observational,Observational Model: Case-Control|Time Perspective: Prospective,23-Dec,"Massachusetts General Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT00006496,,42.36286045,-71.06875297,"Massachusetts General Hospital, Boston",Massachusetts General Hospital,"David Christiani, MD",Suffolk,281,0.317766372,2,Massachusetts,447,48.32005745
51,Safety of T Regulatory Cell Therapy in Subjects With COVID-19 Induced Acute Respiratory Distress Syndrome,Withdrawn,No Results Available,Biological: T regulatory cells,The number of participants that experience the occurrence of infusion associated adverse events (AEs)|The number of patients that experience treatment emergent AEs|The number of patients who receive the target dose for one or more intravenous infusions|The ratio of average daily partial pressure of oxygen (PaO2) to average fraction of inspired oxygen (FiO2) (PaO2:FiO2) over time|World Health Organization (WHO) COVID-19 ordinal scale score for clinical improvement|Change in Sequential Organ Failure Assessment (SOFA) Score over time|Mortality following initial infusion,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,0,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,22-Sep,"Stanford University, Stanford, California, United States",https://ClinicalTrials.gov/show/NCT04737161,,37.43131385,-122.1693654,"Stanford University, Stanford",Stanford University,"Joe L Hsu, MD",Santa Clara,313,0.173702036,3,California,313,3.782659215
52,Mesenchymal Stem Cells (MSCs) for Treatment of Acute Respiratory Distress Syndrome (ARD) in Patients With Malignancies,Completed,No Results Available,Biological: Mesenchymal Stem Cells (MSCs),Adverse Events of Participants Treated with Allogeneic Human Mesenchymal Stem Cells (hMSCs) With Acute Respiratory Distress Syndrome (ARD)|Clinical Improvement of Participants Treated with Allogeneic Human Mesenchymal Stem Cells (hMSCs) With Acute Respiratory Distress Syndrome (ARD)|Improvement in PF or S/F Ratio of Participants Treated with Allogeneic Human Mesenchymal Stem Cells (hMSCs) With Acute Respiratory Distress Syndrome (ARD),"18 Years and older   (Adult, Older Adult)",Phase 1,20,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,13-Jun-19,"University of Texas MD Anderson Cancer Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT02804945,,29.7076703,-95.39782994,"University of Texas MD Anderson Cancer Center, Houston",University of Texas MD Anderson Cancer Center,"Amanda L. Olson, MD",Harris,918,0.290090595,1,Texas,918,39.76410852
53,Titration of PEEP During Mechanical Ventilation in Patients With ARDS Using Electrical Impedance Tomography.,Withdrawn,No Results Available,Device: Electrical Impedance Tomography,Safety - measured by Barotrauma|Safety - measured by Gas Exchange,"2 Years to 35 Years   (Child, Adult)",Not Applicable,0,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1-Jul-20,"Boston Children's Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT02596178,,42.33716075,-71.10568624,"Boston Children's Hospital, Boston",Boston Children's Hospital,,Suffolk,281,0.317766372,3,Massachusetts,447,48.32005745
54,Surfactant Via Endotracheal Tube vs. Laryngeal Mask Airway (LMA) in Preterm Neonates With Respiratory Distress Syndrome,Unknown status,No Results Available,Device: Endotracheal intubation|Device: Laryngeal mask airway|Drug: remifentanil,Avoidance of invasive mechanical ventilation|Number of surfactant doses|Days on any respiratory support|Rate of Pneumothorax|Rate of bronchopulmonary dysplasia (O2 dependence at the later of 28 days of age or 36 weeks postmenstrual age)|Complications during insertion of LMA or endotracheal tube|Mortality rate,2 Hours to 48 Hours   (Child),Phase 4,130,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20-Mar,"Albany Medical Center, Albany, New York, United States",https://ClinicalTrials.gov/show/NCT02164734,,42.6538105,-73.77695852,"Albany Medical Center, Albany",Albany Medical Center,"Joaquim M Pinheiro, MD, MPH",Albany,4,0.319136206,1,New York,120,48.74354077
55,Feasibility Study of Aerosolized Surfaxin in the Prevention of Respiratory Distress Syndrome (RDS) in Premature Infants,Terminated,Has Results,Drug: Aerosolized lucinactant,Number of Participants With Respiratory Distress Syndrome|Area Under the Curve (AUC) for Fraction of Inspired Oxygen (FiO₂)|Arterial Alveolar (a/A) O₂Ratio|Time to Meet Failure Criteria|Number of Participants With Bronchopulmonary Dysplasia (BPD)|Number of Participants Alive and Without BPD|Number of Participants With Intraventricular Hemorrhage (IVH)/Periventricular Leukomalacia (PVL)|Number of Participants With Patent Ductus Arteriosus (PDA)|Number of Participants With Necrotizing Enterocolitis (NEC)|Number of Participants With Pulmonary Hemorrhage|Number of Participants With Acquired Sepsis|Incidence of Mortality|Number of Participants With Air Leak,15 Minutes to 30 Minutes   (Child),Phase 2,17,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,5-Sep,"University of California, San Diego Medical Center - Hillcrest, San Diego, California, United States",https://ClinicalTrials.gov/show/NCT00807235,,33.6431901,-117.8401649,"University of California, San Diego Medical Center - Hillcrest",University of California,"Neil Finer, MD",Orange,0,0.178217076,1,California,651,5.178480972
56,N-Acetyl-cysteine in Early Acute Respiratory Distress Syndrome,Withdrawn,No Results Available,Drug: N-acetyl cysteine,"Ventilator days|Mortality|ICU days|P/F ratio|Use of ""rescue"" maneuvers","18 Years and older   (Adult, Older Adult)",Early Phase 1,0,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30-Jan-21,"Palmetto Health Richland, Columbia, South Carolina, United States",https://ClinicalTrials.gov/show/NCT03346681,,34.027949,-81.03255659,"Palmetto Health Richland, Columbia",Palmetto Health Richland,"Judson Lewis, MD",Richland,4,0.349914803,0,South Carolina,211,58.25872454
57,Non-invasive Fluid Management,Unknown status,No Results Available,Other: NICOM-Guided Diuresis|Other: Standard of Care,"Composite incidence of new acute kidney injury (AKI), new hypotension (mean arterial blood pressure < 60 following diuresis), and new shock (SOFA (Sequential Organ Failure Assessment) score)|7-day cumulative fluid balance|Correlation of non-invasive NICOM derived cardiac parameters with incidence of new acute kidney injury (AKI), new hypotension, and new shock|Incidence of new kidney injury|Ventilator-free days to day 28 (days alive and free from mechanical ventilation)|ICU-free days to day 28 (days alive and out of the ICU)|60-day mortality|Incidence of new shock between the treatment arms (NICOM-guided diuresis, usual care)","18 Years and older   (Adult, Older Adult)",Not Applicable,100,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,20-Dec,"Intermountain Medical Center, Murray, Utah, United States",https://ClinicalTrials.gov/show/NCT02892799,,40.65952605,-111.8911944,"Intermountain Medical Center, Murray",Intermountain Medical Center,"Michael Lanspa, MD",Salt Lake,282,0.192021026,0,Utah,282,9.445963373
58,Treatment of Acute Respiratory Distress Syndrome With Tenecteplase: A Dose Escalation Pilot Study,Withdrawn,No Results Available,Drug: Tenecteplase,Survival to Discharge|Safety Analysis of Bleeding Complications|Improved Pa02/Fi02 ratio|Improved cardiac profile|Incidence of organ failure|Decreased ventilator days|Decreased ICU days,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,0,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,8-Dec,"Medical Center of Central GA, Macon, Georgia, United States",https://ClinicalTrials.gov/show/NCT00431379,,32.8338837,-83.63587671,"Medical Center of Central GA, Macon",Medical Center of Central GA,"Dennis W. Ashley, MD, FACS",Bibb,117,0.379557181,0,Georgia,117,67.42264693
59,Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER),"Active, not recruiting",No Results Available,Biological: Longeveron Mesenchymal Stem Cells (LMSCs)|Other: Placebo,Incidence of Treatment-Emergent Serious Adverse Events|Number of Participants with Abnormal Clinical Significant Laboratory Values in Hematology.|Number of Participants with Changes in Echocardiography Overall Assessment|Number of Participants with Changes to overall assessment of Electrocardiogram|Time to recovery of Sp02|Number of Participants with Abnormal Clinical Significant Lab Values in the Blood Chemistry testing.|Number of Participants with Abnormal Clinical Significant Lab Values in the Coagulation.|Number of Participants with Abnormal Clinical Significant Lab Values in the Urinalysis|Immunity|Change in Imaging via X-ray|Change in Imaging via Computerized Tomography,"18 Years and older   (Adult, Older Adult)",Phase 1,70,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",25-Jul,"Miami VA Healthcare System, Miami, Florida, United States",https://ClinicalTrials.gov/show/NCT04629105,,25.7914998,-80.2162924,"Miami VA Healthcare System, Miami",Miami VA Healthcare System,,Miami-Dade,593,0.221949927,0,Florida,593,18.69846416
60,Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells for COVID-19-Induced Acute Respiratory Distress,Withdrawn,No Results Available,Drug: COVI-MSC|Drug: Placebo,Mortality at Day 28|Mortality at Days 60 and 90|Number of ventilator-free days|Improvement in oxygenation|SOFA score at Day 28,"18 Years and older   (Adult, Older Adult)",Phase 2,0,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",21-Sep,"Fresno Community Hospital, Fresno, California, United States",https://ClinicalTrials.gov/show/NCT04728698,,36.7418363,-119.7837732,"Fresno Community Hospital, Fresno",Fresno Community Hospital,"Mike Royal, MD",Fresno,164,0.193083545,0,California,164,9.774440449
61,Critical Care Results of SARS-CoV-2 ARDS by Dapsone and Standard COVID-19 Treatment,Recruiting,No Results Available,Drug: Dapsone 100 MG,Critical Care Results of SARS-CoV-2 ARDS by Dapsone and Standard COVID-19 Treatment,"18 Years to 100 Years   (Adult, Older Adult)",Early Phase 1,100,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,31-Dec-21,"Hunt Regional Medical Center, Greenville, Texas, United States",https://ClinicalTrials.gov/show/NCT04918914,,33.12201305,-96.12438913,"Hunt Regional Medical Center, Greenville",Hunt Regional Medical Center,,Hunt,23,0.302913231,0,Texas,23,43.72821832
62,Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of ARDS,Withdrawn,No Results Available,Drug: Rapamycin|Drug: Placebo,Survival rate|Change in Clinical Status assessed by the World Health Organization (WHO) scale|Change in Clinical Status assessed by the National Institute of Allergy and Infectious Disease (NIAID) scale,"60 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,0,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",23-Jan,"University Hospital System, San Antonio, Texas, United States",https://ClinicalTrials.gov/show/NCT04482712,,35.3057976,-80.74737175,"University Hospital System, San Antonio",University Hospital System,"Dean L Kellogg, MD, PhD",Mecklenburg,10,0.352393294,0,North Carolina,173,59.02494846
63,Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS,"Active, not recruiting",No Results Available,Biological: Umbilical Cord Lining Stem Cells (ULSC)|Other: Placebo (carrier control),"Incidence of Dose Limiting Toxicity (DLT)|Incidence of Dose Limiting Toxicity (DLT), suspected adverse reaction (SAR), or serious adverse event (SAE)|Treatment-emergent adverse events (AE) and serious adverse events (SAE)|Levels of COVID-19 related ARDS as defined by the Berlin Definition of ARDS|Changes from baseline pulse oximetric saturation SpO2/FiO2 ratio or arterial oxygen pressure pAO2/FiO2 ratio|Number of ventilator-free days (VFD)|Changes in Complete Blood Count (CBC) with differential from baseline|Changes in levels of blood glucose (mg/dL) from baseline|Changes in levels of sodium (mEq/L) from baseline|Changes in levels of potassium (mEq/L) from baseline|Changes in levels of blood urea nitrogen (BUN; mg/dL) from baseline|Changes in levels of alanine transaminase (ALT; U/L) from baseline|Change in Urinalysis (UA) from baseline","18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,17,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",31-Jul-23,"Miami Baptist Hospital, Miami, Florida, United States",https://ClinicalTrials.gov/show/NCT04494386,,25.68511695,-80.33858858,"Miami Baptist Hospital, Miami",Miami Baptist Hospital,,Miami-Dade,593,0.221949927,0,Florida,593,18.69846416
64,Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19),"Active, not recruiting",No Results Available,Biological: Mesenchymal stromal cells|Other: Placebo,Incidence of grade 3-5 infusional toxicities and predefined hemodynamic or respiratory adverse events related to the infusion of MSC|Incidence of a reduction in one or more biomarkers of inflammation by day 7|Trend changes in PaO2:FiO2 ratio|Trend changes in Mean Airway Pressure|Trend changes in peak pressure|Trend changes in plateau pressure|Trend changes in Positive end-expiratory airway pressure (PEEP)|Incidence of mortality|Number of ICU-free days|Number of days alive and ventilator free composite score 3|Change in acute lung injury (ALI) score 2|Incidence of serious adverse events|Number of days alive off supplemental oxygen,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,9,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",23-Dec,"University of Minnesota, Minneapolis, Minnesota, United States",https://ClinicalTrials.gov/show/NCT04466098,,44.9863392,-93.1794558,"University of Minnesota, Minneapolis",University of Minnesota,"David Ingbar, MD",Hennepin,311,0.214906439,0,Minnesota,311,16.52097431
65,RAPA-501-Allo Therapy of COVID-19-ARDS,Terminated,No Results Available,Biological: RAPA-501-Allo off-the-shelf Therapy of COVID-19|Other: Placebo,Dose-Limiting Toxicity (DLT)|Mortality Rate|Ventilation Support|Days of Hospitalization|Number of Deaths|Incidence of Infection|GVHD Incidence,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,1,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",13-Sep-21,"Hackensack University Medical Center, Hackensack, New Jersey, United States",https://ClinicalTrials.gov/show/NCT04482699,,40.8837051,-74.05594088,"Hackensack University Medical Center, Hackensack",Hackensack University Medical Center,"Daniel Fowler, M.D.",Bergen,147,,0,New Jersey,147,
66,Simvastatin Effect on the Incidence of Acute Lung Injury/Adult Respiratory Distress Syndrome (ALI/ARDS),Withdrawn,No Results Available,Drug: Simvastatin|Drug: Placebo,Incidence of ARDS/ALI.,"18 Years and older   (Adult, Older Adult)",Not Applicable,0,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",11-Oct,"OU Medical Center, Oklahoma City, Oklahoma, United States",https://ClinicalTrials.gov/show/NCT01195428,,35.4812872,-97.5010817,"OU Medical Center, Oklahoma City",OU Medical Center,"Jean Keddissi, M.D.",Oklahoma,300,0.302954793,1,Oklahoma,300,43.74106719
67,Identifying PARDS Endotypes,Recruiting,No Results Available,Diagnostic Test: Respiratory epithelial cell brushing,Identification of PARDS Endotypes|Lung Recovery Gene Expression Profile|Correlation of Nasal and Bronchial Gene Expression|Correlation of Endotypes with Lung Cell-specific Biomarkers,"1 Month to 18 Years   (Child, Adult)",,60,Observational,Observational Model: Case-Control|Time Perspective: Prospective,31-Mar-25,"Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",https://ClinicalTrials.gov/show/NCT03539783,,39.14084475,-84.50228847,"Cincinnati Children's Hospital Medical Center, Cincinnati",Cincinnati Children's Hospital Medical Center,,Hamilton,0,0.374327698,0,Ohio,297,65.80595557
68,The Use of Maternal Serum Unconjugated Estriol for Monitoring the Prevention of Neonatal Respiratory Distress Syndrome,Completed,No Results Available,,Respiratory distress syndrome,"18 Years and older   (Adult, Older Adult)",,160,Observational,Observational Model: Case-Only|Time Perspective: Prospective,30-Jun-17,"Eskenazi Hospital, Indianapolis, Indiana, United States",https://ClinicalTrials.gov/show/NCT02112513,,39.77820945,-86.18436604,"Eskenazi Hospital, Indianapolis",Eskenazi Hospital,"David Haas, MD, MSc",Marion,14,0.370007758,2,Indiana,526,64.47044885
69,SP16 as a Therapeutic for COVID-19 Induced ARDS,Recruiting,No Results Available,Drug: SP16 (6mg)|Other: Placebo|Drug: SP16 (12 mg),Safety and tolerability of SP16 in subjects with pneumonia due to SARS-CoV-2|Change in inflammatory cytokines|Change in acute phase reactants|Proportion of subjects requiring ventilation|Improvement from baseline in SpO2|Cumulative days on ventilator|Duration of hospitalization|Time to clinical improvement|Proportion of subjects experiencing TTCI|Subjects time to death|Change from baseline in Horowitz index|Subject's cumulative days in ICU,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,20,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",24-Mar,"UVA Health Center, Charlottesville, Virginia, United States",https://ClinicalTrials.gov/show/NCT05135624,,38.8199578,-77.64132505,"UVA Health Center, Charlottesville",UVA Health Center,,Prince William,24,0.289664078,0,Virginia,24,39.63225106
70,Ketamine Infusion as Sedative Analgesic in Severe ARDS,Completed,No Results Available,,All-Cause mortality|Hospital length of stay|Duration of ventilator days|Infectious complications|Acute Kidney Injury|Hemodynamic instability|Delirium after extubation,"18 Years to 90 Years   (Adult, Older Adult)",,124,Observational,Observational Model: Cohort|Time Perspective: Retrospective,14-Feb-21,"Interfaith Medical Center, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04818827,,40.6785782,-73.93749934,"Interfaith Medical Center, New York",Interfaith Medical Center,"RAMAKANTH PATA, MD",,,,1,New York,893,
71,Randomized Controlled Trial of Surfactant Delivery Via Laryngeal Mask Airway (LMA) Versus Endotracheal Intubation,Completed,Has Results,Device: Endotracheal tube insertion|Device: Laryngeal mask airway insertion,"Rate of Failure of Surfactant Therapy, Either Early (Need for Mechanical Ventilation Within 1 Hour), or Late (FiO2 > 0.60 to Maintain Target SpO2, or Second Dose of Surfactant Within 8 Hours, or Needing More Than 2 Doses of Surfactant).|Number of Surfactant Doses|Days on Assisted Ventilation|Days on Supplemental Oxygen|Rate of Pneumothorax|Rate of BPD (O2 Dependence at the Later of 28 Days of Age or 36 Weeks Postmenstrual Age)|Complications During Insertion of LMA|Mortality Rate",4 Hours to 48 Hours   (Child),Phase 4,61,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12-Nov,"Albany Medical Center, Albany, New York, United States",https://ClinicalTrials.gov/show/NCT01042600,,42.6538105,-73.77695852,"Albany Medical Center, Albany",Albany Medical Center,"Joaquim M Pinheiro, MD, MPH",Albany,4,0.319136206,1,New York,120,48.74354077
72,Feasibility of Upright Bed Position in ARDS Patients,Completed,No Results Available,Other: Intervention Arm,Number of participants with change in hemodynamic stability from baseline when placed in upright position|Number of participants with change in Oxyhemoglobin Saturation from baseline when placed in upright position|Number of participants with Change in Tidal Volume from baseline when placed in upright position|Number of participants with change from baseline in Respiratory Rate when placed in upright position,"18 Years and older   (Adult, Older Adult)",Not Applicable,10,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,15-Jun,"Wake Forest Baptist Health, Medical Intensive Care Unit, Winston-Salem, North Carolina, United States",https://ClinicalTrials.gov/show/NCT02160561,,36.0783207,-80.3336044,"Wake Forest Baptist Health, Medical Intensive Care Unit",Wake Forest Baptist Health,"Peter E Morris, MD",Forsyth,259,0.361796043,2,North Carolina,259,61.93180236
73,Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial,"Active, not recruiting",No Results Available,Drug: Decitabine|Other: Placebo Saline,Proportion of patients who are alive and free of respiratory failure at day 28|Safety as assessed by adverse events|Change in oxygenation index|Change in fraction of inspired oxygen|Overall survival|Length of stay in hospital|Ventilator free days|Time to Polymerase chain reaction (PCR) negativity|Percentage of patients with National Early Warning Score 2 of 3 or more|All-cause mortality at 28 days since randomization|Percentage of change of clinical score based on World Health Organization 9-point scale at day 10 from randomization|Percentage of change of clinical score based on WHO 9-point scale,"18 Years and older   (Adult, Older Adult)",Phase 2,33,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",23-Sep,"Johns Hopkins University, Baltimore, Maryland, United States",https://ClinicalTrials.gov/show/NCT04482621,,39.33020225,-76.62185358,"Johns Hopkins University, Baltimore",Johns Hopkins University,"Franco D'Alessio, M.D",,,,1,Maryland,,
74,A Randomized Trial of GM-CSF in Patients With ALI/ARDS,Completed,Has Results,Drug: Placebo|Drug: GM-CSF,Ventilator-free Days During Days 1-28|Oxygenation Index Change at Day 15 From Day 1|Days Without Organ Failure,"18 Years to 90 Years   (Adult, Older Adult)",Phase 2,132,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",9-Jun,"University of Colorado Health Sciences Center, Denver, Colorado, United States",https://ClinicalTrials.gov/show/NCT00201409,,39.74519125,-104.8375871,"University of Colorado Health Sciences Center, Denver",University of Colorado Health Sciences Center,"Robert Paine, MD",Adams,0,0.223048163,2,Colorado,168,19.03798313
75,Feasibility of Mid-frequency Ventilation in Newborns With RDS: Randomized Crossover Pilot Trial,Completed,No Results Available,Procedure: Conventional Pressure Controlled SIMV|Other: Mid-frequency Ventilation,Average delta pressure|Average Mean Airway Pressure (MAP)|Mean arterial pressure,1 Hour to 7 Days   (Child),Phase 1|Phase 2,12,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,13-May,"University of Alabama at Birmingham, Birmingham, Alabama, United States",https://ClinicalTrials.gov/show/NCT01242462,,33.5016153,-86.80604756,"University of Alabama at Birmingham, Birmingham",University of Alabama at Birmingham,"Ramanchandra Bhat, MD",Jefferson,471,0.48493457,6,Alabama,471,100
76,Significance of Biological Markers in Patients With Acute Lung Injury/Acute Respiratory Disease,Completed,No Results Available,Procedure: Bronchoscopy,"PaO2/FiO2 ratios|Lung compliance|Plateau pressures|Calculation of the Murray Lung Injury Score (obtained at entry and Days 1, 2, 3, 5, 7,10, 14, and 21; analyzed at Year 4)|Development of organ failure|Time on ventilator|Ventilator-free days|ICU and hospital length of stay|Hospital mortality|Development of pneumonia|Development of lung fibrosis|Health-related and lung-specific quality of life","18 Years to 95 Years   (Adult, Older Adult)",Not Applicable,40,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,9-Jun,"Emory University, Atlanta, Georgia, United States",https://ClinicalTrials.gov/show/NCT00217880,,33.80045465,-84.3172378,"Emory University, Atlanta",Emory University,"Theodore J. Standiford, MD",DeKalb,4,0.359792718,1,Georgia,168,61.31247571
77,COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19,Terminated,Has Results,Drug: Colchicine|Drug: Usual Care,Percentage of Patients Requiring Supplemental Oxygen Beyond 8L Nasal Cannula|Percentage of Patients Who Will Require Mechanical Ventillation|Mortality,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2,21,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,31-Jul-20,"Maimonides Medical Center, Brooklyn, New York, United States",https://ClinicalTrials.gov/show/NCT04363437,,40.6395376,-73.998833,"Maimonides Medical Center, Brooklyn",Maimonides Medical Center,"Felix Yang, MD",,,,1,New York,893,
78,Intensive Nutrition in Acute Respiratory Distress Syndrome (ARDS): A Clinical Trial (INTACT),Terminated,Has Results,Behavioral: intensive medical nutrition|Other: control,Infection|Length of Hospital Stay|Days on Mechanical Ventilation|Death,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,78,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,13-Jun,"Rush University Medical Center, Chicago, Illinois, United States",https://ClinicalTrials.gov/show/NCT01921101,,41.87352605,-87.66910151,"Rush University Medical Center, Chicago",Rush University Medical Center,"carol l braunschweig, PhD",Cook,0,0.319824519,3,Illinois,1606,48.9563323
79,Aerosolized Surfactant in Neonatal RDS,Completed,Has Results,Drug: Surfactant,"Number of Participants With Adverse Events as a Measure of Safety and Feasibility|Patient Status as Evaluated by Dose Level|Short Term Efficacy as Assessed by Need for Intubation|Blood Gas Parameters - pH|Blood Gas Parameters - pCO2|Pulse Oximetry|Vital Signs - Heart Rate|Vital Signs - Respiratory Rate|Vital Signs - Systolic Blood Pressure|Number of Doses of Surfactant - Aerosolized & Intratracheal|Pneumothorax, Pneumomediastinum or Other Air Leak|Changes in Cerebral Oxygenation From Baseline as Evaluated at End of Study Intervention|Changes in Surfactant Activity in Gastric Aspirates|Cumulative Duration of Non-invasive and Invasive Ventilation|Duration of Supplemental Oxygen, Intensive Care, Hospital Stay|Age at Start of Feeds, Feeding Progression, Age at Full Enteral Feeds|Need for Blood Transfusions|Growth Parameters|Morbidities Associated With Prematurity|Survival to Hospital Discharge|Survival to Discharge Without Severe Morbidity",up to 24 Hours   (Child),Phase 1|Phase 2,159,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20-Jul,"Hutzel Women's Hospital, Detroit, Michigan, United States",https://ClinicalTrials.gov/show/NCT02294630,,42.35092325,-83.05645774,"Hutzel Women's Hospital, Detroit",Hutzel Women's Hospital,"Beena G. Sood, MD, MS",Wayne,0,0.372694747,1,Michigan,586,65.3011298
80,Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections,Completed,No Results Available,Device: SCD,Mortality at Day 60|Dialysis Dependency|Ventilation at Day 28|Mortality at Day 28|Urinary output change|P02/FiO2 change|Safety Assessments|SCD Integrity,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,22,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,21-Jul-21,"University of Kentucky, Lexington, Kentucky, United States",https://ClinicalTrials.gov/show/NCT04395911,,38.027038,-84.50483742,"University of Kentucky, Lexington",University of Kentucky,,Fayette,3,0.479679108,2,Kentucky,260,98.37527725
82,Study of Descartes-30 in Acute Respiratory Distress Syndrome,Recruiting,No Results Available,Biological: Descartes 30,To assess the safety of Descartes-30 in patients with moderate-to-severe ARDS.,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,30,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,24-May,"University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States",https://ClinicalTrials.gov/show/NCT04524962,,41.71854155,-91.60170736,"University of Iowa Hospitals and Clinics, Iowa City",University of Iowa Hospitals and Clinics,,Johnson,0,0.288428937,0,Iowa,95,39.250408
83,The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19,Not yet recruiting,No Results Available,Drug: MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8)|Drug: MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8)|Drug: MSC-exosomes delivered intravenously every other day (8:8:8),"Measure and report the number of participants with treatment-related-adverse events as assessed by CTCAE v4.0; for patients receiving ARDOXSO™, perinatal MSC-derived exosome therapy.|Tabulate and report the number of IMV days for patients receiving ARDOXSO™ perinatal MSC-derived exosome therapy.|Analyze and report organ failure, associated with ICU mortality in participants confirmed with SARS-CoV2 infection, receiving ARDOXSO™ as an interventional exosome therapy.|Record and analyze respiratory measures (Berlin Score/PEEP) following treatment regime.","18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,55,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",24-Dec,"Mission Community Hospital, Panorama City, California, United States",https://ClinicalTrials.gov/show/NCT04798716,,34.22036305,-118.456474,"Mission Community Hospital, Panorama City",Mission Community Hospital,,Los Angeles,2126,0.184174979,0,California,2126,7.020362911
84,Generating Evidence in ECMO Ventilation Strategies,Recruiting,No Results Available,Other: Standard-Lung Protective Ventilation|Other: Ultra-Lung Protective Ventilation,Protocol fidelity rate|Duration of ECMO|Duration of mechanical ventilation|Duration of ICU admission|Duration of Hospital admission|Survival to discharge|Time to meeting criteria for ECMO weaning|Time to first ECMO weaning trial,"18 Years and older   (Adult, Older Adult)",Not Applicable,20,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,1-Oct-23,"Duke University Medical Center, Durham, North Carolina, United States",https://ClinicalTrials.gov/show/NCT05708365,,36.0095073,-78.9367623,"Duke University Medical Center, Durham",Duke University Medical Center,"Christopher E. Cox, MD",Durham,148,0.353514251,0,North Carolina,148,59.37149161
85,Use of UC-MSCs for COVID-19 Patients,Completed,Has Results,Biological: Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.|Other: Vehicle + Heparin along with best supportive care,"Number of Participants With Pre-Specified Infusion Associated Adverse Events|Number of Subjects With Serious Adverse Events by 31 Days After First Infusion|Percentage of Participants Experiencing Serious Adverse Events (SAEs) Through Study Day 90|Number of Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Adverse Events (AEs) and Serious Adverse Events (SAEs) by Severity|Subjects With Adverse Events and Serious Adverse Events by Severity|Number of Adverse Events and Serious Adverse Events by Relatedness to Treatment|Subjects With Adverse Events by Relatedness to Treatment|Survival at 31 Days Post First Infusion|Survival at 60 Days Post First Infusion|Time to Recovery|Ventilator-Free Days Throughout 28 Days Post Second Infusion|Ventilator-Free Days Throughout 90 Days|Respiratory Rate and Oxygenation Index (ROX Index)|Oxygenation Index (OI)|Positive End-Expiratory Pressure (PEEP) and Plateau Pressure (Pplat)|Sequential Organ Failure Assessment (SOFA) Scores|Smell Identification Test (SIT) Scores|White Blood Cell Count (WBC)|Platelets Count|Hemogoblin|Hematocrit|Neutrophils|Lymphocytes|Glomerular Filtration Rate|Total Protein|Sodium|Potassium|Creatinine|Glucose|Albumin|Alkaline Phosphatase|Alanine Aminotransferase or Serum Glutamate-pyruvate Transaminase (ALT or SGPT)|Aspartate Aminotransferase or Serum Glutamic Oxaloacetic Transaminase (AST or SGOT)|Total Bilirubin|Blood Urea Nitrogen (BUN)|Calcium|Chloride|Carbon Dioxide (CO2)|C-Reactive Protein Levels|Arachidonic Acid/Eicosapentaenoic Acid (AA/EPA) Ratio|D-dimer Levels|25-Hydroxy Vitamin D Levels|Tumor Necrosis Factor-alpha (TNFα)|Tumor Necrosis Factor-beta (TNFβ)|Soluble Tumor Necrosis Factor Receptor 2 (sTNFR2)|Viral Load by SARS-CoV-2 RT-PCR|Number of Participants Reporting Panel Reactive Antibody (PRA) Positivity at Day 3 Post First Infusion|Number of Participants Reporting Panel Reactive Antibody (PRA) Positivity at Day 6 Post First Infusion|Number of Participants Reporting Panel Reactive Antibody (PRA) Positivity at Day 14 Post First Infusion|Number of Participants With Positive, Negative, or Borderline Serology Testing for SARS-CoV-2 IgM/IgG","18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,24,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",31-Oct-20,"Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, Florida, United States",https://ClinicalTrials.gov/show/NCT04355728,,25.78908785,-80.21148042,"Diabetes Research Institute, University of Miami Miller School of Medicine",Diabetes Research Institute,"Camillo Ricordi, MD",Miami-Dade,593,0.221949927,1,Florida,593,18.69846416
86,Short Term Outcomes of Children With Acute Respiratory Distress Syndrome,Completed,No Results Available,,,"0 Years to 18 Years   (Child, Adult)",,,Observational,Observational Model: Defined Population|Time Perspective: Retrospective,5-Aug,"Columbus Children's Hospital, Columbus, Ohio, United States",https://ClinicalTrials.gov/show/NCT00142376,,39.9520639,-82.97900743,"Columbus Children's Hospital, Columbus",Columbus Children's Hospital,"Onsy Ayad, MD",Franklin,0,0.372421808,1,Ohio,449,65.21675088
87,Stellate Ganglion Blockade in COVID-19 Positive Patients,Completed,No Results Available,Procedure: Stellate Ganglion Block,Evaluate the safety of a new modified stellate ganglia block (SGB) in ARDS|Evaluate the efficacy of a new modified stellate ganglia block (SGB) in ARDS,"19 Years to 85 Years   (Adult, Older Adult)",Not Applicable,1,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1-Nov-21,"University of Nebraska Medical Center, Omaha, Nebraska, United States",https://ClinicalTrials.gov/show/NCT04445337,,41.25489615,-95.97710254,"University of Nebraska Medical Center, Omaha",University of Nebraska Medical Center,,Douglas,0,0.258995743,1,Nebraska,187,30.15115472
88,Randomized Controlled Trial of Surfactant Administration by Laryngeal Mask Airway (LMA),Terminated,No Results Available,Device: Surfactant administered via Laryngeal Mask Airway (LMA)|Other: standard of care (nasal CPAP and supplemental oxygen),The primary outcome measure is reaching or not reaching failure criterion (FiO2= 65% while receiving nasal CPAP).|Duration of intubation|Nasal CPAP and requirement for supplemental oxygen|Time to reach full enteral feedings|Incidence of laryngeal edema|Duration of hospitalization,up to 72 Hours   (Child),Not Applicable,380,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,9-Dec,"University of Virginia, Charlottesville, Virginia, United States",https://ClinicalTrials.gov/show/NCT00599651,,38.0410576,-78.5054996,"University of Virginia, Charlottesville",University of Virginia,"John Kattwinkel, MD",Albemarle,12,0.290677473,0,Virginia,12,39.94554148
89,Effects of Volume Guarantee With Pressure Supported vs. Synchronized Intermittent Mandatory Ventilation in VLBW Infants,Suspended,No Results Available,Procedure: PSV+VG mode versus SIMV+VG mode,Respiratory rate|Ventilator variables|Vital signs,72 Hours to 120 Hours   (Child),,16,Observational,Observational Model: Case-Crossover|Time Perspective: Prospective,7-Sep,"Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, United States",https://ClinicalTrials.gov/show/NCT00295230,,46.729553,-94.6858998,"Children's Hospitals and Clinics of Minnesota, Minneapolis",Children's Hospitals and Clinics of Minnesota,"Mark Mammel, MD",Cass,0,0.329913391,1,Minnesota,0,52.07530069
90,Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease),Completed,No Results Available,Biological: Mesenchymal Stromal Cells|Other: Supportive Care,Treatment-related serious adverse events (tSAEs)|Change in clinical status at day 14,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,28,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,11-Jan-23,"Houston Methodist Hospital, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04345601,,29.7108167,-95.39926398,"Houston Methodist Hospital, Houston",Houston Methodist Hospital,"LaQuisa Hill, MD",Harris,918,0.290090595,1,Texas,918,39.76410852
91,Amphetamine Induced Adult Respiratory Distress Syndrome,Completed,No Results Available,Other: Difference in development of Acute Lung Injury in Amphetamine positive and negative patients,Inhalation Injury|Total Burn Surface Area|Length of hospital stay|Stroke Volume|Cardiac Output|Central Venous Pressure,"18 Years and older   (Adult, Older Adult)",,49,Observational,Observational Model: Cohort|Time Perspective: Retrospective,1-Jan-20,"Arrowhead Regional Medical Center, Colton, California, United States",https://ClinicalTrials.gov/show/NCT05611385,,34.0739333,-117.3506771,"Arrowhead Regional Medical Center, Colton",Arrowhead Regional Medical Center,"Aldin Malkoc, MD",San Bernardino,410,0.189699319,1,California,410,8.728209124
93,Prevention of COVID-19 Infection to Severe Pneumonia or ARDS,Unknown status,No Results Available,Drug: EC-18|Drug: Placebo,"Proportion of patients alive and free of respiratory failure through at Day 28|Probability of progression of mild pneumonia patients to severe pneumonia or ARDS within 28 days|Assessment of all-cause mortality|Respiratory failure defined based on resource utilization requiring at least 1 of the following:|Proportion of patients alive and free of invasive mechanical ventilation at a pre-specified timepoint|Proportion of patients alive and discharged from the hospital at a pre-specified timepoint|Lengths of ICU stay|Lengths of alive and respiratory failure-free days|Proportion of patients with objective measures of improvement (returning to room air) at time points (days 7, 14, and 28)|Confirmation of changes in subject's subjective clinical symptoms (e.g., patient questionnaire)","18 Years and older   (Adult, Older Adult)",Phase 2,60,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",21-Nov,"Lincoln Medical Center, Bronx, New York, United States",https://ClinicalTrials.gov/show/NCT04569227,,40.81664755,-73.92447027,"Lincoln Medical Center, Bronx",Lincoln Medical Center,,,,,0,New York,359,
94,Study of Energy Requirements in Critically Ill Newborns,Unknown status,No Results Available,,,24 Hours to 120 Hours   (Child),,60,Observational,Observational Model: Natural History,,"Indiana University, Indianapolis, Indiana, United States",https://ClinicalTrials.gov/show/NCT00006274,,39.77477735,-86.17696358,"Indiana University, Indianapolis",Indiana University,Catherine A. Leitch,Marion,14,0.370007758,0,Indiana,526,64.47044885
96,Iloprost Effects on Gas Exchange and Pulmonary Mechanics,Completed,No Results Available,Drug: Iloprost,Arterial oxygenation|Lung compliance,"18 Years and older   (Adult, Older Adult)",Phase 1,20,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12-Jul,"OU Medical Center, Oklahoma City, Oklahoma, United States",https://ClinicalTrials.gov/show/NCT01274481,,35.4812872,-97.5010817,"OU Medical Center, Oklahoma City",OU Medical Center,"Gary Kinasewitz, MD",Oklahoma,300,0.302954793,1,Oklahoma,300,43.74106719
98,"Efficacy, Safety, Tolerability, and Biomarkers of MN-166 (Ibudilast) in Patients Hospitalized With COVID-19 and at Risk for ARDS","Active, not recruiting",No Results Available,Drug: Ibudilast|Drug: Placebo,"Proportion of subjects free from respiratory failure at Day 7|Proportion of subjects with at least a 1-point improvement in clinical status using the National Institute on Allergy and Infectious Disease 8-point ordinal scale and discharge record at Day 7|Adverse event incidence and severity|Proportion of subjects free from respiratory failure as defined by the need for decreased oxygen requirement (invasive mechanical ventilation, non-invasive ventilation, high-flow oxygen, or ECMO, CPAP, BiPAP, nasal cannula) at Days 14, 28, and 60|Mean change from baseline in clinical status at Days 7, 14, 28, and 60|Incidence of mechanical ventilation or intubation at Day 7, 14, 28, and 60|Proportion of subjects with at least a 1-point improvement in clinical status at Days 14, 28, and 60|All-cause mortality at Days 7,14, 28, and 60|Proportion of subjects discharged from hospital at Days 7,14, 28, and 60","18 Years to 80 Years   (Adult, Older Adult)",Phase 2,40,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",1-Dec-23,"Denver Health and Hospital Authority, Denver, Colorado, United States",https://ClinicalTrials.gov/show/NCT04429555,,39.7279895,-104.9913193,"Denver Health and Hospital Authority, Denver",Denver Health and Hospital Authority,"Kazuko Matsuda, MD PhD MPH",,,,0,Colorado,,
99,Comparative Effectiveness Study of Bubble CPAP Devices in the NICU,Completed,Has Results,"Device: Bubble CPAP- BabiPlus, Respiralogics|Device: Bubble CPAP- B&B Bubbler, B&B Medical devices",Number of Participants With Extubation Failure|Oxygenation - Oxygen Saturation Via Pulse Oximetry Recorded Hourly,1 Day to 100 Days   (Child),Not Applicable,43,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16-Aug,"Cardinal Glennon Children's Hospital, Saint Louis, Missouri, United States",https://ClinicalTrials.gov/show/NCT02392806,,38.6214405,-90.2392793,"Cardinal Glennon Children's Hospital, Saint Louis",Cardinal Glennon Children's Hospital,"Noah H Hillman, M.D.",,,,1,Missouri,,
100,Electrical Activity of Diaphragm as a Means to Predict Extubation Success in Preterm Infants,Completed,No Results Available,,Edi_avg just prior to extubation in infants with extubation success and those with extubation failure|Study the trends of Edi_avg in preterm infants with respiratory distress syndrome requiring mechanical ventilation in first seven days of life.,1 Hour to 28 Days   (Child),,21,Observational,Observational Model: Cohort|Time Perspective: Prospective,15-Oct,"Dartmouth Hitchcock Medcial Center, Lebanon, New Hampshire, United States",https://ClinicalTrials.gov/show/NCT02144363,,43.6754932,-72.2729588,"Dartmouth Hitchcock Medcial Center, Lebanon",Dartmouth Hitchcock Medcial Center,"Neetu Singh, MD, MPH",Grafton,54,0.288225609,1,New Hampshire,54,39.18754928
101,Comparing Weaning of Nasal Continuous Positive Airway Pressure (CPAP) From Preterm Infants,Completed,No Results Available,Other: Gradual pressure wean,Success of weaning on first trial off NCPAP|Weight and corrected GA when come off oxygen|Weight and corrected gestational age (GA) when neonates could come off NCPAP,26 Weeks to 32 Weeks   (Child),Not Applicable,70,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,15-Dec,"Maimonides medcial center, Brooklyn, New York, United States",https://ClinicalTrials.gov/show/NCT02126501,,40.6395527,-73.9984009,"Maimonides medcial center, Brooklyn",Maimonides medcial center,"Shantanu Rastogi, MD",,,,1,New York,,
102,Comparing Bubble and Ventilator Nasal CPAP in Preterm Infants,Completed,No Results Available,,Physiologic parameters,2 Days to 3 Months   (Child),,18,Observational,Time Perspective: Prospective,14-Oct,"Maimonides Medical Center, Brooklyn, New York, United States",https://ClinicalTrials.gov/show/NCT02003846,,40.6395376,-73.998833,"Maimonides Medical Center, Brooklyn",Maimonides Medical Center,"Shantanu Rastogi, MD",,,,1,New York,,
103,Verification of Pulse Oximetry in Neonatal Population,Completed,No Results Available,,,1 Day to 30 Days   (Child),,25,Observational,Observational Model: Case-Control|Time Perspective: Prospective,9-Sep,"Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, United States",https://ClinicalTrials.gov/show/NCT00751439,,46.729553,-94.6858998,"Children's Hospitals and Clinics of Minnesota, Minneapolis",Children's Hospitals and Clinics of Minnesota,"Mark C Mammel, M.D.",Cass,0,0.329913391,1,Minnesota,0,52.07530069
104,Premedication for Less Invasive Surfactant Administration Study (PRELISA),Recruiting,No Results Available,Drug: IV Atropine and Fentanyl Premedication Arm|Drug: IV Normal Saline Placebo Arm,Number of bradycardia and hypoxemia events during LISA procedure|Percent of time spent with cerebral Near Infrared Spectroscopy (NIRS) values <55%|Procedure first attempt success rate|Intubation rate|Mean number of attempts required|Mean duration of bradycardia and hypoxemia events,0 Hours to 72 Hours   (Child),Phase 4,58,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",23-May,"Parkland Health and Hospital System, Dallas, Texas, United States",https://ClinicalTrials.gov/show/NCT05065424,,32.8107052,-96.8385386,"Parkland Health and Hospital System, Dallas",Parkland Health and Hospital System,"Sharmistha Saha, MD",Dallas,614,0.293183356,0,Texas,614,40.72023363
105,Comparison of Two Fetal Lung Maturity Tests,Withdrawn,No Results Available,,cost/time to run test,"Child, Adult, Older Adult",,0,Observational,Observational Model: Cohort|Time Perspective: Prospective,10-May,"Oklahoma State University Medical Center, Tulsa, Oklahoma, United States",https://ClinicalTrials.gov/show/NCT00613977,,36.14646185,-95.999582,"Oklahoma State University Medical Center, Tulsa",Oklahoma State University Medical Center,"Joseph R Johnson, D.O.",Tulsa,379,0.304087461,0,Oklahoma,379,44.09123078
106,Safety Study of Inhaled Carbon Monoxide to Treat Acute Respiratory Distress Syndrome (ARDS),Completed,No Results Available,Drug: Inhaled Carbon Monoxide at 100ppm (4 participants)|Drug: Placebo for Inhaled Carbon Monoxide at 100ppm (2 participants)|Drug: Inhaled Carbon Monoxide at 200ppm (4 participants)|Drug: Placebo for Inhaled Carbon Monoxide at 200ppm (2 participants),Number of administration associated adverse events.|Incidence of serious adverse events (SAEs).|Comparison between the calculated carboxyhemoglobin (COHb) level at 90 minutes using the Coburn-Forster-Kane (CFK) equation and measured COHb level at 90 minutes|Mean daily Sequential Organ Failure Assessment (SOFA) score|Partial pressure of arterial oxygen (PaO2)/FiO2 ratio|Oxygenation index (OI)|Lung injury score (LIS)|Vasopressor-free days|Ventilator-free days (VFDs)|ICU-free days|Hospital-free days,"18 Years and older   (Adult, Older Adult)",Phase 1,12,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",19-Aug,"Massachusetts General Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT02425579,,42.36286045,-71.06875297,"Massachusetts General Hospital, Boston",Massachusetts General Hospital,"Laura E Fredenburgh, MD",Suffolk,281,0.317766372,2,Massachusetts,447,48.32005745
107,Fluid Restriction in Respiratory Distress of the Newborn,Completed,No Results Available,Other: Fluid Management Intervention,Time from birth to first oral feeding|Duration of Respiratory Support|Total Duration of NICU stay,up to 12 Hours   (Child),Not Applicable,65,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,31-Mar-21,"Icahn School of Medicine at Mount Sinai, New York, New York, United States",https://ClinicalTrials.gov/show/NCT03120585,,40.789793,-73.95325356,"Icahn School of Medicine at Mount Sinai, New York",Icahn School of Medicine at Mount Sinai,"Abhishek Makkar, MD",New York,761,,2,New York,761,
108,Crossover Comparison of Tidal Volume Delivery During Nasal Intermittent Positive Pressure Ventilation in Preterm Infants: Infant Cannula vs. Nasal Continuous Positive Airway Pressure Prongs,Unknown status,No Results Available,Device: Nasal interface,"Relative tidal volume delivery, breath type I|Relative tidal volume delivery, breath type II|Relative tidal volume delivery, breath type III|Ventilator pressure delivery|Ventilator flow delivery|Heart rate|Oxygen saturation|Transcutaneous carbon dioxide tension|Transcutaneous oxygen tension",up to 28 Days   (Child),Not Applicable,20,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30-Jun-20,"Arkansas Children's Hospital, Little Rock, Arkansas, United States",https://ClinicalTrials.gov/show/NCT04326270,,34.74084135,-92.29159166,"Arkansas Children's Hospital, Little Rock",Arkansas Children's Hospital,,Pulaski,8,0.432534222,1,Arkansas,209,83.8004656
109,Physiological Changes With High-Flow Nasal Cannula,Completed,No Results Available,Procedure: High flow nasal cannula|Procedure: Nasal CPAP,% Unventilated Lung|Geometric Center of Ventilation (CoV)|End-expiratory lung volume,23 Weeks to 29 Weeks   (Child),Not Applicable,80,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,14-Feb-22,"Sharp Mary Birch Hospital for Women & Newborns, San Diego, California, United States",https://ClinicalTrials.gov/show/NCT03700606,,32.7982372,-117.1549791,"Sharp Mary Birch Hospital for Women & Newborns, San Diego",Sharp Mary Birch Hospital for Women & Newborns,"Anup Katheria, MD",San Diego,570,0.184924401,1,California,570,7.252046248
110,Pulmozyme to Improve COVID-19 ARDS Outcomes,Recruiting,No Results Available,Drug: Pulmozyme|Drug: Placebo,Ventilator-free days at 28 days|change in airway resistance|change in lung compliance|oxygenation (PaO2/FiO2 ratio)|length of stay (ICU and hospital)|rate of barotrauma|mortality.,"3 Years and older   (Child, Adult, Older Adult)",Phase 2,60,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",31-Dec-21,"Boston Children's Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04402944,,42.33716075,-71.10568624,"Boston Children's Hospital, Boston",Boston Children's Hospital,,Suffolk,281,0.317766372,3,Massachusetts,447,48.32005745
112,Genetic Regulation of Surfactant Deficiency,Completed,No Results Available,Drug: Nutrient,"Association of specific variants or interactions among variants in SFTPB, SFTPC, and ABCA3 with neonatal respiratory distress syndrome|Association of specific variants or interactions among variants in SFTPB, SFTPC, and ABCA3 with fractional synthetic rate and/or fractional catabolic rate of surfactant phospholipids, surfactant protein-B, and surfactant protein-C",1 Day to 6 Months   (Child),,525,Observational,Observational Model: Case-Control|Time Perspective: Prospective,13-Mar,"St. Louis Children's Hospital, Saint Louis, Missouri, United States",https://ClinicalTrials.gov/show/NCT00828243,,38.6378019,-90.26499538,"St. Louis Children's Hospital, Saint Louis",St. Louis Children's Hospital,"F. S. Cole, M.D.",,,,1,Missouri,,
113,The Use of Heliox Via Nasal CPAP to Prevent Early CPAP Failure in Premature Infants: A Feasibility Study,Completed,No Results Available,Other: Heliox gas,Nasal CPAP failure resulting in endotracheal intubation|Bronchopulmonary dysplasia|Hospital length of stay|Death|Pulmonary interstitial emphysema|Pneumothorax,1 Minute to 12 Hours   (Child),Not Applicable,13,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,11-Aug,"Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States",https://ClinicalTrials.gov/show/NCT00739115,,21.2998428,-157.8334591,"Kapiolani Medical Center for Women and Children, Honolulu",Kapiolani Medical Center for Women and Children,"Taylor Sawyer, DO",Honolulu,148,,1,Hawaii,148,
114,Antepartum Betamethasone Treatment for Prevention of Respiratory Distress in Infants Born by Elective Cesarean Section,Terminated,No Results Available,Drug: Betamethasone,The primary outcome to be studied is the need for NICU admission and/or oxygen therapy or PPV for >30 minutes.,"Child, Adult, Older Adult",Phase 2|Phase 3,67,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",7-Sep,"Emory University affiliated newborn intensive care units, Atlanta, Georgia, United States",https://ClinicalTrials.gov/show/NCT00139256,,33.7971368,-84.32224,"Emory University affiliated newborn intensive care units, Atlanta",Emory University affiliated newborn intensive care units,"Lucky Jain, M.D.",DeKalb,4,0.359792718,1,Georgia,168,61.31247571
115,Study to Evaluate ARD-101 in Adults With Obesity,Completed,No Results Available,Drug: ARD-101|Drug: Placebo,Relative Change in Body Weight (%)|Incidence of treatment-emergent adverse events (TEAE)|Change in Blood Lipid Concentrations|Change in Waist Circumference|Change in Hemoglobin A1c,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,20,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,9-Nov-22,"Altman Clinical and Translational Research Institute, University of California, San Diego, San Diego, California, United States",https://ClinicalTrials.gov/show/NCT05121441,,32.8791723,-117.2266377,"Altman Clinical and Translational Research Institute, University of California",Altman Clinical and Translational Research Institute,,San Diego,570,0.184924401,2,California,570,7.252046248
116,Study to Evaluate ARD-101 in Adults Receiving Bariatric Surgery,Completed,No Results Available,Drug: ARD-101,Relative Change in Body Weight (%)|Incidence of treatment-emergent adverse events (TEAE)|Change in Blood Lipid Concentrations|Change in Waist Circumference|Change in Hemoglobin A1c,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,12,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3-Feb-23,"Altman Clinical and Translational Research Institute, University of California, San Diego, San Diego, California, United States",https://ClinicalTrials.gov/show/NCT05215847,,32.8791723,-117.2266377,"Altman Clinical and Translational Research Institute, University of California",Altman Clinical and Translational Research Institute,,San Diego,570,0.184924401,2,California,570,7.252046248
117,Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury,Unknown status,No Results Available,Drug: Heparin|Drug: 0.9% Sodium-chloride,Mean daily PaO2 to FiO2 ratio|Duration of mechanical ventilation|ICU length of stay|Mortality Rate|Incidence of adverse drug events,"18 Years and older   (Adult, Older Adult)",Phase 4,50,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",31-Dec-21,"Frederick Health Hospital, Frederick, Maryland, United States",https://ClinicalTrials.gov/show/NCT04397510,,39.4229752,-77.4149544,"Frederick Health Hospital, Frederick",Frederick Health Hospital,,Frederick,0,0.346744248,0,Maryland,18,57.27854947
118,Assessment of Occult Lung Stress During Lung Protective Mechanical Ventilation,Not yet recruiting,No Results Available,Other: Esophageal Catheter,"Transpulmonary Driving Pressure|Driving Pressure|Work of Breathing (WOB)|Pressure-Time Product (PTP)|Lung Compliance (C, l)|Chest Wall Compliance (C, cw)|Respiratory System Compliance (C, rs)|Oxygen Saturation|PaO2/FiO2 (P/F) Ratio","18 Years and older   (Adult, Older Adult)",Not Applicable,60,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,1-Apr-24,"Tisch Hospital, New York, New York, United States",https://ClinicalTrials.gov/show/NCT05675696,,40.74207345,-73.97433663,"Tisch Hospital, New York",Tisch Hospital,"Beno Oppenheimer, MD",New York,761,0.330219043,0,New York,761,52.16979281
119,Noninvasive Estimation of Work of Breathing,Terminated,No Results Available,Other: changes in ventilator settings,Accuracy of lung mechanics measurements,"18 Years and older   (Adult, Older Adult)",Not Applicable,5,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,4-May-17,"Columbia University Medical Center, New York, New York, United States",https://ClinicalTrials.gov/show/NCT02867228,,40.8419836,-73.94368971,"Columbia University Medical Center, New York",Columbia University Medical Center,"David H Chong, MD",New York,761,0.330219043,0,New York,761,52.16979281
120,Cord Blood-Derived Mesenchymal Stem Cells for the Treatment of COVID-19 Related Acute Respiratory Distress Syndrome,Recruiting,No Results Available,Other: Best Practice|Biological: Mesenchymal Stem Cell,"Incidence of composite serious adverse events (Phase I)|Patients alive without grade 3, 4 infusional toxicity (Phase II)|Patients alive with grade 3 or 4 infusional toxicity (Phase II)|Patients not alive (Phase II)|Proportion of successfully extubated patients who present intubated on ventilator support (Phase I)|Rate of successful progression to intubation in patients who require supplemental oxygen but who are otherwise able to breathe without assistance (Phase I)|Overall survival rate (Phase I)|Survival rate in patients who present intubated on ventilator support (Phase I)|Survival rate in patients who require supplemental oxygen but who are otherwise able to breathe without assistance (Phase I)|Clinical parameters (Phase I)|Oxygenation parameters (Phase I)|Respiratory parameters (Phase I)|Laboratory markers (Phase I)|Hospitalization stay (Phase I)|Intensive care unit stay (Phase I)|Incidence of infusion-related adverse events (Phase I)","18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,70,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30-Apr-24,"M D Anderson Cancer Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04565665,,29.78672775,-95.63072032,"M D Anderson Cancer Center, Houston",M D Anderson Cancer Center,Amanda Olson,Harris,918,0.290090595,0,Texas,918,39.76410852
121,Mid and Standard Frequency Ventilation in Infants With Respiratory Distress Syndrome,"Active, not recruiting",No Results Available,Device: Mid frequency ventilation|Device: Standard frequency ventilation,Alive ventilator free days|Alive at day 28 after birth|Ventilator free|Bronchopulmonary dysplasia|Air leak syndrome|Pulmonary hemorrhage|Severe (grade 3-4) intracranial hemorrhage|Alive and continuous positive airway pressure/ventilator free|Alive and oxygen free|Postnatal steroids|Necrotizing enterocolitis|Neurodevelopmental impairment|Bronchopulmonary dysplasia or death|Neurodevelopmental impairment or death|Necrotizing enterocolitis or death|Death,1 Day to 3 Days   (Child),Phase 2|Phase 3,60,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,31-Oct-24,"University of Alabama at Birmingham, Birmingham, Alabama, United States",https://ClinicalTrials.gov/show/NCT03231735,,33.5016153,-86.80604756,"University of Alabama at Birmingham, Birmingham",University of Alabama at Birmingham,"Waldemar A Carlo, MD",Jefferson,471,0.48493457,6,Alabama,471,100
122,Tenecteplase in Patients With COVID-19,Completed,Has Results,Drug: Tenecteplase|Drug: Placebo,Number of Participants Free of Respiratory Failure|Number of Participants With Occurrences of Bleeding|Number of Participants With In-hospital Deaths at 14 Days|Number of Participants With Death at 28 Days|Number of Ventilator-free Days|Number of Respiratory Failure-free Days|Number of Vasopressor-free Days|Number of Vasopressor Doses at 24 Hours|P/F Ratio|Number of ICU-free Days|Hospital Length of Stay|Number of Participants With New-onset Renal Failure|Number of Participants With Need for Renal Replacement Therapy,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,13,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",10-Mar-22,"Mount Sinai Hospital, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04505592,,40.78996445,-73.95322824,"Mount Sinai Hospital, New York",Mount Sinai Hospital,"Hooman Poor, MD",New York,761,0.330219043,1,New York,761,52.16979281
123,Effect of Low Tidal Volume Ventilation in Improving Oxygenation and Thus Reducing Acute Lung Injury in the Cardiac Surgical Patient,Completed,No Results Available,Other: Ventilation strategy,"Time to extubation|Oxygenation at 4 hours, 8 hours, 12 hours and 24 hours post surgery.","18 Years and older   (Adult, Older Adult)",Not Applicable,150,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,11-Jan,"Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT00538161,,42.33837185,-71.10970568,"Beth Israel Deaconess Medical Center, Boston",Beth Israel Deaconess Medical Center,"Daniel Talmor, MD",Suffolk,281,0.317766372,4,Massachusetts,447,48.32005745
124,Observational Crossover Study Comparing Oxygenation and Ventilation Using SiPAP Versus CPAP in LBW Infants,Completed,No Results Available,Device: SiPAP,,"Child, Adult, Older Adult",,20,Observational,Observational Model: Case-Crossover|Time Perspective: Prospective,11-May,"Childrens Hospital and Clinics of MN - St. Paul, St. Paul, Minnesota, United States",https://ClinicalTrials.gov/show/NCT01053455,,44.9537029,-93.0899578,"Childrens Hospital and Clinics of MN - St. Paul, St. Paul",Childrens Hospital and Clinics of MN - St. Paul,"Andrea Lampland, MD",Ramsey,0,0.220875926,1,Minnesota,135,18.36643743
125,Post-Hospital Case Management to Improve Clinical Outcomes in Individuals Requiring Mechanical Ventilation,Completed,No Results Available,Behavioral: Targeted Case Management|Behavioral: Usual care,Scores for quality of life measures,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,600,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,9-Feb,"University of Washington, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT00149513,,47.6543466,-122.3080606,"University of Washington, Seattle",University of Washington,"Gordon Rubenfeld, MD",King,450,0.211214428,2,Washington,450,15.37959145
126,Carbon Monoxide to Prevent Lung Inflammation,Completed,No Results Available,Procedure: Bronchoscopy|Procedure: Bronchoalveolar lavage|Drug: Endotoxin|Drug: Carbon Monoxide,,18 Years to 40 Years   (Adult),Phase 1,35,Interventional,Allocation: Randomized|Primary Purpose: Treatment,11-Mar-10,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",https://ClinicalTrials.gov/show/NCT00094406,,39.0019296,-77.1044561,"National Institutes of Health Clinical Center, 9000 Rockville Pike",National Institutes of Health Clinical Center,"Anthony F Suffredini, M.D.",Montgomery,22,0.337506251,3,Maryland,150,54.42262855
127,Airway Pressure Release Ventilation (APRV) Versus AC/VC Conventional Ventilation,Unknown status,No Results Available,Device: Mechanical Ventilation,P/F Ratio on Day 3 of Mechanical Ventilation|Amount/Duration of Sedative & Vasoactive Medication|Evaluate Feasibility & Clinical Compliance with 2 APRV Paper Protocols.,"18 Years and older   (Adult, Older Adult)",Phase 2,246,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16-Jun,"Intermountain Medical Center, Murray, Utah, United States",https://ClinicalTrials.gov/show/NCT01339533,,40.65952605,-111.8911944,"Intermountain Medical Center, Murray",Intermountain Medical Center,"Eliotte Hirshberg, MD",Salt Lake,282,0.192021026,0,Utah,282,9.445963373
128,LISA in the Delivery Room for Extremely Preterm Infants,Recruiting,No Results Available,Procedure: LISA,Need for intubation and/any mechanical ventilation|Need for mechanical ventilation within 7 days of life|Mechanical Ventilation|High Frequency Ventilation|Mechanical ventilator days|Bronchopulmonary dysplasia|Severe intraventricular hemorrhage|Pneumothorax|Desaturation (SpO2 <80) and Bradycardia (HR <100) events|Proportion of infants requiring >1 LISA attempt,5 Minutes to 20 Minutes   (Child),Not Applicable,60,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,31-Dec-24,"Venkatakrishna Kakkilaya, Dallas, Texas, United States",https://ClinicalTrials.gov/show/NCT04715373,,32.8119829,-96.8392037,"Venkatakrishna Kakkilaya, Dallas",Venkatakrishna Kakkilaya,"Venkatakrishna Kakkilaya, MBBS",Dallas,614,0.293183356,0,Texas,614,40.72023363
129,ETCare: Safety and Preliminary Efficacy Trial,Completed,No Results Available,Other: #1 Respiratory Care Solution,The incidence of adverse events related to administration.|Feasibility and immediate intolerance,"Child, Adult, Older Adult",Early Phase 1,10,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,5-Sep,"McKay-Dee Hospital Center, Ogden, Utah, United States",https://ClinicalTrials.gov/show/NCT01688440,,41.1837644,-111.952635,"McKay-Dee Hospital Center, Ogden",McKay-Dee Hospital Center,"Robert D. Christensen, MD",Weber,64,0.194564555,1,Utah,64,10.23229375
130,Efficacy and Safety of a Lung Recruitment Protocol in Children With Acute Lung Injury,Completed,Has Results,Procedure: Recruitment maneuver,Oxygenation|Number of Participants With Ventilator Induced Lung Injury,"1 Month to 18 Years   (Child, Adult)",Not Applicable,12,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12-Dec,"Children's Hospital Boston, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT00830284,,42.33716075,-71.10568624,"Children's Hospital Boston, Boston",Children's Hospital Boston,,Suffolk,281,0.317766372,1,Massachusetts,447,48.32005745
131,Duration of Continuous Positive Airway Pressure and Pulmonary Function Testing in Preterm Infants,Completed,Has Results,Device: CPAP and room air,Changes in the Measurements of Functional Residual Capacity (FRC) in Randomized Premature Infants|Measurements of Passive Respiratory Compliance in Randomized Premature Infants|Passive Respiratory Resistance in Randomized Premature Infants|Measurements of Tidal Flow Volume Loops Will be Done in the Randomized Premature Infants.,up to 1 Year   (Child),Not Applicable,50,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,17-Sep,"Oregon Health & Science University, Portland, Oregon, United States",https://ClinicalTrials.gov/show/NCT02249143,,45.4981929,-122.6864957,"Oregon Health & Science University, Portland",Oregon Health & Science University,"Cindy T McEvoy, MD, MCR",Multnomah,165,0.16653337,2,Oregon,165,1.566470661
132,Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and Sepsis,Completed,No Results Available,Drug: vasoactive intestinal peptide,,"18 Years and older   (Adult, Older Adult)",Phase 1,18,Interventional,Primary Purpose: Treatment,,"Veterans Affairs Medical Center - Northport, Northport, New York, United States",https://ClinicalTrials.gov/show/NCT00004494,,40.89379105,-73.30875346,"Veterans Affairs Medical Center - Northport, Northport",Veterans Affairs Medical Center - Northport,Sami I. Said,Suffolk,281,0.317766372,1,New York,281,48.32005745
133,A Comparison of Methods of Discontinuing Nasal CPAP in Premature Infants <30 Weeks Gestation,Completed,Has Results,Device: Discontinue NCPAP after weaning pressures|Device: Discontinue NCPAP without weaning pressures,Number of Days on NCPAP or Mechanical Ventilation|Duration of Endotracheal Ventilation|Number of Participants Who Failed to Wean Off NCPAP|Number of Participants Who Developed Bronchopulmonary Dysplasia|Number of Participants Who Developed Necrotizing Enterocolitis|Number of Days of Life at Which Infant Starting Taking All Feeds by Mouth|Length of Hospital Stay|Number of Participants Who Developed Air Leak Disorders,"Child, Adult, Older Adult",Not Applicable,66,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,31-Mar-19,"The University of Texas Health Science Center at Houston, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT03292562,,29.7029537,-95.4031995,"The University of Texas Health Science Center at Houston, Houston",The University of Texas Health Science Center at Houston,"Brittany Duyka, MD",Harris,918,0.290090595,2,Texas,918,39.76410852
134,Efficacy of Recombinant Human Clara Cell 10 Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome,Completed,Has Results,Drug: Half normal saline|Drug: Low Dose rhCC10|Drug: High dose rhCC10,Survival Without Evidence of Chronic Pulmonary Insufficiency of Prematurity (CPIP) at 12 Months Corrected Gestational Age (CGA)|Long Term Efficacy - Survival Without Evidence of Chronic Pulmonary Insufficiency of Prematurity (CPIP) at 6 Months Corrected Gestational Age (CGA)|Safety and Efficacy - Number of Participants With Adverse Events|Short Term Efficacy - Number of Neonates With Oxygen Requirement at 36 Weeks Post Menstrual Age,24 Weeks to 29 Weeks   (Child),Phase 2,88,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",25-Aug-17,"Tufts Medical Center, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT01941745,,42.3494397,-71.06308468,"Tufts Medical Center, Boston",Tufts Medical Center,"Jonathan Davis, MD",Suffolk,281,0.317766372,3,Massachusetts,447,48.32005745
135,Comparison Study of High Frequency Percussive Ventilation With Conventional Ventilation,Withdrawn,No Results Available,Device: High Frequency Percussive Ventilation,Ventilator Associated Pneumonia|Cytokine profiles|Length of stay|Ventilator Days,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,0,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,31-Dec-09,"Parkland Health and Hospital System, Dallas, Texas, United States",https://ClinicalTrials.gov/show/NCT00308022,,32.8107052,-96.8385386,"Parkland Health and Hospital System, Dallas",Parkland Health and Hospital System,"Randall Friese, MD",Dallas,614,0.293183356,0,Texas,614,40.72023363
136,The Effects of Different Ventilator Strategies on Inflammation and Injury in Normal Lungs,Terminated,No Results Available,Other: Ventilator settings,"cytokine levels in serum and bronchial aspirate|arterial blood gases|subject post-operative outcome:mortality, pulmonary complications, major cardiac morbidity, LOS, readmission","18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,1,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,10-Mar,"UMDNJ/University Hospital, Newark, New Jersey, United States",https://ClinicalTrials.gov/show/NCT01003730,,40.73942,-74.1896076,"UMDNJ/University Hospital, Newark",UMDNJ/University Hospital,"Ellise Delphin, MD",Essex,7,0.336131483,0,New Jersey,267,53.99761989
137,A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome,Recruiting,No Results Available,Drug: ARD-101,Incidence of Treatment-Emergent Adverse Events (TEAE)|Efficacy Evaluation of Hyperphagia in Prader-Willi Syndrome|Relative Change in Body Weight (%),"17 Years to 65 Years   (Child, Adult, Older Adult)",Phase 2,12,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,31-May-23,"Stanford University, Palo Alto, California, United States",https://ClinicalTrials.gov/show/NCT05153434,,37.4387861,-122.1569334,"Stanford University, Palo Alto",Stanford University,,Santa Clara,313,0.173702036,3,California,313,3.782659215
138,Follow-up at School-age of Children Who Participated in the Efficacy Study of Nitric Oxide for Premature Infants,Completed,No Results Available,Drug: Inhaled nitric oxide|Drug: Placebo,Examine school-readiness at school-age in premature infants treated with iNO or placebo in the first week of life|Examine health status at early school-age,4 Years to 6 Years   (Child),Phase 3,160,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",6-Sep,"The University of Chicago, Comer Children's Hospital,, Chicago, Illinois, United States",https://ClinicalTrials.gov/show/NCT00152542,,41.79139685,-87.60084387,"The University of Chicago, Comer Children's Hospital",The University of Chicago,"Michael D Schreiber, M.D.",Cook,0,0.319824519,1,Illinois,1606,48.9563323
139,Extubation Readiness Study in Very Low Birthweight Infants,Terminated,No Results Available,Other: spontaneous breathing trial,time to successful extubation|bronchopulmonary dysplasia|extubation failure rate,48 Hours to 14 Weeks   (Child),Not Applicable,81,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,16-Apr,"The Hospital of the University of Pennsylvania, Phialdelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT01471431,,39.9501477,-75.1938829,"The Hospital of the University of Pennsylvania, Phialdelphia",The Hospital of the University of Pennsylvania,"Ann-Johanna Giaccone, MD",Philadelphia,528,0.359212402,1,Pennsylvania,528,61.13307138
140,Restore Resilience in Critically Ill Children,Completed,No Results Available,Other: R2 Bundle,Change in circadian activity ratio (CAR) - Acute Phase|Melatonin levels|Slow-wave EEG activity|Daily R2 bundle feasibility|Daily R2 bundle adherence|Daily R2 bundle system barriers|Pain free days|Agitation free days|Delirium free days|Iatrogenic withdrawal syndrome free days|Peak daily dose of all sedative agents|Cumulative dose of all sedative agents|Total PICU days of sedation|Time to physiological stability|Parent perception of being well-cared-for|Change in circadian activity ratio (CAR) - Recovery,6 Months to 17 Years   (Child),Not Applicable,56,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,31-Dec-21,"Johns Hopkins University - Charlotte Bloomberg Children's Center, Baltimore, Maryland, United States",https://ClinicalTrials.gov/show/NCT04695392,,39.2957979,-76.5910806,"Johns Hopkins University - Charlotte Bloomberg Children's Center, Baltimore",Johns Hopkins University - Charlotte Bloomberg Children's Center,"Martha AQ Curley, RN, PhD",,,,2,Maryland,,
141,Pulmonary Vascular Effects of Respiratory Rate & Carbon Dioxide,Withdrawn,No Results Available,Other: HLR|Other: EHR,mean pulmonary artery pressure (mPAP)|Right ventricular systolic function,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,0,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,14-Aug,"Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT01927237,,42.33837185,-71.10970568,"Beth Israel Deaconess Medical Center, Boston",Beth Israel Deaconess Medical Center,"Daniel Talmor, MD MPH",Suffolk,281,0.317766372,4,Massachusetts,447,48.32005745
142,T-Cell Mitochondrial Respiration Response to Ketone Monoester Supplement in Healthy Volunteers and COVID-19,Recruiting,No Results Available,Diagnostic Test: Agilent Seahorse XF Cell Mito Stress Test,Spare Respiratory Capacity (SRC)|Basal Respiration|ATP production-coupled Respiration|Maximal Respiration|Non-Mitochondrial Respiration|Oxygen Consumption Rate (OCR)|extracellular acidification rate (ECAR),"18 Years and older   (Adult, Older Adult)",,15,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,31-Jul-23,"Christina Barkauskas, Durham, North Carolina, United States",https://ClinicalTrials.gov/show/NCT05798260,,36.0043423,-78.9359336,"Christina Barkauskas, Durham",Christina Barkauskas,"Christina Barkauskas, MD",Durham,148,0.353514251,0,North Carolina,148,59.37149161
143,Long Term Follow up of Children Enrolled in the REDvent Study,Recruiting,No Results Available,Diagnostic Test: Ventilation Inhomogeneity|Diagnostic Test: Diaphragm Ultrasound|Diagnostic Test: Respiratory Inductance Plethysmography|Diagnostic Test: Spirometry|Diagnostic Test: Functional Residual Capacity|Diagnostic Test: MIP/MEP|Diagnostic Test: 6 minute walk test|Diagnostic Test: Neurocognitive Testing|Diagnostic Test: Emotional Health Assessment|Diagnostic Test: Health Related Quality of Life|Diagnostic Test: Functional Status|Diagnostic Test: Respiratory Status Questionnaire,Ventilation In-homogeneity using lung clearance index with nitrogen washout|Neurocognitive function using a standardized score derived from Batelle-2 or WISC-5 cognitive tests|Health Related Quality of Life as measured by PedsQL generic core scale|Functional Status as measured by the pediatric functional status scale|Functional Residual Capacity (Lung volume at end-expiration).|Phase Angle (a measure of thoraco-abdominal asynchrony and abnormal respiratory mechanics)|Diaphragm Thickness on exhalation|Diaphragm Thickness on inspiration|Diaphragm Thickening fraction (measure of contractile activity)|Forced Expiratory Volume in 1 second (FEV1)|Forced Vital Capacity (FVC)|Forced expiratory flow at 25-75% (FEF 25-75)|VT - tidal volume from spirometry during tidal breathing|Total Lung Capacity- TLC measured during spirometry|Forced vital capacity- measured during spirometry|Respiratory Muscle Strength Maximum inspiratory pressure (MIP)|Respiratory Muscle Strength Maximum expiratory pressure (MEP)|Respiratory Status - questionnaire detailing respiratory medications and therapies as well as healthcare utilization.|Emotional Health Outcomes using the (BASC-3) to assess emotional and behavioral abnormalities and UCLA Reaction Index to assess post traumatic stress,"1 Month to 18 Years   (Child, Adult)",,240,Observational,Observational Model: Cohort|Time Perspective: Prospective,1-Mar-24,"Children's Hospital Los Angeles, Los Angeles, California, United States",https://ClinicalTrials.gov/show/NCT03709199,,34.0976912,-118.2900801,"Children's Hospital Los Angeles, Los Angeles",Children's Hospital Los Angeles,,Los Angeles,2126,0.184174979,1,California,2126,7.020362911
144,Effect of Steroid Administration on Maternal Blood Levels of hLPCAT1 mRNA,Recruiting,No Results Available,Other: blood draw,Change in LPCAT1 mRNA levels in maternal plasma after antenatal steroid administration|Number of participants admitted to the NICU with high LPCAT1 mRNA levels|Correlate the LPCAT1 mRNA copy number to need for intubation in the nicu,18 Years to 40 Years   (Adult),,80,Observational,Observational Model: Case-Control|Time Perspective: Prospective,22-May,"Detroit Medical Ceter, Detroit, Michigan, United States",https://ClinicalTrials.gov/show/NCT03562182,,42.35554,-83.0544499,"Detroit Medical Ceter, Detroit",Detroit Medical Ceter,"Maurice Recanati, MD",Wayne,0,0.372694747,0,Michigan,586,65.3011298
145,Lung Ultrasound to Diagnose Transient Tachypnea of the Newborn (TTN) Versus Respiratory Distress Syndrome (RDS) in Neonates,Completed,No Results Available,Other: Respiratory Distress Group|Other: Control Group,lung ultrasound,"28 Weeks and older   (Child, Adult, Older Adult)",,36,Observational,Observational Model: Case-Control|Time Perspective: Prospective,13-Jun,"Icahn School of Medicine at Mount Sinai, New York, New York, United States",https://ClinicalTrials.gov/show/NCT01517958,,40.789793,-73.95325356,"Icahn School of Medicine at Mount Sinai, New York",Icahn School of Medicine at Mount Sinai,"Ian Holzman, MD",New York,761,0.330219043,2,New York,761,52.16979281
146,Curosurf and Survanta Treatment(CAST)of RDS in Very Premature Infants,Terminated,Has Results,Drug: Survanta (beractant)|Drug: Curosurf (poractant),Comparison Respiratory Support (Mean Airway Pressure) for Survanta (Beractant) and Curosurf (Poractant) at 48 Hours After Surfactant Administration.|Comparison of Respiratory Support (Mean Airway Pressure) for Curosurf (Poractant) and Survanta (Beractant) 72 Hours After Surfactant Administration|Comparison Respiratory Support (Mean Airway Pressure x Percent Fraction of Inspired Oxygen) for Survanta (Beractant) and Curosurf (Poractant) at 48 Hours After Surfactant Administration.|Comparison Respiratory Support (Mean Airway Pressure x Percent Fraction of Inspired Oxygen) for Survanta (Beractant) and Curosurf (Poractant) at 72 Hours After Surfactant Administration.|Comparison of Infants Successfully Extubated at 48 Hours for Curosurf (Poractant) and Survanta (Beractant) Groups|Comparison of Infants Successfully Extubated at 72 Hours for Curosurf (Poractant) and Survanta (Beractant) Groups|Comparison of Hemodynamically Significant Patent Ductus Arteriosus (PDA) in Patients Treated With Curosurf (Poractant) and Survanta (Beractant)|Changes in Blood Flow Through the Patent Ductus Arteriosus (PDA) Following Second Dose of Survanta (Beractant) and Poractant Alfa (Curosurf)|Change in Anterior Cerebral Artery Blood Flow Velocity Following Second Dose of Surfactant|Patients With Bronchopulmonary Dysplasia (Supplemental Oxygen at 36 Week Post Menstrual Age)|Bronchopulmonary Dysplasia (Supplemental Oxygen at 36 Week Post Menstrual Age) or Death Before Discharge From NICU.,up to 8 Hours   (Child),Phase 4,52,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,9-Jan,"Boston Medical Center, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT00767039,,42.33417195,-71.07464492,"Boston Medical Center, Boston",Boston Medical Center,"Alan M Fujii, MD",Suffolk,281,0.317766372,0,Massachusetts,447,48.32005745
147,Pragmatic Investigation of Volume Targeted Ventilation-1,"Active, not recruiting",No Results Available,Procedure: mode of mechanical ventilation,Percentage of patients receiving Assist Volume Control|assist volume control duration|Percentage of mode crossover|exhaled tidal volume|Number of ventilator free days|intensive care length of stay,"18 Years and older   (Adult, Older Adult)",Not Applicable,139,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,23-Dec,"Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States",https://ClinicalTrials.gov/show/NCT03909854,,36.08983775,-80.26771223,"Wake Forest Baptist Medical Center, Winston-Salem",Wake Forest Baptist Medical Center,"Kevin Gibbs, MD",Forsyth,259,0.361796043,0,North Carolina,259,61.93180236
148,Does a Rescue Course of Betamethasone in Pregnant Women With PPROM Decrease Neonatal Morbidity?,Recruiting,No Results Available,Drug: Betamethasone|Drug: Placebo,Length of stay in the neonatal intensive care unit (NICU)|Composite neonatal morbidity|Duration of oxygen and ventilatory support|Development of Respiratory Distress Syndrome (RDS)|Grade III or IV intraventricular hemorrhage (IVH)|Neonatal Sepsis|Necrotizing enterocolitis (NEC) stage 2 or 3|Perinatal death,18 Years to 50 Years   (Adult),Phase 2|Phase 3,98,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",30-Nov-23,"University of Texas Medical Branch in Galveston, Galveston, Texas, United States",https://ClinicalTrials.gov/show/NCT02939742,,29.3013479,-94.7976958,"University of Texas Medical Branch in Galveston, Galveston",University of Texas Medical Branch in Galveston,"Antonio Saad, MD",Galveston,26,0.294301711,0,Texas,26,41.06597237
149,Trans Thoracic Manipulation of Ventilation/Perfusion: the V/Q System,Enrolling by invitation,No Results Available,Device: V/Q System,Change in Arterial Oxygenation Levels,"18 Years and older   (Adult, Older Adult)",Not Applicable,36,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,24-May,"Emory University Hospital, Atlanta, Georgia, United States",https://ClinicalTrials.gov/show/NCT04369599,,33.792151,-84.32208293,"Emory University Hospital, Atlanta",Emory University Hospital,"Maxwell Weinmann, MD",DeKalb,4,0.359792718,1,Georgia,168,61.31247571
151,Humidified High Flow Nasal Cannula as Compared to Nasal Continuous Positive Airway Pressure,Completed,No Results Available,Device: High Flow Nasal Cannula,Mean esophageal pressure|Vital signs,"72 Hours and older   (Child, Adult, Older Adult)",Phase 3,16,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,7-Sep,"Children's Hospital and Clinics of Minnesota, Minneapolis, Minnesota, United States",https://ClinicalTrials.gov/show/NCT00356668,,46.729553,-94.6858998,"Children's Hospital and Clinics of Minnesota, Minneapolis",Children's Hospital and Clinics of Minnesota,"Mark C Mammel, MD",Cass,0,0.329913391,1,Minnesota,0,52.07530069
152,Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome,Completed,Has Results,Biological: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells,Incidence of Pre-specified Infusion Associated Adverse Events|Incidence of Severe Adverse Events (SAEs)|Ventilator Free Days at Study Day 28|Duration of Vasopressor Use (Days)|ICU Free Days to Day 28|Hospital Survival to Day 60|Mortality at Hospital Discharge,"18 Years and older   (Adult, Older Adult)",Phase 1,9,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,15-Feb,"University of California San Francisco Medical Center, San Francisco, California, United States",https://ClinicalTrials.gov/show/NCT01775774,,37.7627945,-122.4580139,"University of California San Francisco Medical Center, San Francisco",University of California San Francisco Medical Center,,,,,3,California,337,
153,Retrospective Review of Mechanically Ventilated Patients Using a Continuous Data Collection System.,Completed,Has Results,,Successful Extubation,"1 Day to 35 Years   (Child, Adult)",,278,Observational,Observational Model: Cohort|Time Perspective: Retrospective,9-Jan-17,"Boston Children's Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT02184208,,42.33716075,-71.10568624,"Boston Children's Hospital, Boston",Boston Children's Hospital,,Suffolk,281,0.317766372,3,Massachusetts,447,48.32005745
154,Study of the Pathobiology of Bronchopulmonary Dysplasia in Newborns,Completed,No Results Available,,,"0 Years and older   (Child, Adult, Older Adult)",,200,Observational,,,"Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT00006058,,39.94769755,-75.19498022,"Children's Hospital of Philadelphia, Philadelphia",Children's Hospital of Philadelphia,Roberta A. Ballard,Philadelphia,528,0.359212402,1,Pennsylvania,528,61.13307138
155,Clinical Trial of Nebulized Hypertonic Saline to Attenuate Post-Traumatic Acute Lung Injury,Terminated,No Results Available,Drug: Nebulized hypertonic saline,change in the respiratory parameters|death within 28 days|lung dysfunction scores|ventilator-free days (VFD)|MOF scores (Denver MOF score),"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,13,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,6-Nov-18,"Denver Health Medical Center, Denver, Colorado, United States",https://ClinicalTrials.gov/show/NCT01667666,,39.72731935,-104.9911984,"Denver Health Medical Center, Denver",Denver Health Medical Center,"Ernest E Moore, MD",,,,0,Colorado,,
156,ED Lung Protective Ventilation to Reduce Complications,Completed,Has Results,Procedure: lung protective ventilation,Number of Patients That Experience Pulmonary Complications After Admission From the Emergency Department|Number of Patients That Die During the Hospitalization,"18 Years and older   (Adult, Older Adult)",,1705,Observational,Observational Model: Other|Time Perspective: Other,16-Mar,"Washinton University School of Medicine in St. Louis, Saint Louis, Missouri, United States",https://ClinicalTrials.gov/show/NCT02543554,,38.6351441,-90.2629289,"Washinton University School of Medicine in St. Louis, Saint Louis",Washinton University School of Medicine in St. Louis,"Brian M Fuller, MD, MSCI",,,,1,Missouri,468,
157,MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients,Recruiting,No Results Available,Drug: MRG-001|Drug: Placebo,"Safety and Tolerability|Change in percentages from baseline in circulating white blood cell subpopulations|Change in Plerixafor concentration (ng/ml) from baseline in blood|Change in Tacrolimus concentration (ng/ml) from baseline in blood|Change from baseline in ALT, AST, INR, Albumin, Bilirubin, LDH, BUN, eGFR|Change in percentages from baseline in circulating stem cells and immune cells|All-cause mortality assessed at 14, 28 and 60 days following randomization.|Time to clinical improvement from randomization by at least 2 points on the 8-point ordinal scale of WHO clinical improvement scale assessed up to 14 and 60 days (1=Asymptomatic, no limitations of activities; 8=death).","18 Years and older   (Adult, Older Adult)",Phase 2,40,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",1-Jul-22,"Johns Hopkins Medicine, Baltimore, Maryland, United States",https://ClinicalTrials.gov/show/NCT04646603,,39.2992161,-76.5933799,"Johns Hopkins Medicine, Baltimore",Johns Hopkins Medicine,"Russell N Wesson, M.B.Ch.B",,,,0,Maryland,,
159,Biomarkers of Lung Injury With Low Tidal Volume Ventilation Compared With Airway Pressure Release Ventilation,Terminated,No Results Available,Other: low-tidal-volume ventilation|Other: APRV,The study will be powered to detect a decrease in plasma IL-6 levels (pg/ml) from ARDSNet to APRV|Changes in dose of sedation medications|Riker score|Lung mechanics|Oxygenation with APRV versus ARDSNet,"18 Years and older   (Adult, Older Adult)",Not Applicable,3,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16-Sep,"Boston Medical Center, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT01038531,,42.33417195,-71.07464492,"Boston Medical Center, Boston",Boston Medical Center,"George O'Connor, MD",Suffolk,281,0.317766372,0,Massachusetts,447,48.32005745
160,Acute Lung Injury Ventilator Evaluation (ALIVE),Terminated,No Results Available,Other: Low-tidal-volume ventilation|Other: Airway Pressure Release Ventilation (APRV),"Impact of APRV and ARDSNet ventilator modes upon plasma expression of Interleukin-6 (IL-6)|Impact of APRV and ARDSNet ventilator modes upon plasma expression of Soluble receptors of tumor necrosis factor alpha (sTNFa-R1)|Impact of APRV and ARDSNet ventilator modes upon static lung compliance (L/cmH2O).|Impact of APRV and ARDSNet ventilator modes upon plasma expression of Interleukin-8 (IL-8)|Impact of APRV and ARDSNet ventilator modes upon plasma expression of Interleukin-1 receptor antagonist (IL1-r-a)|Impact of APRV and ARDSNet ventilator modes upon plasma expression of Surfactant, pulmonary-associated protein D (SP-D)|Impact of APRV and ARDSNet ventilator modes upon Oxygenation (PaO2)|Impact of APRV and ARDSNet ventilator modes upon Ventilation (PaCO2)|Impact of APRV and ARDSNet ventilator modes upon Tissue metabolism (lactate)|Impact of APRV and ARDSNet ventilator modes upon Non-spontaneous tidal volumes|Impact of APRV and ARDSNet ventilator modes upon sedation utilized|Impact of APRV and ARDSNet ventilator modes upon Riker Sedation-Agitation Scale score|Impact of APRV and ARDSNet ventilator modes upon Cardiac output","18 Years and older   (Adult, Older Adult)",Not Applicable,4,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,14-Oct,"University of Wisconsin-Madison, Madison, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT01901354,,43.08027445,-89.43095872,"University of Wisconsin-Madison, Madison",University of Wisconsin-Madison,"Suresh Agarwal, MD",Dane,39,0.244724763,0,Wisconsin,39,25.73929029
161,Genetic Variability and Biomarkers in Children With Acute Lung Injury,Withdrawn,No Results Available,,Development of ALI or ARDS,"2 Weeks to 18 Years   (Child, Adult)",,0,Observational,Observational Model: Case-Control|Time Perspective: Prospective,13-Jun,"Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT01048996,,43.0515268,-87.9194418,"Children's Hospital of Wisconsin, Milwaukee",Children's Hospital of Wisconsin,"Michael Quasney, PhD, MD",Milwaukee,381,0.258229187,0,Wisconsin,381,29.91417442
163,Work of Breathing During Non-invasive Ventilation in Premature Neonates,Completed,No Results Available,Other: Noninvasive neurally adjusted ventilatory assist (NIV NAVA)|Other: Nasal intermittent positive pressure ventilation (NIPPV),"Phase angle (θ)|Tidal volume (arbitrary units, AU)|Minute ventilation (AU/min)|Respiratory rate (breaths/min)|Transcutaneous oxygen (mmHg)|Transcutaneous carbon dioxide (mmHg)|Oxygen saturation (%)|Peak inspiratory pressure (cmH2O)|Positive end expiratory pressure (cmH2O)|Trigger delay (ms)|Asynchrony index (%)",up to 12 Months   (Child),Not Applicable,15,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,18-Jun,"Arkansas Children's Hospital, Little Rock, Arkansas, United States",https://ClinicalTrials.gov/show/NCT02788110,,34.74084135,-92.29159166,"Arkansas Children's Hospital, Little Rock",Arkansas Children's Hospital,"David N Matlock, MD",Pulaski,8,0.432534222,1,Arkansas,209,83.8004656
164,"Mechanical Ventilation, Directed by Esophageal Pressure Measurements, in Patients With Acute Lung Injury",Completed,No Results Available,Procedure: Placement of an esophageal balloon measurements|Other: Low tidal volume ventilation|Other: Transpulmonary pressure-directed ventilation (EPVent),Oxygenation as measured by the PO2/FiO2 (P/F) ratio|Ventilator free days|Markers of inflammation|Mortality|Length of stay,"18 Years and older   (Adult, Older Adult)",Not Applicable,63,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,10-May,"Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT00127491,,42.33837185,-71.10970568,"Beth Israel Deaconess Medical Center, Boston",Beth Israel Deaconess Medical Center,"Daniel S Talmor, MD, MPH",Suffolk,281,0.317766372,4,Massachusetts,447,48.32005745
165,IRAK4 Inhibition in Treatment of COVID-19 With ARDS (I-RAMIC),Terminated,No Results Available,Drug: PF-06650833|Drug: Placebo,All-cause mortality at Day 29|Disease Severity (8 point scale)|Mortality|P/F ratio|Change of the SOFA score.|Duration (days) of mechanical ventilation|Ventilator free days.|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,7,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",6-Oct-21,"Yale New Haven Hospital, New Haven, Connecticut, United States",https://ClinicalTrials.gov/show/NCT04575610,,41.3046035,-72.9355941,"Yale New Haven Hospital, New Haven",Yale New Haven Hospital,"Hyung Chun, MD",South Central Connecticut Planning Region,,,0,Connecticut,,
166,Timing and Intensity of the Exposures and Attributable Burden of Acute Lung Injury,Completed,No Results Available,,Development of ALI|Quality adjusted survival,"18 Years and older   (Adult, Older Adult)",,6600,Observational,Observational Model: Cohort|Time Perspective: Prospective,20-Dec,"Mayo Clinic, Rochester, Minnesota, United States",https://ClinicalTrials.gov/show/NCT00980915,,44.0225389,-92.46660746,"Mayo Clinic, Rochester",Mayo Clinic,"Ognjen Gajic, M.D.",Olmsted,218,0.217462963,2,Minnesota,218,17.31132208
167,Weaning From Mechanical Ventilation Using Permissive Hypercarbia,Terminated,No Results Available,Procedure: Permissive hypercarbia,Time for weaning from positive pressure support mechanical ventilation|Percentage of subjects/group successfully weaned within seven days of trial participation,"18 Years and older   (Adult, Older Adult)",Not Applicable,3,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,14-Jun-07,"Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT00357929,,40.2653862,-76.67321279,"Penn State Milton S. Hershey Medical Center, Hershey",Penn State Milton S. Hershey Medical Center,"Kane M High, MD",Dauphin,142,0.354720751,0,Pennsylvania,142,59.74448032
168,PAL to Improve Oral Feeding for Infants With Chronic Lung Disease,Recruiting,No Results Available,Device: Pacifier Activated Lullaby ®,Oral Feeding|Length of Stay|Length of Respiratory Support,1 Day to 33 Weeks   (Child),Not Applicable,60,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",31-Dec-23,"University of Missouri Healthcare, Columbia, Missouri, United States",https://ClinicalTrials.gov/show/NCT05446389,,38.9403808,-92.3277375,"University of Missouri Healthcare, Columbia",University of Missouri Healthcare,,Boone,0,0.368950589,1,Missouri,110,64.14362573
169,Macrophage Programing in Acute Lung Injury: MiniBAL,Recruiting,No Results Available,Other: Non-Bronchoscopic Mini Bronchoalveolar Lavage,Evaluate host response to ARDS|Macrophage signaling|Resident alveolar Macrophages|Recruited versus resident macrophages|Ventilator associated pneumonia (VAP),"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,56,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,30-Dec-23,"Intermountain Health - St. Joseph's Hospital - National Jewish Health, Denver, Colorado, United States",https://ClinicalTrials.gov/show/NCT05767671,,39.7390914,-104.9421121,"Intermountain Health - St. Joseph's Hospital - National Jewish Health, Denver",Intermountain Health - St. Joseph's Hospital - National Jewish Health,,,,,0,Colorado,,
170,Inhaled Nitric Oxide (iNO) as an Adjunct to Neonatal Resuscitation,Completed,Has Results,Drug: iNO|Other: Nitrogen,"Maximum Factional Inspired Oxygen Percent (FiO2)|Rate of Hyperoxia|Pre and Postductal Saturation Levels|Heart Rate During Resuscitation|Need for Intubation|Intraventricular Hemorrhage > Grade 2|Infants With Patent Ductus Arteriosus (PDA) Requiring Treatment|Retinopathy of Prematurity (ROP)> Stage 2|Mechanical Ventilation, Non-invasive Ventilation (NIV), and Length of Stay in Days (LOS)|Bronchopulmonary Dysplasia|Late Onset Sepsis",1 Minute to 2 Minutes   (Child),Not Applicable,33,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",1-May-17,"University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States",https://ClinicalTrials.gov/show/NCT01220687,,35.48428685,-97.49863299,"University of Oklahoma Health Sciences Center, Oklahoma City",University of Oklahoma Health Sciences Center,"Kris Sekar, M.D.",Oklahoma,300,0.302954793,1,Oklahoma,300,43.74106719
171,Long-Term Results in Mechanically Ventilated Individuals With Acute Lung Injury/Acute Respiratory Distress Syndrome,Completed,No Results Available,,Mortality,"18 Years and older   (Adult, Older Adult)",,520,Observational,Observational Model: Cohort|Time Perspective: Prospective,12-Oct,"University of Maryland Medical Center, Baltimore, Maryland, United States",https://ClinicalTrials.gov/show/NCT00300248,,39.28827365,-76.62439437,"University of Maryland Medical Center, Baltimore",University of Maryland Medical Center,"Peter J. Pronovost, MD, PhD",,,,2,Maryland,123,
172,Assessing Respiratory Variability During Mechanical Ventilation in Acute Lung Injury (ALI),Withdrawn,No Results Available,,"The degree of variability in tidal volume (measured as % variation about the mean) stratified by ventilator mode.|Alternative measures of variability and complexity for each ventilator mode.|Correlations between clinical parameters such as disease severity, vital signs, sedation levels, and variability.","18 Years and older   (Adult, Older Adult)",,0,Observational,Observational Model: Case-Control|Time Perspective: Prospective,16-Mar,"Boston Medical Center, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT01083355,,42.33417195,-71.07464492,"Boston Medical Center, Boston",Boston Medical Center,"George O'Connor, MD",Suffolk,281,0.317766372,0,Massachusetts,447,48.32005745
174,CPAP vs.Unsynchronized NIPPV at Equal Mean Airway Pressure,Unknown status,No Results Available,Other: continuous positive airway pressure|Other: nasal intermittent positive pressure ventilation,Number of Apnea/bradycardia events|Number of of desaturation events|Mean oxygen saturation by pulse oximetry and proportion of time below 88%|Mean transcutaneous PCO2 and proportion of time >55 torr|Mean fraction of inspired oxygen|Mean respiratory rate|Mean degrees of phase lag by RIP|Number of episodes of feeding intolerance|Instances of treatment failure,up to 6 Months   (Child),Not Applicable,80,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30-Jun-22,"Women and Infants Hospital of Rhode Island, Providence, Rhode Island, United States",https://ClinicalTrials.gov/show/NCT03670732,,41.8108373,-71.4125038,"Women and Infants Hospital of Rhode Island, Providence",Women and Infants Hospital of Rhode Island,"Sunil Shaw, PhD",Providence,237,0.285023813,0,Rhode Island,237,38.19771608
175,Extending CPAP Therapy in Stable Preterm Infants to Increase Lung Growth and Function,Recruiting,No Results Available,Other: Additional 2 weeks of CPAP,Alveolar Volume|Lung Diffusion|Forced Expiratory Flows,1 Day to 12 Weeks   (Child),Phase 2|Phase 3,130,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,31-Dec-23,"Doernbecher Neonatal Care Center at Oregon Health & Science University, Portland, Oregon, United States",https://ClinicalTrials.gov/show/NCT04295564,,45.4977777,-122.6859705,"Doernbecher Neonatal Care Center at Oregon Health & Science University, Portland",Doernbecher Neonatal Care Center at Oregon Health & Science University,,Multnomah,165,0.16653337,2,Oregon,165,1.566470661
176,IC14 Antibodies to Treat Individuals With Acute Lung Injury,Terminated,No Results Available,Drug: IC14,"Alveolar lavage concentrations of interleukin-8 (measured post-treatment at Days 2, 3, 6, 7, and 8)|Worst Murray Lung Injury Score|Worst Multiple Organ Dysfunction (MOD) Score (Marshall) (measured at Days 1 through 7, and Day 28)|Infections-nosocomial and/or surgical site infections|Ventilator-free days|Mortality (measured at Day 28)","18 Years to 70 Years   (Adult, Older Adult)",Phase 2,13,Interventional,Allocation: Randomized|Masking: Double|Primary Purpose: Treatment,7-Jun,"University of Washington, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT00233207,,47.6543466,-122.3080606,"University of Washington, Seattle",University of Washington,"Margaret Neff, MD",King,450,0.211214428,2,Washington,450,15.37959145
177,PECO Air Purification in Hospital Rooms to Improve Health Outcomes for Pediatric Respiratory Distress,Completed,No Results Available,Device: Photo Electrochemical Oxidation (PECO) for Air Purification,Length of stay|Readmission rate,1 Year to 17 Years   (Child),Not Applicable,274,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,31-Dec-18,"Mercyhealth Hospital - Rockton Avenue, Rockford, Illinois, United States",https://ClinicalTrials.gov/show/NCT03647397,,42.2983049,-89.09870329,"Mercyhealth Hospital - Rockton Avenue, Rockford",Mercyhealth Hospital - Rockton Avenue,Nikhil Rao,Winnebago,26,0.33495662,1,Illinois,87,53.63441174
178,"Antenatal Betamethasone Compared to Dexamethasone - ""BETACODE TRIAL""",Completed,No Results Available,Drug: Betamethasone(Celestone soluspan) and Dexamethasone,Respiratory distress syndrome|Intraventricular hemorrhage|Neonatal mortality|Periventricular leukomalacia|Necrotizing enterocolitis|Neonatal sepsis,18 Years to 45 Years   (Adult),Not Applicable,,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,5-Apr,"Stony Brook University Hospital, Stony Brook, New York, United States",https://ClinicalTrials.gov/show/NCT00418353,,40.90826935,-73.1151875,"Stony Brook University Hospital, Stony Brook",Stony Brook University Hospital,"Andrew A Elimian, M.D",Suffolk,281,0.317766372,1,New York,281,48.32005745
179,Evaluate the Safety of agenT-797 in Participants With Moderate to Severe Difficulty Breathing Secondary to SARS-CoV-2,Completed,No Results Available,Drug: agenT-797,Number Of Participants With Treatment-emergent Adverse Events|Number Of Participants With Dose-limiting Toxicities|Time To Extubation|Mean Daily Sequential Organ Failure Assessment Score|Change From Baseline In C-reactive Protein|Decay In Quantitative Viral Burden From Upper And Lower Respiratory Tract Samples|Time From Dosing To Viral Clearance|Number Of Participants Experiencing Viral Reactivation And Fungal Infections,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,20,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2-Jun-22,"Saint John's Cancer Institute, Santa Monica, California, United States",https://ClinicalTrials.gov/show/NCT04582201,,18.3395934,-64.9143798,"Saint John's Cancer Institute, Santa Monica",Saint John's Cancer Institute,Medical Director,Saint Thomas - Saint John District,,,1,United States Virgin Islands,,
180,Feasibility and Impact of Volume Targeted Ventilation in the Delivery Room,Recruiting,No Results Available,Device: Volume Targeted Ventilation (VTV) using the Philips Respironics NM3 monitor|Device: Tidal Volume Measurement using the Philips Respironics NM3 monitor,Timing of initiation of mechanical ventilation,5 Minutes to 60 Minutes   (Child),Not Applicable,40,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",31-Dec-23,"Baystate Medical Center, Springfield, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT03938532,,42.12152205,-72.60300615,"Baystate Medical Center, Springfield",Baystate Medical Center,"Ruben Vaidya, MD",Hampden,119,0.34748054,0,Massachusetts,119,57.50617367
181,Oscillatory Versus Non-Oscillatory Nasal Continuous Airway Pressure Neonatal Respiratory Support,Withdrawn,No Results Available,Device: Nasal CPAP|Device: Oscillatory NCPAP,Physiologic respiratory stability of Oscillating versus Non-Oscillating NCPAP|Need for mechanical ventilation following the initiation of NCPAP.|Total duration of non-invasive and invasive respiratory support in each study group.|total amount of oxygen exposure in each study group. Total amount of oxygen exposure in each study group.,up to 28 Days   (Child),Not Applicable,0,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,17-Apr,"Valley Children's Healthcare, Madera, California, United States",https://ClinicalTrials.gov/show/NCT01277874,,36.8840366,-119.8003218,"Valley Children's Healthcare, Madera",Valley Children's Healthcare,"Donald Null, MD",Madera,10,0.198127805,0,California,10,11.33387023
182,Nasal High Frequency Ventilation in Preterm Infants: A Pilot Study,Completed,Has Results,Other: Nasal high frequency ventilation,"pCO2 Measurements Post-intervention, as Compared to Pre-intervention Values|Transcutaneous CO2 Measurements as a Trend Throughout Intervention",7 Days to 3 Months   (Child),Phase 1,14,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,8-Feb,"Children's Hospital of Iowa NICU, Iowa City, Iowa, United States",https://ClinicalTrials.gov/show/NCT00296231,,41.6573635,-91.5496586,"Children's Hospital of Iowa NICU, Iowa City",Children's Hospital of Iowa NICU,"Tarah T Colaizy, MD, MPH",Johnson,0,0.288428937,2,Iowa,95,39.250408
183,Prazosin to Prevent COVID-19 (PREVENT-COVID Trial),Terminated,Has Results,Drug: Prazosin|Other: Standard of care,"Death|Hospitalized, Requiring Mechanical Ventilation and/or High Flow Nasal Cannula and/or ICU/CCU Admission (or Equivalent) and/or ECMO|Hospitalized, Requiring Supplemental Oxygen, Not Requiring ICU/CCU Level Care (or Interventions Listed Under Outcome 2)|Cumulative Incidence of Grade 3 and 4 Adverse Events|Number of Participants With Serious Adverse Events|Incidence of Symptomatic Hypotension or Hypotension Requiring Cessation of Prazosin|Number of Participants With Laboratory Abnormalities in Peripheral Blood|Duration of Laboratory Abnormalities in Peripheral Blood|Number of Participants With Laboratory Abnormalities in Plasma|Duration of Laboratory Abnormalities in Plasma","45 Years to 85 Years   (Adult, Older Adult)",Phase 2,5,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,31-Mar-22,"Johns Hopkins Hospital, Baltimore, Maryland, United States",https://ClinicalTrials.gov/show/NCT04365257,,39.2964392,-76.59239403,"Johns Hopkins Hospital, Baltimore",Johns Hopkins Hospital,"Chetan Bettegowda, MD/PhD",,,,1,Maryland,123,
184,Non-invasive Vagal Neurostimulation (nVNS) for Traumatic Brain Injury (TBI)-Induced Acute Respiratory Distress,Recruiting,No Results Available,Device: nVNS|Other: SOC,Days free of invasive mechanical ventilation|Days free of death|Adverse Events/Serious Adverse Events (AEs/SAEs)|Incidence of abnormal Physical examinations|Incidence of abnormal vital signs|Incidence of abnormal laboratory results|All-cause mortality|Days free of organ failure|Days free of renal support|Days free of vasoactive support|Number of ICU-free days|Length of hospital stay|Forced Expiratory Volume (FEV1)|Neurological functioning|PROMIS CAT score (Patient-Reported Outcomes Measurement Information System (PROMIS) computer adaptive testing (CAT))|Post concussion symptom scale (PCSS),"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,46,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,25-Dec,"AHN Allegheny General Hospital, Pittsburgh, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04935697,,40.4569171,-80.0033123,"AHN Allegheny General Hospital, Pittsburgh",AHN Allegheny General Hospital,"Boyle Cheng, PhD",Allegheny,580,0.350498218,0,Pennsylvania,580,58.43908692
185,REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia,Completed,No Results Available,Biological: CK0802|Drug: Placebo,"Regimen related ≥ grade 3 toxicity within 48 hours of first infusion|28-day treatment success, defined as S28|Time to extubation|Oxygenation improvement|Ventilator free days|Organ failure free days|ICU free days|All-cause mortality","18 Years and older   (Adult, Older Adult)",Phase 1,45,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",22-Oct-21,"Johns Hopkins Hospital, Baltimore, Maryland, United States",https://ClinicalTrials.gov/show/NCT04468971,,39.2964392,-76.59239403,"Johns Hopkins Hospital, Baltimore",Johns Hopkins Hospital,,,,,1,Maryland,123,
186,Evaluation of Safety & Efficacy of BIO-11006 Inhalation Solution in Patients With ARDS,Completed,No Results Available,Drug: BIO-11006|Drug: Placebo,Incidence of treatment-emergent adverse events|Incidence of mortality|Number of Intensive Care Unit (ICU)-free days|Number of ventilator-free days|Change in oxygen saturation / fraction of inspired oxygen (S/F) ratio|Change in pro-inflammatory biomarkers from baseline to end of treatment,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,38,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",15-Jun-20,"University of Chicago Medicine, Chicago, Illinois, United States",https://ClinicalTrials.gov/show/NCT03202394,,41.7904074,-87.60488421,"University of Chicago Medicine, Chicago",University of Chicago Medicine,"Brian Dickson, MD",Cook,0,0.319824519,1,Illinois,1606,48.9563323
187,"Hospital-wide Incidence, Clinical Characteristics and Outcomes of ARDS","Active, not recruiting",No Results Available,Diagnostic Test: Estimation of hospital-wide incidence of ARDS,Hospital-wide incidence of ARDS|Sensitivity and specificity for bilateral opacities of both chest radiographs and chest ultrasound done within 12 hours as compared to the reference standard CT scans,"18 Years and older   (Adult, Older Adult)",,9999,Observational,Observational Model: Cohort|Time Perspective: Prospective,15-Oct-23,"Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT03546699,,42.33837185,-71.10970568,"Beth Israel Deaconess Medical Center, Boston",Beth Israel Deaconess Medical Center,"Alberto Goffi, MD",Suffolk,281,0.317766372,4,Massachusetts,447,48.32005745
188,Comparative Evaluation of Albumin and Starch Effects in Acute Lung Injury (ALI),Terminated,Has Results,Drug: 5% human albumin|Drug: 6% hetastarch,Change in Extravascular Lung Water (EVLW)|Change in Oxygenation (PaO2/FiO2 Ratio)|Ventilator-free Days,"18 Years and older   (Adult, Older Adult)",Phase 3,31,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",16-Nov,"Grady Memorial Hospital, Atlanta, Georgia, United States",https://ClinicalTrials.gov/show/NCT00796419,,33.7517323,-84.38200521,"Grady Memorial Hospital, Atlanta",Grady Memorial Hospital,"Greg S Martin, MD, MSc",Fulton,0,0.356858322,0,Georgia,538,60.40530904
189,Treatment of ARDS With Instilled T3,Recruiting,No Results Available,Drug: Liothyronine Sodium (T3) (modified formulation),Change in Extravascular Lung Water Index (EVLWI)|Change in Arterial Oxygenation,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,68,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,10-Oct-23,"Essentia Health - St. Mary's Medical Center, Duluth, Minnesota, United States",https://ClinicalTrials.gov/show/NCT04115514,,46.79254985,-92.09390686,"Essentia Health - St. Mary's Medical Center, Duluth",Essentia Health - St. Mary's Medical Center,"Timothy P Rich, MD",Saint Louis,,,0,Minnesota,,
190,Observational Cohort Study of Distribution of Ventilation in Pediatrics Requiring Mechanical Ventilation by Electrical Impedance Tomography,Completed,No Results Available,,Distribution of Ventilation|Distribution of Ventilation Changes Over Time,1 Day to 17 Years   (Child),,11,Observational,Observational Model: Cohort|Time Perspective: Prospective,4-Nov-18,"Boston Children's Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT02247700,,42.33716075,-71.10568624,"Boston Children's Hospital, Boston",Boston Children's Hospital,"Brian K Walsh, PhD, RRT",Suffolk,281,0.317766372,3,Massachusetts,447,48.32005745
191,Forced Oscillometry in Infants With Bronchopulmonary Dysplasia,Recruiting,No Results Available,Device: Non-invasive forced airway oscillometry,Forced oscillation technique measurements|Post-bronchodilator forced oscillation technique measurements (in subjects already receiving this therapy),"Child, Adult, Older Adult",,70,Observational,Observational Model: Cohort|Time Perspective: Prospective,24-Dec,"Children's Mercy Hospital, Kansas City, Missouri, United States",https://ClinicalTrials.gov/show/NCT04270045,,39.0844038,-94.57750828,"Children's Mercy Hospital, Kansas City",Children's Mercy Hospital,,Jackson,0,0.368181424,0,Missouri,274,63.90583885
192,LIPS-B: Lung Injury Prevention Study With Budesonide and Beta,Completed,Has Results,Drug: Budesonide|Drug: Placebo|Drug: Formoterol,Change in Oxygen Saturation to Fraction of Inspired Oxygen Concentration (SpO2/FiO2) Ratio|Number of Participants Experiencing Categorical Change in Oxygen Saturation to Fraction of Inspired Oxygen Concentration (SpO2/FiO2) Ratio|Number of Subjects Who Needed Mechanical Ventilation|Number of Subjects Who Developed Acute Respiratory Distress Syndrome (ARDS)|Hospital Length of Stay|Intensive Care Unit (ICU) Length of Stay,"18 Years and older   (Adult, Older Adult)",Phase 2,61,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",15-Dec,"University of Arizona, Tucson, Arizona, United States",https://ClinicalTrials.gov/show/NCT01783821,,32.23563985,-110.9517441,"University of Arizona, Tucson",University of Arizona,"Emir Festic, MD",Pima,296,0.186115489,2,Arizona,296,7.620270349
193,The Effects of Music Therapy on Adult Patients Requiring Mechanical Ventilation in the ICU,Enrolling by invitation,No Results Available,Other: Toning|Other: Ocean drum & SOK melody|Other: SOK|Behavioral: Process|Other: Holding Harmonic Container,Cumulative Length of Time on Ventilator|Cumulative Length of Stay in Hospital|Respiration Rate|Heart Rate|Oxygen Saturation|Amount of sedation|Richmond Agitation-Sedation Scale (RASS)|State-Trait Anxiety Inventory (STAI) (Short Form)|Confusion Assessment Method for the ICU (CAM-ICU)|Pain score|Wong-Baker FACES ® Pain Rating Scale|ICU length of stay,"18 Years and older   (Adult, Older Adult)",Not Applicable,178,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,24-Sep,"Mount Sinai West, New York, New York, United States",https://ClinicalTrials.gov/show/NCT03642002,,40.7697129,-73.98690738,"Mount Sinai West, New York",Mount Sinai West,"Joanne Loewy, DA, LCAT, MT-BC",New York,761,,0,New York,761,
194,Clinical Evaluation of a Closed Loop Oxygen Controller for Neonatal Respiratory Care,Terminated,No Results Available,,PART 1: Test and modify the instruction set for the computerized oxygen controller to achieve a goal of less than six (6) operator required interruptions per hour for oxygen saturation deviations outside of study guidelines.|PART 2: Perform a within patient cross-over trial of the computerized oxygen controller versus standard of care and evaluate the area under the time curve for oxygen exposure between the two control methods.|Part 3,up to 3 Months   (Child),,20,Observational,Observational Model: Case-Crossover|Time Perspective: Prospective,13-Mar,"Primary Children's Medical Center, Salt Lake City, Utah, United States",https://ClinicalTrials.gov/show/NCT00887731,,40.7711317,-111.8387864,"Primary Children's Medical Center, Salt Lake City",Primary Children's Medical Center,"Donald N-u-l-l, MD",Salt Lake,282,0.192021026,0,Utah,282,9.445963373
195,A Study Promoting Critical Illness Recovery in the Elderly,Recruiting,No Results Available,Device: cycle ergometry,"Number of patients in the intervention arm the are able to undergo a cycling session|Short Physical Performance Battery (SPPB)|Handgrip strength|Intensive Care Unit (ICU) Length of Stay|Hospital Length of Stay|Number of Hospital Readmissions|Number of Emergency Department Visits|Number of Ventilator Free Days|Mortality|Short Form-36|Accelerometer Activity Monitoring Results|Muscle Ultrasound--thickness, size, echogenicity; DXA scans|Translational Outcomes","55 Years and older   (Adult, Older Adult)",Not Applicable,42,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,23-Aug,"Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States",https://ClinicalTrials.gov/show/NCT02963558,,36.08983775,-80.26771223,"Wake Forest Baptist Medical Center, Winston-Salem",Wake Forest Baptist Medical Center,"Rita Bakhru, MD",Forsyth,259,0.361796043,0,North Carolina,259,61.93180236
196,Telehealth-Enhanced Patient-Oriented Recovery Trajectory After ICU,Completed,No Results Available,Other: Telehealth,Acceptability|participants will complete the 4-item Likert response Feasibility of Intervention Measure (FIM)|Appropriateness|cognitive impairment|depression|physical impairments|QOL|anxiety|PTSD symptoms will be measured using the PTSD Checklist for DSM-5 (PCL-5),"18 Years and older   (Adult, Older Adult)",Not Applicable,91,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research,28-Feb-23,"Vanderbilt University Medical Center, Nashville, Tennessee, United States",https://ClinicalTrials.gov/show/NCT03926533,,36.14092375,-86.80163418,"Vanderbilt University Medical Center, Nashville",Vanderbilt University Medical Center,,Davidson,614,0.384689218,2,Tennessee,614,69.00921291
197,Lung Injury Prediction Study,Completed,No Results Available,,Acute Lung Injury or Acute Respiratory Distress Syndrome|Survival,"18 Years and older   (Adult, Older Adult)",,300,Observational,Observational Model: Cohort,10-Feb,"Mayo Clinic, Rochester, Minnesota, United States",https://ClinicalTrials.gov/show/NCT00889772,,44.0225389,-92.46660746,"Mayo Clinic, Rochester",Mayo Clinic,"Ognjen Gajic, M.D.",Olmsted,218,0.217462963,2,Minnesota,218,17.31132208
198,Neotech RAM Cannula Versus Conventional Binasal Prong Continuous Positive Airway Pressure (CPAP) to Treat Respiratory Distress in Low Birth Weight Neonates,Terminated,No Results Available,Device: RAM Cannula|Device: Binasal Prong CPAP,Oxygenation|Ventilation|Esophageal pressure measurements|Apnea,"Child, Adult, Older Adult",Not Applicable,8,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,17-Feb,"Children's Hospitals and Clinics of Minnesota, Saint Paul, Minnesota, United States",https://ClinicalTrials.gov/show/NCT02168257,,46.729553,-94.6858998,"Children's Hospitals and Clinics of Minnesota, Saint Paul",Children's Hospitals and Clinics of Minnesota,"Neil P Mulrooney, MD",Cass,0,0.329913391,1,Minnesota,0,52.07530069
199,hCT-MSCs for COVID19 ARDS,Terminated,Has Results,Biological: Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University.|Other: Placebo,Number of Infusion Reactions|Number of Delayed Reactions|Number of Participants With Formation of New Anti-HLA Antibodies|Time to Recovery|Number of Participants With an Increase in PaO2/FiO2 Ratio|Days to Hospital Discharge to Home|Number of Ventilator Free Days|Number of Oxygen-free Days|Number of Screened Patients Who Are Enrolled and Randomized,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,12,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",16-Feb-22,"Boca Raton Regional Hospital, Boca Raton, Florida, United States",https://ClinicalTrials.gov/show/NCT04399889,,26.3587364,-80.10189891,"Boca Raton Regional Hospital, Boca Raton",Boca Raton Regional Hospital,"Joanne Kurtzberg, MD",Palm Beach,401,0.220609298,0,Florida,401,18.28400956
200,Comparison of Two Methods of High Frequency Oscillatory Ventilation in Individuals With Acute Respiratory Distress Syndrome,Completed,No Results Available,Procedure: High Frequency Oscillatory Ventilation-Hi|Procedure: High Frequency Oscillatory Ventilation-Lo,Number of ventilator free days|Changes in plasma concentration of IL-6|Number of intensive care unit free days|Mortality|Number of hospital free days|Changes in plasma IL1ra|Changes in plasma IL-1|Changes in plasma IL-10|Changes in plasma surfactant protein D|Changes in plasma von Willebrand factor,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,9-Jun,"Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States",https://ClinicalTrials.gov/show/NCT00399581,,39.29121285,-76.54906955,"Johns Hopkins Bayview Medical Center, Baltimore",Johns Hopkins Bayview Medical Center,"Roy G. Brower, MD",,,,1,Maryland,123,
201,Assessment of Analgesics and Sedatives in Mechanically Ventilated Patients With COVID-19,Completed,No Results Available,,"Difference in cumulative analgesia and sedation dose in appropriate units (e.g. mg, micrograms, etc.)|Patterns of analgesia and sedation weaning as determined by a protocol","18 Years to 90 Years   (Adult, Older Adult)",,353,Observational,Observational Model: Other|Time Perspective: Retrospective,31-Dec-22,"Wilkes University, Wilkes-Barre, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT05336656,,41.2444276,-75.8902922,"Wilkes University, Wilkes-Barre",Wilkes University,"Marc M Perreault, MSc, PharmD, BCPS, FSCPH, FOPQ",Luzerne,71,0.36072048,1,Pennsylvania,71,61.59929274
202,Airway Pressure Release Ventilation in Acute Lung Injury,Terminated,Has Results,Device: APRV|Device: Conventional MV,Amount of Sedatives Used,"18 Years and older   (Adult, Older Adult)",Not Applicable,2,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,15-Oct-08,"Johns Hopkins Hospital Medical Intensive Care Unit, Baltimore, Maryland, United States",https://ClinicalTrials.gov/show/NCT00750204,,39.3299013,-76.6205177,"Johns Hopkins Hospital Medical Intensive Care Unit, Baltimore",Johns Hopkins Hospital Medical Intensive Care Unit,"Roy G Brower, M.D.",,,,1,Maryland,123,
203,Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS,Completed,Has Results,Biological: ExoFlo|Other: Intravenous normal saline,Evaluation of 60-day Mortality Rate|Overall Survival Rates|Proportion of Discharged Patients|Time to Discharge|Incidence of Treatment Emergent Serious Adverse Events|Ventilation Free Days,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,102,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",22-May-21,"Helen Keller Hospital, Sheffield, Alabama, United States",https://ClinicalTrials.gov/show/NCT04493242,,34.746119,-87.70076057,"Helen Keller Hospital, Sheffield",Helen Keller Hospital,"Amy Lightner, MD",Colbert,22,0.460859438,1,Alabama,22,92.55718819
204,Early Caffeine and LISA Compared to Caffeine and CPAP in Preterm Infants,Recruiting,No Results Available,Procedure: Less Invasive Surfactant Administration LISA|Procedure: Continuous Positive Airway Pressure CPAP,Frequency of subjects requiring endotracheal intubation between the two groups (LISA vs CPAP) in the first 72 hours of life|Duration of mechanical ventilation and/or CPAP|Oxygen at 36 weeks corrected age|Frequency of Grade III and IV intraventricular hemorrhage|Neurodevelopment outcome at 24 months of corrected gestational age|Neurodevelopment outcome at 2 Years of Age|Need for repeat surfactant dosing,24 Weeks to 29 Weeks   (Child),Not Applicable,180,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,25-Jun,"University of California, Irvine, Irvine, California, United States",https://ClinicalTrials.gov/show/NCT04209946,,33.6431901,-117.8401649,"University of California, Irvine",University of California,Anup Katheria,Orange,0,0.178217076,1,California,651,5.178480972
205,Synchronized Intermittent Mandatory Ventilation (SIMV) Versus Nasal Intermittent Positive Pressure Ventilation (NIPPV) In Preterm Infants With Respiratory Distress,Completed,No Results Available,Other: Extubation to Nasal IPPV,"Incidence of Mechanical Ventilation via endotracheal tube at 7 days of age|Overall clinical outcomes at 7 days, 28 days, and 36 weeks postmenstrual age",10 Minutes to 120 Minutes   (Child),Phase 4,110,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,9-Jan,"Women's and Children's Hospital, Room l-919, 1240, N.Mission Road, Los Angeles, California, United States",https://ClinicalTrials.gov/show/NCT00486850,,38.95738465,-92.28842943,"Women's and Children's Hospital, Room l-919",Women's and Children's Hospital,"Rangasamy Ramanathan, MD",Boone,0,0.368950589,1,Missouri,110,64.14362573
206,MICU Recovery Clinic,Recruiting,No Results Available,"Other: Questionnaires, Physical and Cognitive Function",Physical Function|Cognitive Function|Anxiety/ Depression Screening|Post Traumatic Stress Disorder Screening|Functional Status|Resilience|Quality of Life|Hospital Readmissions|Mortality,"Child, Adult, Older Adult",,250,Observational,Observational Model: Cohort|Time Perspective: Prospective,24-Jun,"Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States",https://ClinicalTrials.gov/show/NCT02560129,,36.08983775,-80.26771223,"Wake Forest Baptist Medical Center, Winston-Salem",Wake Forest Baptist Medical Center,"Rita Bakhru, MD",Forsyth,259,0.361796043,0,North Carolina,259,61.93180236
208,COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111,Completed,Has Results,Drug: Veru-111,Number of Subjects That Are Alive Without Respiratory Failure at Day 29.|World Health Organization Ordinal Scale Clinical Improvement|Proportion of Subjects With Fever Normalization and SPO2 Greater Than 94% by Visit|Proportion of Subjects Alive and Discharged From Hospital by Visit|Patients Alive and Free of Respiratory Failure,"18 Years and older   (Adult, Older Adult)",Phase 2,39,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",13-Aug-21,"HonorHealth, Scottsdale, Arizona, United States",https://ClinicalTrials.gov/show/NCT04388826,,33.4885727,-111.9229832,"HonorHealth, Scottsdale",HonorHealth,Barnette,Maricopa,1004,0.188377743,1,Arizona,1004,8.31964474
209,Airway Inflammatory Response During Illness in Children With Respiratory Failure,Withdrawn,No Results Available,,"Mean log transformed IL-10:IL-12p70 ratio in tracheal secretion, bronchial secretion, and serum within 48-hours of mechanical ventilation|Blood oxygenation saturation and hemodynamic changes following non-bronchoscopic BAL|Mean log transformed IL-10:IL-12p70 ratio in tracheal secretion, bronchial secretion, and serum between days 3-4|Mean log transformed IL-10:IL-12p70 ratio in tracheal secretion, bronchial secretion, and serum between days 5-7",up to 17 Years   (Child),,0,Observational,Observational Model: Cohort|Time Perspective: Prospective,19-Aug,"University of North Carolina Hospital at Chapel Hill, Chapel Hill, North Carolina, United States",https://ClinicalTrials.gov/show/NCT02047877,,35.9049122,-79.0469134,"University of North Carolina Hospital at Chapel Hill, Chapel Hill",University of North Carolina Hospital at Chapel Hill,"Daniel Lercher, MD",Orange,0,0.178217076,0,North Carolina,13,5.178480972
210,Seattle-PAP Bubble Nasal CPAP and Work of Breathing,Completed,No Results Available,Device: Seattle-PAP,Work of Breathing|Video Recordings of Chest and Abdomen Movements during Breathing,6 Hours to 72 Hours   (Child),Phase 1,40,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,15-Oct,"Texas Children's Hospital, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT02210026,,29.7069019,-95.40233496,"Texas Children's Hospital, Houston",Texas Children's Hospital,"Charles V Smith, PhD",Harris,918,0.290090595,1,Texas,918,39.76410852
212,"Evaluating Health Outcomes and QOL After ALI Among Participants of the ALTA, OMEGA, EDEN, and SAILS ARDS Network Trials",Completed,No Results Available,,"Individual Physical Function and Mental Health domains from SF-36 (for participants who complete the phone surveys); 6-minute walk distance and memory evaluation (for participants who attend the study visits)|Quality of life, mental health, memory and cognition, physical functioning, fatigue, walking ability, lung function, muscle strength, weight, dietary changes, and changes in muscle and fat composition","18 Years and older   (Adult, Older Adult)",,922,Observational,Observational Model: Cohort|Time Perspective: Prospective,14-Oct,"University of Maryland Medical Center, Baltimore, Maryland, United States",https://ClinicalTrials.gov/show/NCT00719446,,39.28827365,-76.62439437,"University of Maryland Medical Center, Baltimore",University of Maryland Medical Center,"Dale M. Needham, MD, PhD",,,,2,Maryland,123,
213,Non-Invasive Monitoring of Respiratory Function in Spontaneously Breathing Patients With COVID-19 Infection,Unknown status,No Results Available,Device: AirGo Respiratory Monitor,"Endotracheal intubation during present hospitalization, recorded through chart review|Improvement in hypoxemia as indicated by oxygen saturation and requirement for supplemental oxygen, recorded through chart review|Premature need for removal of the band, recorded through investigator report|In-hospital mortality, recorded through chart review","18 Years and older   (Adult, Older Adult)",,500,Observational,Observational Model: Cohort|Time Perspective: Prospective,31-Dec-20,"Massachusetts General Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04356443,,42.36286045,-71.06875297,"Massachusetts General Hospital, Boston",Massachusetts General Hospital,,Suffolk,281,0.317766372,2,Massachusetts,447,48.32005745
214,Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS),Recruiting,No Results Available,Biological: ExoFlo|Other: Intravenous normal saline,Evaluation of 60-day All-cause Mortality|Time to death|Ventilator-free days (VFDs)|Oxygen free days|ICU free days|Incidence of Treatment Emergent Serious Adverse Events (TESAEs),"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,970,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",3-Aug-24,"Dignity Health, Chandler, Arizona, United States",https://ClinicalTrials.gov/show/NCT05354141,,33.27665205,-111.7903694,"Dignity Health, Chandler",Dignity Health,"Amy Lightner, MD",Maricopa,1004,0.188377743,0,Arizona,1004,8.31964474
215,"Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19",Terminated,Has Results,Drug: PLN-74809|Drug: Placebo,"Number of Participants With Treatment-related Adverse Events and Laboratory Abnormalities, Assessed by CTCAE V5.0","18 Years and older   (Adult, Older Adult)",Phase 2,6,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2-Aug-21,"Valleywise Health Medical Center, Phoenix, Arizona, United States",https://ClinicalTrials.gov/show/NCT04565249,,33.45696975,-112.0269822,"Valleywise Health Medical Center, Phoenix",Valleywise Health Medical Center,Pliant Therapeutics,Maricopa,1004,0.188377743,0,Arizona,1004,8.31964474
217,Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START),Completed,Has Results,Biological: Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells|Biological: Plasma-Lyte A,Numbers of Patients Occurred Pre-specified Infusion Associated Events Occurring Within 6 Hours of Study Infusion|Numbers of Patients Occurred Any Cardiac Arrest or Death Within 24 Hours of Study Infusion|Numbers of Patients Occurred Any Unexpected Severe Adverse Events (Including All-cause Deaths)|PaO2:FiO2 Change From Baseline to Day 3|Lung Injury Score From Baseline to Day 3|Oxygenation Index Change From Baseline to Day 2|SOFA Score Change From Baseline to Day 3|Number of Patients Death to Day 28|Mortality to Day 60|Number of Ventilator-free Days to Day 28|Non-pulmonary Organ-failure-free Days to Day 28|Angiopoietin 2 Change From Baseline to 6 h|Angiopoietin 2 Change From Baseline to 24 h|Interleukin 6 Change From Baseline to 6 h|Interleukin 6 Change From Baseline to 24 h|Interleukin 8 Change From Baseline to 6 h|Interleukin 8 Change From Baseline to 24 h|RAGE Change From Baseline to 6 h|RAGE Change From Baseline to 24 h,"18 Years and older   (Adult, Older Adult)",Phase 2,60,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",9-Feb-18,"University of California San Francisco, San Francisco, California, United States",https://ClinicalTrials.gov/show/NCT02097641,,37.7627257,-122.4582568,"University of California San Francisco, San Francisco",University of California San Francisco,"Michael A Matthay, MD",,,,2,California,337,
218,Continuous Exhaled Breath Condensate pH in Mechanically Ventilated Patients,Unknown status,No Results Available,,,"1 Hour and older   (Child, Adult, Older Adult)",,120,Observational,,9-Jan,"University of Virginia, Charlottesville, Virginia, United States",https://ClinicalTrials.gov/show/NCT00429637,,38.0410576,-78.5054996,"University of Virginia, Charlottesville",University of Virginia,"John F Hunt, MD",Albemarle,12,0.290677473,0,Virginia,12,39.94554148
219,Safety Study of Inhaled Carbon Monoxide to Treat Sepsis-Induced Acute Respiratory Distress Syndrome (ARDS),Recruiting,No Results Available,Drug: Inhaled Carbon Monoxide at CFK equation-determined personalized dose (200-500 ppm to achieve a COHb level of 6-8%)|Other: Inhaled Medical air,"Primary Safety Outcome: Number of pre-specified administration-related adverse events (AEs).|Accuracy of the Coburn-Forster-Kane (CFK) equation-based personalized iCO dosing algorithm to achieve a COHb level of 6-8%|Lung injury score (LIS) on days 1-5 and day 7|PaO2/FiO2 ratio on days 1-5 and day 7|Oxygenation Index (OI) on days 1-5 and day 7|Dead Space Fraction (Vd/Vt) on days 1-3 and day 7|Sequential Organ Failure Assessment (SOFA) score on days 1-5, 7, 14, 28|Ventilator-free days at day 28|ICU-free days at day 28|Hospital-free days at day 60|Hospital mortality to day 28 and 60|Montreal Cognitive Assessment- MoCA-Blind|Hayling Sentence Completion Test","18 Years and older   (Adult, Older Adult)",Phase 1,36,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",25-Sep,"Massachusetts General Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04870125,,42.36286045,-71.06875297,"Massachusetts General Hospital, Boston",Massachusetts General Hospital,"Rebecca M Baron, MD",Suffolk,281,0.317766372,2,Massachusetts,447,48.32005745
220,Non-Invasive Ventilation Via a Helmet Device for Patients Respiratory Failure,Completed,Has Results,Device: Non invasive ventilation using a helmet hyperbaric device|Other: Noninvasive ventilation via facemask,Need for Endotracheal Intubation|Hospital Length of Stay|Number of Participants Functional Status After Discharge|Ventilator-free Days|Hospital Mortality|Intensive Care Unit Length of Stay,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,83,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16-May,"University of Chicago Medical Center, Chicago, Illinois, United States",https://ClinicalTrials.gov/show/NCT01680783,,41.7892741,-87.6036009,"University of Chicago Medical Center, Chicago",University of Chicago Medical Center,"John P Kress, MD",Cook,0,0.319824519,1,Illinois,1606,48.9563323
221,The Oscillation for Acute Respiratory Distress Syndrome (ARDS) Treated Early (OSCILLATE) Trial,Terminated,No Results Available,Device: SensorMedics 3100B High Frequency Oscillatory Ventilator|Procedure: Lung Protective Ventilation,All-cause hospital mortality|Mortality at other time-points|Barotrauma|Organ Dysfunction|Duration of mechanical ventilation|Duration of ICU & Hospital Stay|Quality of Life at 6 months,"16 Years to 85 Years   (Child, Adult, Older Adult)",Phase 3,548,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12-Sep,"Denver Health Medical Centre, Denver, Colorado, United States",https://ClinicalTrials.gov/show/NCT01506401,,39.7279895,-104.9913193,"Denver Health Medical Centre, Denver",Denver Health Medical Centre,"Niall D Ferguson, MD, MSc",,,,0,Colorado,,
222,Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation,Completed,No Results Available,Drug: etanercept,,"12 Months and older   (Child, Adult, Older Adult)",Phase 1|Phase 2,15,Interventional,Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment,3-Sep,"University of Michigan, Ann Arbor, Michigan, United States",https://ClinicalTrials.gov/show/NCT00029328,,42.2942142,-83.71003894,"University of Michigan, Ann Arbor",University of Michigan,"Kenneth Cooke, M.D.",Washtenaw,92,0.349973993,2,Michigan,92,58.27702309
223,Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant,Completed,Has Results,Drug: Etanercept,"Percent of Patients With a Greater Than or Equal to 10% Improvement in FEV1, or FVC, and DLCO|Percentage of Participants That Experience Grade 3 to 4 Adverse Events","6 Years and older   (Child, Adult, Older Adult)",Phase 2,34,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,9-Feb,"The University of Michigan Cancer Center, Ann Arbor, Michigan, United States",https://ClinicalTrials.gov/show/NCT00141726,,42.277145,-83.7382071,"The University of Michigan Cancer Center, Ann Arbor",The University of Michigan Cancer Center,"Gregory A Yanik, MD",Washtenaw,92,0.349973993,4,Michigan,92,58.27702309
224,"A Phase 2/3, Randomized, Double Blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of FP-025 in Patients With Severe to Critical COVID 19 With Associated Acute Respiratory Distress Syndrome (ARDS)",Terminated,No Results Available,Drug: FP-025 100 mg|Drug: FP-025 300 mg|Drug: Placebo,The proportion of patients alive and not requiring non-invasive or invasive ventilation|Proportion of patients on invasive mechanical ventilation|Proportion of patients alive|Proportion of patients alive and not requiring non-invasive or invasive ventilation,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,90,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",18-Apr-22,"Velocity Chula Vista, Chula Vista, California, United States",https://ClinicalTrials.gov/show/NCT04750278,,32.6400541,-117.0841955,"Velocity Chula Vista, Chula Vista",Velocity Chula Vista,"Susan Shelby, Ph.D.",San Diego,570,0.184924401,0,California,570,7.252046248
225,Epidemiology of Surfactant Protein-B Deficiency,Recruiting,No Results Available,,"Statistical association of rare, functionally disruptive genomic variant with RDS|Statistical associations between risk of neonatal respiratory distress syndrome and excess, rare functional variants in gene pathways",up to 1 Year   (Child),,7000,Observational,Observational Model: Case-Control|Time Perspective: Prospective,30-Jun-24,"Washington University School of Medicine, Saint Louis, Missouri, United States",https://ClinicalTrials.gov/show/NCT00014859,,38.6389509,-90.25985928,"Washington University School of Medicine, Saint Louis",Washington University School of Medicine,"F. Sessions Cole, MD",,,,0,Missouri,,
226,Trial of Therapeutic Hypothermia in Patients With ARDS,Recruiting,No Results Available,Device: Hypothermia|Drug: Neuromuscular Blocking Agents|Device: Standard of care,"28-day ventilator-free days (VFDs)|28-day ICU-free days|Survival|non neurologic Sequential Organ Failure (SOFA) scores|Oxygen saturation (SpO2)|Plateau airway pressure|Mean airway pressure|Airway driving pressure|Oxygen saturation index|Core temperature|Urine output|comprehensive metabolic panel blood test (includes sodium, potassium, chloride, bicarb, BUN, creatinine, glucose, albumin, total protein, AST, SLT, alkaline phosphatase, and bilirubin)|Complete blood count with differential count and platelet count|Plasma biomarkers measured by immunoassay and including IL-1ß, IL-6, IL-8, IL-18, surfactant protein D, soluble ICAM-1, MMP8, and soluble TNF receptor-I)|Serum electrolytes|Fingerstick blood glucose level","18 Years to 75 Years   (Adult, Older Adult)",Phase 2,340,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30-Jun-24,"Emory University, Atlanta, Georgia, United States",https://ClinicalTrials.gov/show/NCT04545424,,33.80045465,-84.3172378,"Emory University, Atlanta",Emory University,"Jeffrey D Hasday, MD",DeKalb,4,0.359792718,1,Georgia,168,61.31247571
227,CPAP Or Nasal Cannula Oxygen for Preterm Infants: A Randomized Controlled Trial,Completed,No Results Available,Procedure: Continuous positive airway pressure|Procedure: Nasal Cannula,The number of episodes with oxygen saturations less than 85% for ≥ 10 seconds|The coefficient of variability of oxygen saturations (relative standard deviation)|The proportion of time with oxygen saturations > 95 % among infants requiring supplemental oxygen|The proportion of time spent outside oxygen saturation target ranges (91-95%) among infants requiring supplemental oxygen|The proportion of time with oxygen saturations less than 85%|The median supplemental oxygen concentration|The median transcutaneous carbon dioxide value|The number of episodes (≥ 10 seconds) with oxygen saturations less than 80 %|The number of recorded episodes (≥ 10 seconds) of bradycardia < 100/min|The median cNIRS value|The median aNIRS value,"Child, Adult, Older Adult",Not Applicable,38,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,29-Mar-23,"UAB Hospital, Birmingham, Alabama, United States",https://ClinicalTrials.gov/show/NCT04792099,,33.50649375,-86.80258,"UAB Hospital, Birmingham",UAB Hospital,"Waldemar A Carlo, MD",Jefferson,471,0.48493457,2,Alabama,471,100
229,Add-on Reparixin in Adult Patients With ARDS,Recruiting,No Results Available,Drug: Reparixin 600mg|Other: Matching Placebo,"Change in oxygenation index (OI) from baseline to day 7 of treatment|Ventilator free days (VFD) at day 28|Change in oxigenation index (OI) from baseline to day 4|Acute lung injury score [composite of PaO2/FIO2 ratio, PEEP, lung compliance (plateau airway pressure minus PEEP/TV) and extent of pulmonary infiltrates] at 2, 3, 7, 14 days (if still intubated)|Sequential Organ Failure Assessment (SOFA) score at 2, 3, 7, 14 days (if still intubated)|Ventilatory ratio (product of minute ventilation and PaCO2) at 2, 3, 7, 14 days (if still intubated)|Incidence of Extracorporeal Membrane Oxygenation (ECMO) by day 14|Use of vasoactive medications by day 14|Chest X-Rays assessment of pulmonary edema by ""radiographic assessment of lung edema"" (RALE) score at 2, 3, 7, 14 days|Percentage of patients achieving pressure support ventilation equal to 5 cmH20 with PEEP equal to 5 cmH20 for 2 hours (measure of weaning) by day 28 and at hospital discharge|Intensive Care Unit free days by day 28 and at hospital discharge|Hospital-free days by day 28 and at hospital discharge|Incidence of tracheostomies by day 28 and at hospital discharge|Incidence of transfer to long term acute care (LTAC) facility by day 28 and at hospital discharge|All-cause mortality by day 28|All-cause mortality by day 60|Change from baseline to day 3, 7 and 14 days in plasma levels of IL-6, IL-8, PAI-1, TNFr-1, ICAM-1 RAGE|Plasma levels (free and bound) of DF1681Y (acidic form of reparixin) and relevant metabolites (DF2188Y, DF2243Y, and ibuprofen (DF1674Y))|Incidence of Treatment Emergent AEs (TEAEs) and SAEs (TESAEs) from the beginning of study treatment to up to the end of study participation.|eGFR, absolute value and change from screening to day 3(±8h), day 7±1, day 14±2, day 21±2 (if still receiving reparixin), day 28±2|Incidence of secondary infections defined as new by day 28±2","18 Years and older   (Adult, Older Adult)",Phase 2,66,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",23-Sep,"The University of Alabama at Birmingham Hospital, Birmingham, Alabama, United States",https://ClinicalTrials.gov/show/NCT05496868,,33.5020323,-86.8057495,"The University of Alabama at Birmingham Hospital, Birmingham",The University of Alabama at Birmingham Hospital,"Enrico Minnella, MD",Jefferson,471,0.48493457,6,Alabama,471,100
230,Arrow Chloragard Peripherally-Inserted Central Catheters (PICC) Study,Unknown status,No Results Available,Device: Arrow PICC with Chloragard Technology,Incidence of symptomatic and asymptomatic catheter-related venous thrombosis (CVRT)|Incidence of catheter occlusion|Incidence of catheter-related bloodstream infections,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,17-Sep,"University of Kentucky Medical Center, Lexington, Kentucky, United States",https://ClinicalTrials.gov/show/NCT03019302,,38.02975155,-84.5066808,"University of Kentucky Medical Center, Lexington",University of Kentucky Medical Center,,Fayette,3,0.479679108,3,Kentucky,260,98.37527725
231,Safety and Efficacy Study of Inhaled Carbon Monoxide to Treat Acute Respiratory Distress Syndrome (ARDS),"Active, not recruiting",No Results Available,Drug: Inhaled Carbon Monoxide at 200 ppm|Other: Inhaled Medical air,"Primary Safety Outcome: Number of pre-specified administration-related adverse events.|Primary Efficacy Outcome: Change in Mitochondrial DNA (mtDNA) level from day 1 to day 5|Lung injury score (LIS) on days 1-5, and on day 7|PaO2/FiO2 ratio on days 1-5, and on day 7|Oxygenation Index (OI) on days 1-5, and day 7|Dead Space Fraction (Vd/Vt) on days 1-3, and day 7|Sequential Organ Failure Assessment (SOFA) score on days 1-5, 7, 14, 28|Change in biomarkers of autophagy|Change in biomarkers of inflammation and inflammasome activation|Change in lipid mediators|Change in biomarkers of mitochondrial quality control","18 Years and older   (Adult, Older Adult)",Phase 2,32,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",23-Dec,"Massachusetts General Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT03799874,,42.36286045,-71.06875297,"Massachusetts General Hospital, Boston",Massachusetts General Hospital,"Rebecca Baron, MD",Suffolk,281,0.317766372,2,Massachusetts,447,48.32005745
232,Ultra-Low Tidal Volume Mechanical Ventilation in ARDS Through ECMO,Not yet recruiting,No Results Available,Device: Venovenous ECMO,Proportion of patients adhering to the study protocol|Proportion of patients crossing over to VV ECMO|Number of patients recruited for the study|Ventilator-free days|Length of stay|Number of patients with non-pulmonary organ dysfunction|Number of patients with barotrauma|Mortality|Health-related quality of life,"18 Years and older   (Adult, Older Adult)",Not Applicable,72,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,23-Dec,"New York Presbyterian Hospital, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04832789,,40.74726345,-73.82519383,"New York Presbyterian Hospital, New York",New York Presbyterian Hospital,"Niall Ferguson, MD, MSc",,,,0,New York,,
233,Nasal High-frequency Jet Ventilation (nHFJV) Following Extubation in Preterm Infants,"Active, not recruiting",No Results Available,Other: Nasal high-frequency jet ventilation (nHFJV)|Other: Nasal intermittent positive pressure ventilation (NIPPV),72 hour rate of reintubation to invasive mechanical ventilation|7 day rate of reintubation to invasive mechanical ventilation|Total number of days of invasive mechanical ventilation|Rates of moderate to severe bronchopulmonary dysplasia (BPD),up to 72 Hours   (Child),Not Applicable,40,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,31-Dec-22,"University of Utah, Salt Lake City, Utah, United States",https://ClinicalTrials.gov/show/NCT03558737,,40.7628137,-111.8368719,"University of Utah, Salt Lake City",University of Utah,"Bradley Yoder, MD",Salt Lake,282,0.192021026,0,Utah,282,9.445963373
234,Implementation of Lung Protective Ventilation in Patients With Acute Respiratory Failure,Unknown status,No Results Available,,Ventilator free days to day 28|30 day mortality|90 day mortality|Hospital discharge disposition|Hospital mortality|Time to first ICU activity,"18 Years and older   (Adult, Older Adult)",,8000,Observational,Observational Model: Cohort|Time Perspective: Prospective,22-Dec,"Colin Grissom, Murray, Utah, United States",https://ClinicalTrials.gov/show/NCT03225807,,40.6590658,-111.891794,"Colin Grissom, Murray",Colin Grissom,"Colin Grissom, MD",Salt Lake,282,0.192021026,0,Utah,282,9.445963373
235,Understanding the Role of Genes and Biomarkers in the Inflammation and Blood Clotting Process in Children With Acute Lung Injury,Completed,No Results Available,,Number of ventilator-free days|Mortality and organ dysfunction,"30 Days to 18 Years   (Child, Adult)",,396,Observational,Observational Model: Cohort|Time Perspective: Prospective,16-Dec,"Children's Hospital Central California, Fresno, California, United States",https://ClinicalTrials.gov/show/NCT00605527,,36.9915398,-119.7889248,"Children's Hospital Central California, Fresno",Children's Hospital Central California,"Anil Sapru, MD, MAS",Madera,10,0.198127805,1,California,10,11.33387023
237,Linking Endotypes and Outcomes in Pediatric Acute Respiratory Distress Syndrome,Recruiting,No Results Available,,28 Day Mortality in Pediatric ARDS.|Presence of two or more endotypes in Pediatric ARDS.|Occurrence of de novo sub-phenotypes in pediatric ARDS using biomarkers and whole genome transcriptomics of peripheral blood.|ventilator-free days at 28 days.,44 Weeks to 17 Years   (Child),,500,Observational,Observational Model: Cohort|Time Perspective: Prospective,24-Dec,"Arkansas Children's Hospital, Little Rock, Arkansas, United States",https://ClinicalTrials.gov/show/NCT04113434,,34.74084135,-92.29159166,"Arkansas Children's Hospital, Little Rock",Arkansas Children's Hospital,"Nadir Yehya, M.D.",Pulaski,8,0.432534222,1,Arkansas,209,83.8004656
238,Severe ARDS: Generating Evidence,Completed,No Results Available,,Hospital Mortality|Use of Adjunctive Therapy|Ventilator-Free Days|ICU-Free Days|Organ Failure,"18 Years and older   (Adult, Older Adult)",,2400,Observational,Observational Model: Cohort|Time Perspective: Other,30-Apr-17,"University of Arizona, Tucson, Arizona, United States",https://ClinicalTrials.gov/show/NCT03021824,,32.23563985,-110.9517441,"University of Arizona, Tucson",University of Arizona,"Nida Qadir, MD",Pima,296,0.186115489,2,Arizona,296,7.620270349
239,Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection,Completed,Has Results,Drug: Alteplase 50 MG [Activase],PaO2/FiO2 Change (Increase) From Pre-to-post Intervention|Achievement of PaO2/FiO2 ≥ 200 or 50% Increase in PaO2/FiO2|National Early Warning Score 2 (NEWS2)|28 Days In-hospital Mortality|ICU-free Days|Ventilator-free Days,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,50,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30-Sep-21,"Scripps Memorial Hospital La Jolla, La Jolla, California, United States",https://ClinicalTrials.gov/show/NCT04357730,,32.88436395,-117.2249398,"Scripps Memorial Hospital La Jolla, La Jolla",Scripps Memorial Hospital La Jolla,"Ernest E Moore, MD",San Diego,570,0.184924401,1,California,570,7.252046248
240,Feeding the Critically Ill During Phases of Altered Redox Status,Completed,No Results Available,Other: Jevity 1.5,Daily Plasma F2-Isoprostane levels|Thyroid Stimulating Hormone (TSH)|Triiodothyronine (T3)|Thyroxine (T4)|Reverse Triiodothyronine (rT3),"18 Years and older   (Adult, Older Adult)",Not Applicable,35,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,13-Oct-18,"Rush University Medical Center, Chicago, Illinois, United States",https://ClinicalTrials.gov/show/NCT03085615,,41.87352605,-87.66910151,"Rush University Medical Center, Chicago",Rush University Medical Center,"Liam B McKeever, MS, PhD(c)",Cook,0,0.319824519,3,Illinois,1606,48.9563323
241,Zofin (Organicell Flow) for Patients With COVID-19,"Active, not recruiting",No Results Available,Biological: Zofin|Other: Placebo,Incidence of any infusion associated adverse events|Incidence of Severe Adverse Events|All Cause Mortality|Survival Rate|Cytokine Levels|D-dimer Levels|C-reactive protein Levels|Quantification of the COVID-19|Improved Organ Failure|Chest Imaging Changes,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,20,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",31-Aug-23,"George C. Shapiro, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04384445,,38.777076,-76.881161,"George C. Shapiro, New York",George C. Shapiro,"George C Shapiro, MD, FACC",Prince George's,89,0.344198989,0,Maryland,89,56.49168426
242,Enhancing Utilization of Non-Invasive Positive Pressure Ventilation in Critical Care,Completed,No Results Available,,,"18 Years and older   (Adult, Older Adult)",,800,Observational,Observational Model: Case-Control|Time Perspective: Prospective,9-Dec,"Tufts Medical Center, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT00458926,,42.3494397,-71.06308468,"Tufts Medical Center, Boston",Tufts Medical Center,"Nicholas S. Hill, MD",Suffolk,281,0.317766372,3,Massachusetts,447,48.32005745
243,Early Versus Delayed Enteral Feeding to Treat People With Acute Lung Injury or Acute Respiratory Distress Syndrome (The EDEN Study),Completed,No Results Available,Behavioral: Minimal (Trophic) Feeding|Behavioral: Full Feeding,"Number of ventilator-free days (VFD)|Mortality before hospital discharge, with unassisted breathing|Number of intensive care unit-free days|Number of organ failure-free days (liver, kidney, heart, central nervous system, and hematologic)|Incidence of ventilator-associated pneumonia|Number of days from first meeting criteria for weaning readiness to Day 28|VFDs and mortality in participants with a partial pressure of oxygen in arterial blood (PaO2)/fraction of inspired oxygen (FIO2) less than or equal to 200 or with shock at the time of study entry|Change in plasma and mini-bronchoalveolar lavage (BAL) levels of interleukin (IL)-6, IL-8, von Willebrand factor (VWF), surfactant protein D (SPD), and total protein concentrations|Health-related quality of life; healthcare utilization; and psychological, neurocognitive, and physical activity outcomes|Duration of survival after hospital discharge using the National Death Index","13 Years and older   (Child, Adult, Older Adult)",Phase 3,1000,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,11-May,"University of San Francisco-Fresno Medical Center, Fresno, California, United States",https://ClinicalTrials.gov/show/NCT00883948,,36.7377981,-119.7871247,"University of San Francisco-Fresno Medical Center, Fresno",University of San Francisco-Fresno Medical Center,"Arthur P. Wheeler, MD",Fresno,164,0.193083545,1,California,164,9.774440449
244,Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study,Completed,No Results Available,Drug: Poly-ICLC,"Frequency of AE greater than or equal to grade 2 by subjects who receive drug|Intranasal cytokines, nasal NO production, inflammatory cells in nasal wash","18 Years to 70 Years   (Adult, Older Adult)",Phase 1,57,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Primary Purpose: Treatment,16-Dec-09,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",https://ClinicalTrials.gov/show/NCT00646152,,39.0019296,-77.1044561,"National Institutes of Health Clinical Center, 9000 Rockville Pike",National Institutes of Health Clinical Center,"Richard T Davey, M.D.",Montgomery,22,0.337506251,3,Maryland,150,54.42262855
245,Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome,"Active, not recruiting",No Results Available,Biological: Human Mesenchymal Stromal Cells|Biological: Cell Reconstitution Media,Change in oxygenation index (OI)|Acute Lung Injury Score (LIS)|Pulmonary Dead Space Fraction|Chest radiograph assessment of pulmonary edema (RALE score)|Ventilator free-days|Duration of assisted ventilation over 28 days|Percentage of patients achieving pressure support ventilation for 2 hours|Occurrence of Infection|Sequential Organ Failure Assessment (SOFA) over 7 days|All-cause hospital mortality|Glasgow Outcome Score (GCS)|Percentage of patients occurred any thromboembolic events|Plasma angiopoietin-2|Plasma Receptor for Advanced Glycation Endproducts (RAGE)|Plasma interleukin-6|Plasma interleukin-8|Plasma Soluble tumor necrosis factor 1 (sTNF-1)|Plasma protein C|Plasma lipoxin A4|Plasma Resolvin D1|Plasma angiopoietin-1|Plasma keratinocyte growth factor (KGF)|Urine microalbumin|Total protein in min-bronchoalveolar lavage (mBAL)|Tolerability of the hMSCs - incidence of pre-specified infusion-associated events and unexpected severe adverse events,"18 Years and older   (Adult, Older Adult)",Phase 2,120,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",1-Jul-24,"University of California Davis Medical Center, Sacramento, California, United States",https://ClinicalTrials.gov/show/NCT03818854,,38.5526924,-121.45179,"University of California Davis Medical Center, Sacramento",University of California Davis Medical Center,"Michael Matthay, MD",Sacramento,396,0.187571687,1,California,396,8.070453038
246,Sleep Intervention During Acute Lung Injury,Completed,No Results Available,Drug: Dexmedetomidine|Drug: Midazolam and Fentanyl,Specific Aim 1: To assess the short-term effect of an α2 adrenergic agent on sleep quality in critically ill patients with ALI/ARDS.|Specific Aim 2: To assess the short-term effect of an α2 adrenergic agent on sleep-modulating inflammatory cytokines in critically ill patients with ALI/ARDS.|Specific aim 3: To determine the effect of α2 adrenergic agent on the in-vitro production of sleep-modulating inflammatory cytokines by peripheral blood mononuclear cells of patients with ALI/ARDS.,"18 Years to 85 Years   (Adult, Older Adult)",Phase 4,90,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",19-Jan,"Southern Arizona VA Health Care System, Tucson, Arizona, United States",https://ClinicalTrials.gov/show/NCT01050699,,32.18144915,-110.9647969,"Southern Arizona VA Health Care System, Tucson",Southern Arizona VA Health Care System,"Sairam Parthasarathy, MD",Pima,296,0.186115489,1,Arizona,296,7.620270349
247,Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19,Terminated,Has Results,Drug: Naltrexone|Drug: Ketamine|Other: Placebo,Progression of Oxygenation Needs|Renal Failure|Liver Failure|Cytokine Storm|COVID Mortality|Length of Hospital Stay|Intensive Care Unit (ICU) Admission|Intensive Care Unit (ICU) Duration|Intubation|Intubation Duration|Time Until Recovery,"18 Years and older   (Adult, Older Adult)",Phase 2,70,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",1-Apr-21,"William Beaumont Hospital, Royal Oak, Michigan, United States",https://ClinicalTrials.gov/show/NCT04365985,,42.5150439,-83.19410268,"William Beaumont Hospital, Royal Oak",William Beaumont Hospital,"Matthew Sims, MD PhD",Oakland,409,0.349430056,0,Michigan,409,58.10886531
248,Early Versus Delayed Enteral Feeding and Omega-3 Fatty Acid/Antioxidant Supplementation for Treating People With Acute Lung Injury or Acute Respiratory Distress Syndrome (The EDEN-Omega Study),Terminated,No Results Available,Behavioral: Minimal (Trophic) Feeding|Behavioral: Full Feeding|Dietary Supplement: Omega-3 Fatty Acids and Antioxidant Supplements|Dietary Supplement: Placebo,"Number of ventilator-free days (VFD)|Mortality before hospital discharge, with unassisted breathing|Number of intensive care unit-free days|Number of organ failure-free days (liver, kidney, heart, central nervous system, and hematologic)|Incidence of ventilator-associated pneumonia|Number of days from first meeting criteria for weaning readiness to Day 28|VFDs and mortality in participants with a partial pressure of oxygen in arterial blood (PaO2)/fraction of inspired oxygen (FIO2) less than or equal to 200 or with shock at the time of study entry|Change in plasma and mini-bronchoalveolar lavage (BAL) levels of interleukin (IL)-6, IL-8, von Willebrand factor (VWF), surfactant protein D (SPD), and total protein concentrations|Health-related quality of life; healthcare utilization; and psychological, neurocognitive, and physical activity outcomes|Duration of survival after hospital discharge using the National Death Index","13 Years and older   (Child, Adult, Older Adult)",Phase 3,272,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",9-Apr,"University of San Francisco-Fresno Medical Center, Fresno, California, United States",https://ClinicalTrials.gov/show/NCT00609180,,36.7377981,-119.7871247,"University of San Francisco-Fresno Medical Center, Fresno",University of San Francisco-Fresno Medical Center,"Arthur Wheeler, MD",Fresno,164,0.193083545,1,California,164,9.774440449
250,Sigh Ventilation to Increase Ventilator-Free Days in Victims of Trauma at Risk for Acute Respiratory Distress Syndrome,Completed,No Results Available,Other: Sigh breaths,"Ventilator-free days (VFDs)|All-cause mortality|ICU-free days|The occurrence of complications of treatment|Percentage of patients discharged to extended care facilities, on mechanical ventilation, or to in-patient or home hospice|Newly requiring continuous oxygen therapy at discharge","18 Years to 89 Years   (Adult, Older Adult)",Not Applicable,524,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,8-Oct-22,"UCSF Fresno Community Regional Medical Center, Fresno, California, United States",https://ClinicalTrials.gov/show/NCT02582957,,36.7435693,-119.7822114,"UCSF Fresno Community Regional Medical Center, Fresno",UCSF Fresno Community Regional Medical Center,"Richard Albert, MD",Fresno,164,0.193083545,3,California,164,9.774440449
251,Hypertonic Saline With Dextran for Treating Hypovolemic Shock and Severe Brain Injury,Completed,No Results Available,Drug: Hypertonic Saline-Dextran Solution|Drug: Lactated Ringer's Solution,Adult respiratory distress syndrome symptoms (measured 28 days post-injury)|Multiple organ failure syndrome|28 day mortality|Nosocomial infections|Duration of hospital and ICU stay|Duration of mechanical ventilation|Neurologic outcome for patients with traumatic brain injury based on the Glasgow Outcome Score and Disability Rating Score (measured at 6 and 12 months post-injury),"18 Years and older   (Adult, Older Adult)",Not Applicable,209,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,7-Mar,"University of Washington, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT00113685,,47.6543466,-122.3080606,"University of Washington, Seattle",University of Washington,Eileen Bulger,King,450,0.211214428,2,Washington,450,15.37959145
252,Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms,"Active, not recruiting",No Results Available,Device: gammaCore® Sapphire (non-invasive vagus nerve stimulator)|Other: Standard of care therapies,summarize and compare the incidence of clinical events in patients randomized to use of gammaCore Sapphire plus standard of care vs standard of care alone in patients hospitalized for CoViD-19.|evaluate cytokine trends|evaluate supplemental oxygen requirements|decrease mortality of CoViD-19 patients|delay onset of ventilation|compare clinical improvement in patients randomized to use of gammaCore Sapphire plus standard of care vs standard of care alone in patients hospitalized for CoViD-19.,"18 Years and older   (Adult, Older Adult)",Not Applicable,21,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1-Dec-23,"AHN Allegheny General Hospital, Pittsburgh, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04382391,,40.4569171,-80.0033123,"AHN Allegheny General Hospital, Pittsburgh",AHN Allegheny General Hospital,"Tariq Cheema, MD",Allegheny,580,0.350498218,0,Pennsylvania,580,58.43908692
253,"A Double Blind, Randomized, Controlled Study to Evaluate CHF 5633 (Synthetic Surfactant) and Poractant Alfa in Neonates With Respiratory Distress Syndrome (RDS) (POC)",Completed,Has Results,Drug: CHF5633|Drug: Poractant alfa,Oxygen Requirement and Ventilatory Support -- SpO2/FiO2 Ratio|Fraction of Inspired Oxygen (FiO2) (Percent) During the First 24 h and up to Day 7|Number of Patients With Bronchopulmonary Dysplasia and Mortality,1 Hour to 24 Hours   (Child),Phase 2,123,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",24-May-18,"University of South Alabama - USA Children's and Women's Hospital, Mobile, Alabama, United States",https://ClinicalTrials.gov/show/NCT02452476,,30.6974625,-88.0778358,"University of South Alabama - USA Children's and Women's Hospital, Mobile",University of South Alabama - USA Children's and Women's Hospital,"Rangasamy Ramanathan, MD",Mobile,157,0.457822218,1,Alabama,157,91.61823355
254,A Study to Evaluate the Use of the Neotech RAM Nasal Cannula for CPAP and Bi-PAP Application in Infants 28-42 Weeks Gestation in a Neonatal Intensive Care Unit (NICU),Terminated,No Results Available,Other: RAM Nasal Cannula,NCPAP|Bi-PAP|High Flow Humidity,28 Weeks to 42 Weeks   (Child),Not Applicable,14,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,8-Jul-21,"Englewood Hospital and Medical Center, Englewood, New Jersey, United States",https://ClinicalTrials.gov/show/NCT04096235,,40.9041902,-73.9686547,"Englewood Hospital and Medical Center, Englewood",Englewood Hospital and Medical Center,,Bergen,147,,0,New Jersey,147,
255,Evaluation of the Clinical Impact of Corticosteroid Duration on SARS-CoV-2 (COVID-19 WHO),Recruiting,No Results Available,,All-cause in-hospital mortality at 28 days|Bacteremia|Mechanical ventilator-free days|ICU LOS|Hospital LOS|hospital acquired pneumonia (HAP)|ventilator-associated pneumonia (VAP)|C. diff infection (CDI),"18 Years and older   (Adult, Older Adult)",,400,Observational,Observational Model: Cohort|Time Perspective: Retrospective,19-Oct-23,"Methodist Dallas Medical Center, Dallas, Texas, United States",https://ClinicalTrials.gov/show/NCT05595031,,32.76125335,-96.82504596,"Methodist Dallas Medical Center, Dallas",Methodist Dallas Medical Center,"Kristen Rahmanzadeh, PharmD",Dallas,614,0.293183356,0,Texas,614,40.72023363
256,Oscillatory Versus Non-oscillatory Nasal Continuous Airway Pressure Neonatal Respiratory Support,Withdrawn,No Results Available,Device: Regular Nasal CPAP using a conventional ventilator|Device: High Frequency Nasal CPAP,Respiratory Index Score (RSI),up to 4 Months   (Child),Not Applicable,0,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,26-Sep,"UC Davis Health, Sacramento, California, United States",https://ClinicalTrials.gov/show/NCT03711565,,38.53655635,-121.762774,"UC Davis Health, Sacramento",UC Davis Health,,Yolo,14,0.185756482,0,California,14,7.509283562
257,A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19,Terminated,Has Results,Drug: SNDX-6352|Drug: Placebo,Count Of Participants Alive And Free Of Respiratory Failure At Day 29|Count Of Participants With Secondary Clinical Improvement Outcomes At Day 29|Time To Clinical Improvement|Change From Baseline At Day 29 In Oxygenation In Hospitalized Adults With Respiratory Signs And Symptoms Secondary To COVID-19 Treated With Axatilimab|Change From Baseline At Day 15 In Biomarkers Following Treatment With Axatilimab|Count Of Participants Experiencing Adverse Events And Serious Adverse Events|Count Of Participants Requiring Ventilation Support|Count Of Participants Considered Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Free By Day 15|Pharmacokinetics: Serum Concentration Of Axatilimab And Anti-drug Antibodies,"18 Years and older   (Adult, Older Adult)",Phase 2,1,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",13-Jul-20,"HonorHealth, Scottsdale, Arizona, United States",https://ClinicalTrials.gov/show/NCT04415073,,33.4885727,-111.9229832,"HonorHealth, Scottsdale",HonorHealth,,Maricopa,1004,0.188377743,1,Arizona,1004,8.31964474
258,Calfactant for Direct Acute Respiratory Distress Syndrome,Terminated,No Results Available,Drug: Calfactant|Drug: Room Air (placebo),Mortality Rate|Duration of mechanical ventilation,"12 Years to 85 Years   (Child, Adult, Older Adult)",Phase 3,332,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",11-Feb,"University of Florida, Gainesville, Florida, United States",https://ClinicalTrials.gov/show/NCT00682500,,29.6328784,-82.34901329,"University of Florida, Gainesville",University of Florida,"Douglas Willson, MD",Alachua,210,0.228647823,0,Florida,210,20.76911447
259,MSCs in COVID-19 ARDS,Terminated,No Results Available,Biological: Remestemcel-L|Drug: Placebo,Number of all-cause mortality|Number of days alive off mechanical ventilatory support|Number of adverse events|Number of participants alive at day 7|Number of participants alive at day 14|Number of participants alive at day 60|Number of participants alive at day 90|Number of participants alive at 12 Months|Number of participants with resolution and/or improvement of ARDS|Severity of ARDS|Length of stay|Readmissions|Length of Stay in Intensive Care Unit|Clinical Improvement Scale|Change in plasma hs-CRP concentration|Change in serum hs-CRP concentration|Change in IL-6 inflammatory marker level|Change in IL-8 inflammatory marker level|Change in TNF-alpha inflammatory marker level|Pulmonary symptoms,"18 Years and older   (Adult, Older Adult)",Phase 3,223,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2-Jan-22,"Dignity Health, Gilbert, Arizona, United States",https://ClinicalTrials.gov/show/NCT04371393,,33.28757155,-111.7515924,"Dignity Health, Gilbert",Dignity Health,"Annetine C Gelijns, PhD",Maricopa,1004,0.188377743,0,Arizona,1004,8.31964474
260,Nebulised Heparin in Patients With Severe COVID-19,Recruiting,No Results Available,Drug: Nebulised unfractionated heparin (UFH),Alive and Ventilator Free Score,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,300,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",24-Jun,"Frederick Health Hospital, Frederick, Maryland, United States",https://ClinicalTrials.gov/show/NCT04545541,,39.4229752,-77.4149544,"Frederick Health Hospital, Frederick",Frederick Health Hospital,"Frank MP van Haren, MD, PhD",Frederick,0,0.346744248,0,Maryland,18,57.27854947
261,Pre-hospital Ventilation Clinical Study,Enrolling by invitation,No Results Available,Device: 731 Series Ventilator,Ventilator modes used|Ventilator settings used|Ventilator Alarm type|Ventilator Alarm Frequency,"Child, Adult, Older Adult",,500,Observational,Observational Model: Case-Only|Time Perspective: Prospective,30-Jun-24,"East Baton Rouge EMS, Baton Rouge, Louisiana, United States",https://ClinicalTrials.gov/show/NCT05604430,,30.3737883,-91.07608261,"East Baton Rouge EMS, Baton Rouge",East Baton Rouge EMS,"Dan Godbee, MD",East Baton Rouge Parish,,,0,Louisiana,,
263,A Phase 1/2 Study to Assess MultiStem® Therapy in Acute Respiratory Distress Syndrome,Completed,No Results Available,Biological: MultiStem|Biological: Placebo,Frequency of sustained hypoxemia or hypotension|Suspected Unexpected Serious Adverse Reactions (SUSARs)|Frequency of adverse events|Changes in vital signs|Changes in blood safety laboratories|Ventilator-free days|ICU-free days|Total length of hospital stay|All-cause mortality|Changes in levels of oxygenation|Changes in positive end-expiratory airway pressure|Changes in respiratory physiologic measures including lung compliance and airway resistance (peak and plateau pressures),"18 Years to 90 Years   (Adult, Older Adult)",Phase 1|Phase 2,36,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",19-Jul,"University Hospitals - Cleveland Medical Center, Cleveland, Ohio, United States",https://ClinicalTrials.gov/show/NCT02611609,,41.5057921,-81.6062368,"University Hospitals - Cleveland Medical Center, Cleveland",University Hospitals - Cleveland Medical Center,"Geoff Bellingan, MD",Cuyahoga,680,0.376333276,1,Ohio,680,66.42597874
264,Implementation of Nudges to Promote Utilization of Low Tidal Volume Ventilation (INPUT) Study,Recruiting,No Results Available,Behavioral: RT-targeted accountable justification|Behavioral: Default order set|Behavioral: physician-targeted accountable justification|Other: Standard of Care,fidelity to LPV|sustainability|Total duration of exposure to tidal volume >8 cc/kg and >10 cc/kg IBW|hospital mortality|ICU length of stay|hospital length of stay|hospital discharge disposition|mechanical ventilation duration|initial tidal volume administered|Duration of time exposed to plateau pressure (Pplat)>30 mmHg|total cumulative doses of sedative medications during and after mechanical ventilation|Total number of days with acute brain dysfunction during hospitalization,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,15100,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research,31-May-24,"Princeton Medical Center, Plainsboro, New Jersey, United States",https://ClinicalTrials.gov/show/NCT04663802,,40.339764,-74.6238206,"Princeton Medical Center, Plainsboro",Princeton Medical Center,"Meeta Kerlin, MD, MSCE",Middlesex,0,0.328731542,0,New Jersey,185,51.70993282
265,INR-Triggered Transfusion In GI Bleeders From ER,Terminated,No Results Available,Other: Transfuse plasma to High INR target|Other: Transfuse plasma to Low INR target,Mean change in PaO2/fraction of inspired oxygen (FiO2) ratio|Bleeding complication (y/n)|Transfusion-related acute lung injury|28 day and ICU Mortality|ICU and Hospital length of Stay|Change in oxygen saturation (SPO2)/FiO2 ratio (∆S/F) before and after transfusion|Ventilator-free days,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,50,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention",15-Aug,"University of Colorado Hospital, Aurora, Colorado, United States",https://ClinicalTrials.gov/show/NCT01461889,,39.7425435,-104.841661,"University of Colorado Hospital, Aurora",University of Colorado Hospital,"Marc Moss, MD",Adams,0,0.223048163,0,Colorado,168,19.03798313
266,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With COVID-19",Unknown status,No Results Available,Biological: SOC plus 15mg/kg EB05 IV|Other: SOC plus Placebo IV,"the proportion of patients that are alive without any need for oxygen support defined as a score of 3 or less on the WHO COVID-19 nine-point scale|Time to therapeutic response (primary efficacy endpoint).|The proportion of patients with clinical improvement, defined as a decrease of two points or more on the WHO 9 - point ordinal scale at Day 28|The proportion of patients that are alive and discharged home without any need for oxygen support (WHO Scale of ≤ 2) at Day 28.|The proportion of patients that are alive and free of respiratory failure (WHO scale ≤ 4) at Day 28.|The proportion of patients with clinical improvement, defined as a decrease of two points or more on the WHO 9 - point ordinal scale at Day 60.|The proportion of patients with clinical improvement, defined as a decrease of one point or more on the WHO 9 - point ordinal scale at Day 28.|The proportion of patients with clinical improvement, defined as a decrease of one point or more on the WHO 9 - point ordinal scale at Day 60.|The proportion of patients that are alive and discharged home without any need for oxygen support (WHO Scale of ≤ 2) at Day 60.|The proportion of patients that are alive and free of respiratory failure (WHO scale ≤ 4) at Day 60.|Time to clinical improvement by 2 points on the WHO ordinal scale described above.|Time to clinical improvement by 1 point on the WHO ordinal scale described above.|Change in the NEWS-2 Scale at 28 days.|Time to News-2 = 0.|The proportion of patients that experience disease progression, defined as an increase of one point or more in the WHO 9-point ordinal scale, at Day 28.|Ventilator-free days.|Duration of ventilation.|Mortality rate at 28-days and 60-days post-treatment initiation.|Duration of hospitalization.|Time to independence from supplementary oxygen therapy.|Time to normalization of oxygen saturation, defined as SaO2/SpO2 > 94% sustained a minimum of 24 hours.|Change in Sequential Organ Failure Assessment (SOFA) score, while hospitalized.|Radiological response to treatment based on Thoracic Computerized Tomography Scan (CT-Scan) or Chest X-Ray.|Change in cytokines, including IL-6, and C-reactive protein (CRP) levels.|Time to resolution of fever for at least 48 hours without antipyretics.|The decision by the attending physician to initiate treatment with another targeted immunomodulator (i.e. dexamethasone).|Change in the Berlin ARDS severity scale.|Change in Acute Kidney Injury Network (AKIN) classification.|Change in troponin levels.","18 Years and older   (Adult, Older Adult)",Phase 2,396,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",21-Apr,"UCSF Fresno, Fresno, California, United States",https://ClinicalTrials.gov/show/NCT04401475,,36.7435693,-119.7822114,"UCSF Fresno, Fresno",UCSF Fresno,,Fresno,164,0.193083545,2,California,164,9.774440449
267,LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19),Completed,No Results Available,Drug: LSALT peptide|Drug: Placebo,"To evaluate the proportion of subjects alive and free of respiratory failure and free of the need for continued renal replacement therapy (RRT) on Day 28 (as per Protocol AB002 - Version 1, dated 09JUNE2020)|All-cause mortality|The presence of and severity of ARDS as an ordinal outcome of the proportion of patients who have none, mild, moderate, or severe ARDS|Time to each of mild, moderate, or severe ARDS|The number of ventilation-free days and ECMO-free days|Time on nasal cannula or oxygen mask|Length of stay in ICU and hospital (admission to discharge)|Virologic clearance rate|Worst PaO2/FiO2 ratio following enrollment|Change in PaO2/FiO2 ratio|Vasopressor-free days|Change from maximal radiographic damage to EOT|Change in baseline modified Medical Research Council (mMRC) score|Change in Acute Physiologic Assessment and Chronic Health Evaluation (APACHE) II score|Proportion of patients with extrapulmonary organ dysfunction using the daily Sequential Organ Failure Assessment (SOFA) score|Change in liver function by Alanine Aminotransferase (ALT) test|Change in liver function by Aspartate Transferase (AST) test|Change in liver function by total bilirubin test|Change in renal function by serum creatinine (SCr) test|Change in renal function by estimated Glomerular Filtration Rate (eGFR) test|Change in hs-troponin levels|Change in Activated Coagulation Time (ACT)|Change in activated Partial Thromboplastin Time (aPTT)|Change in Prothrombin Time (PT)/International Normalized Ratio (INR)|Change in antiviral IgG, IgA, and IgM levels|Total healthcare costs from admission to discharge between treatment groups|Change in serum cytokines including IL-1a, IL-1b, and ferritin levels as well as other exploratory biomarkers drawn at the same time as LSALT peptide concentrations|Change in baseline antiviral immunoglobulins (IgG, IgM, IgA) at EOS","18 Years to 80 Years   (Adult, Older Adult)",Phase 2,61,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2-Jun-22,"VA San Diego Healthcare System, San Diego, California, United States",https://ClinicalTrials.gov/show/NCT04402957,,32.87487075,-117.2315823,"VA San Diego Healthcare System, San Diego",VA San Diego Healthcare System,,San Diego,570,0.184924401,1,California,570,7.252046248
268,Poractant Alfa - Curosurf and SARS-COV-19 ARDS (Covid-19),Terminated,No Results Available,Drug: CUROSURF® (poractant alfa),"Number of days alive and ventilator-free days|Number of days alive and free from invasive ventilation|Number of alive and free days from non-invasive ventilation (NIV)|Change from baseline in PaO2/FiO2 ratio measured at 6 hours and 12 hours following administration of each dose in the treated group and at the similar time points in the control group|Change from baseline in PaO2/FiO2 ratio at additional timepoints|Length of ICU stay (days)|Change from baseline in ventilatory parameter (Tidal volume- TV)|Delta Sequential Organ Failure Assessment (SOFA) Score and sub-component measure|Incidence of all the AEs, AEs related to poractant alfa (treated cohort) (ADRs), serious AEs (SAEs) and AEs leading to death|Change from baseline in blood gas analysis acid-base balance parameters (pH)|Percentage of patients alive and with PaO2/ FiO2 improvement of >20% following administration of each dose in the treated group and at similar timepoints in the control group|Percentage of patients alive and with PaO2/ FiO2 improvement of >20% following at the additional timepoints administration of each dose in the treated group and at similar time points in the control group|Change from baseline in FiO2|Change from baseline in ventilatory parameter (respiratory rate (RR))|Change from baseline in ventilatory parameter (dynamic compliance (Cdyn))|Change from baseline in ventilatory parameter (static compliance (Cstat))|Change from baseline in ventilatory parameter (positive end-expiratory pressure (PEEP)|Change from baseline in ventilatory parameter (peak inspiratory pressure (PIP))|Change from baseline in ventilatory parameter (plateau pressure (Pplat))|Change from baseline in blood gas analysis acid-base balance parameter (pCO2)|Change from baseline in blood gas analysis acid-base balance parameter (pO2)|Change from baseline in blood gas analysis acid-base balance parameter (HCO3)|Change from baseline in blood gas analysis acid-base balance parameter (lactate)|Mortality|Percentage of patients with improvement in severity status defined as a decrease in the severity score|Percentage of patients alive and out of ICU|Percentage of patients alive and free of organ failure|Percentage of patients alive and free of respiratory failure|Number of days alive and ventilatory-free","18 Years to 80 Years   (Adult, Older Adult)",Phase 2,22,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,18-Mar-22,"Henry Ford Health System, Detroit, Michigan, United States",https://ClinicalTrials.gov/show/NCT04502433,,42.3635796,-83.0749603,"Henry Ford Health System, Detroit",Henry Ford Health System,"Clark Howard, Prof. /MD",Wayne,0,0.372694747,0,Michigan,586,65.3011298
269,"Biomarkers, Genomics, Physiology in Critically Ill and ECMO Patients","Active, not recruiting",No Results Available,Device: Ventilator,Change in plasma IL-6 level from baseline to low driving pressure ventilation|Change in plasma sRAGE from baseline to low driving pressure ventilation,"18 Years and older   (Adult, Older Adult)",Not Applicable,80,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,1-Mar-23,"University of California San Diego Health, La Jolla, California, United States",https://ClinicalTrials.gov/show/NCT04669444,,32.85150015,-117.181876,"University of California San Diego Health, La Jolla",University of California San Diego Health,"Robert L Owens, MD",CAL Fire San Diego Unit,,,2,California,570,
270,VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation,Completed,No Results Available,Drug: VentaProst (inhaled epoprostenol delivered via a dedicated delivery system),Reduction in Respiratory Failure|Reduction in Cardiac/Circulatory Failure|Improvement in Oxygenation|Improved Clinical Outcomes,"18 Years and older   (Adult, Older Adult)",Phase 2,11,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",29-Jun-21,"Ohio State University, Columbus, Ohio, United States",https://ClinicalTrials.gov/show/NCT04452669,,40.00570905,-83.02866466,"Ohio State University, Columbus",Ohio State University,"Veronica Franco, MD",Franklin,0,0.372421808,1,Ohio,449,65.21675088
271,"A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact",Recruiting,No Results Available,Drug: AeroFact|Other: nCPAP,Incidence of intubation/cannulation and instilled surfactant|Percent of patients with respiratory symptoms requiring intervention across groups|Percent of patients requiring supplemental oxygen and visits for medical care (Doctor's office/ER/Hospitalization)|Percent of patients requiring repeat surfactant dosing between groups,26 Weeks to 31 Weeks   (Child),Phase 2,261,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",31-Aug-24,"University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States",https://ClinicalTrials.gov/show/NCT03969992,,34.7482832,-92.32455449,"University of Arkansas for Medical Sciences, Little Rock",University of Arkansas for Medical Sciences,"Andy Clark, PhD",Pulaski,8,0.432534222,0,Arkansas,209,83.8004656
272,Tolerability and Efficacy of RJX in Patients With COVID-19,"Active, not recruiting",No Results Available,Drug: Rejuveinix (RJX) Active Comparator|Drug: Placebo Comparator,"Safety as measured by DLTs and drug related SAE's|Tolerability and Efficacy measured by progression of disease through an ordinal scale.|Efficacy measured by time to resolution of respiratory failure|Efficacy as measured by day of ICU care.|Safety, Tolerability, Efficacy measured by mortality over 28 Days.|Efficacy measured by mean change in baseline clinical status on Days 7 and 14.|Efficacy measured by mean change in hospitalization days on Days 7 and 14.|Efficacy measured by time to coming off supplemental oxygen on Days 7 and 14.|Safety and Efficacy measured by time from first dose to renal therapy.","18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,237,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",23-Feb,"Memorial Hermann Memorial City Medical Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04708340,,29.78170415,-95.54671017,"Memorial Hermann Memorial City Medical Center, Houston",Memorial Hermann Memorial City Medical Center,,Harris,918,0.290090595,0,Texas,918,39.76410852
273,Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT),Terminated,Has Results,Drug: Placebo|Drug: Ruxolitinib,Percentage of Participants Who Have Died Due to Any Cause|Number of Ventilator Free Days|Number of ICU Free Days|Oxygen Free Days|Vasopressor Free Days|Hospital Free Days|Percentage of Participants With at Least 2-point Improvement in the COVID-19 Ordinal Scale|Percentage of Participants With at Least 1-point Improvement in the COVID-19 Ordinal Scale|Time to Improvement From Baseline Category to Earliest 1-point Improvement in the COVID-19 Ordinal Scale|Percentage of Participants With the COVID-19 Ordinal Scale Reported|Change in the COVID-19 9-point Ordinal Scale|Change in SOFA Score|Number and Percentage of Participants With Treatment-related Side Effects and Serious Adverse Events,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,211,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",26-Feb-21,"Honor Health Research Institute, Scottsdale, Arizona, United States",https://ClinicalTrials.gov/show/NCT04377620,,33.5813908,-111.8830819,"Honor Health Research Institute, Scottsdale",Honor Health Research Institute,,Maricopa,1004,0.188377743,1,Arizona,1004,8.31964474
274,Acute Respiratory Distress Syndrome Clinical Network (ARDSNet),Completed,No Results Available,Procedure: Low Tidal Volume Ventilation|Procedure: Positive End-Expiratory Pressure|Drug: Lysofylline|Drug: Methylprednisolone|Drug: Ketoconazole|Procedure: Fluid Management|Procedure: Pulmonary Artery Catheter,Vary by protocol,"13 Years and older   (Child, Adult, Older Adult)",Phase 3,,Interventional,Intervention Model: Factorial Assignment|Primary Purpose: Treatment,4-Jul,"University of California, San Francisco, California, United States",https://ClinicalTrials.gov/show/NCT00000579,,33.6431901,-117.8401649,"University of California, San Francisco",University of California,"Edward Abraham, MD",Orange,0,0.178217076,1,California,651,5.178480972
275,The Safety and Efficacy of Lucinactant for Inhalation in Premature Neonates 26 to 32 Weeks Gestational Age,Completed,Has Results,Drug: Lucinactant delivered via investigational delivery device|Drug: nCPAP,Number of Participants With Respiratory Failure or Death Due to Respiratory Distress Syndrome (RDS)|Incidence of Respiratory Failure or Death Due to RDS|Time to nCPAP Failure|Incidence of Respiratory Failure or Death Due to RDS With Poisson Distribution Modeling|Number of Participants With Bronchopulmonary Dysplasia (BPD),26 Weeks to 32 Weeks   (Child),Phase 2,221,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",6-Aug-19,"University of Alabama at Birmingham, Birmingham, Alabama, United States",https://ClinicalTrials.gov/show/NCT02636868,,33.5016153,-86.80604756,"University of Alabama at Birmingham, Birmingham",University of Alabama at Birmingham,"Steven Simonson, MD",Jefferson,471,0.48493457,6,Alabama,471,100
276,A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19,Completed,Has Results,Drug: APL-9|Other: Vehicle Control,"Number of Subjects Who Experienced Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs|Hospital Length of Stay|Overall Survival|Change From Baseline in Sequential Organ Failure Assessment (SOFA) Score Over Time|Total Duration of Mechanical Ventilation|Total Duration of Oxygen Therapy|Serum Concentration of APL-9 Over Time|Change From Baseline at EOT Visit in Biomarkers of Complement Activation: Components C3 and C4|Change From Baseline at EOT Visit in Biomarkers of Complement Activation: Components C3a, C4a, C5a and Terminal Complement Complex (TCC)|Change From Baseline at EOT Visit in Biomarkers of Complement Activation: Complement Bb|Change From Baseline at EOT Visit in Biomarkers of Complement Activation: Alternative Complement Pathway Hemolytic Activity (AH50)|Change From Baseline at EOT Visit in Biomarkers of Coagulopathy: Reticulocytes|Change From Baseline at EOT Visit in Biomarkers of Coagulopathy: Schistocytes|Change From Baseline at EOT Visit in Biomarkers of Coagulopathy: Lactate Dehydrogenase|Change From Baseline at EOT Visit in Biomarkers of Coagulopathy: D-Dimer and Ferritin|Change From Baseline at EOT Visit in Biomarkers of Coagulopathy: Haptoglobin and Fibrinogen|Change From Baseline at EOT Visit in Biomarkers of Inflammation: C-reactive Protein (CRP)|Change From Baseline at EOT Visit in Biomarkers of Inflammation: Tumor Necrosis Factor Alpha (TNFα), Interleukin-1-beta (IL-1β) and Interleukin-6 (IL-6)","18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,72,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",13-Feb-21,"University of California at San Francisco - Fresno, Fresno, California, United States",https://ClinicalTrials.gov/show/NCT04402060,,36.7377981,-119.7871247,"University of California at San Francisco - Fresno, Fresno",University of California at San Francisco - Fresno,,Fresno,164,0.193083545,2,California,164,9.774440449
277,A Study in Preterm Neonates With RDS to Compare CUROSURF® Administration Through LISA and Conventional Administration,Terminated,No Results Available,Combination Product: LISA combination product (Curosurf+catheter CHF6440)|Drug: Curosurf through conventional administration (endotracheal tube),"Main Safety Outcome: Number and percentage of neonates with adverse events started during the procedure for surfactant administration and judged related to the procedure|Main Safety Outcome: Incidence of AEs (including neonatal complications of prematurity), incidence of adverse drugs reactions, incidence of serious adverse events, incidence of AEs leading to death|Main Safety Outcome: Number of first failed attempts to insert the catheter/endotracheal tube and percentage of neonates with first failed attempt|Main Safety Outcome: Incidence of death at 36 weeks PMA|Main Safety Outcome: Incidence of bronchopulmonary dysplasia at 36 weeks PMA|Main Safety Outcome: Health status at discharge or 40 weeks PMA (whichever comes first): feeding status, hearing status, growth parameters, need for respiratory support or respiratory medication|Main Efficacy Outcome: Percentage of neonates needing invasive mechanical ventilation|Main Efficacy Outcome: Median duration of invasive mechanical ventilation|Main Efficacy Outcome: Preductal Oxygen Saturation (SpO2), Fraction of Inspired Oxygen (FiO2) and SpO2/FiO2 ratio|Main Efficacy Outcome: Percentage of neonates requiring at least one additional surfactant dose",30 Minutes to 24 Hours   (Child),Phase 3,33,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,13-Aug-22,"Chiesi Clinical Trial Site 84029, Little Rock, Arkansas, United States",https://ClinicalTrials.gov/show/NCT02772081,,40.6725315,-112.762883,"Chiesi Clinical Trial Site 84029, Little Rock",Chiesi Clinical Trial Site 84029,"Rangasamy Ramanathan, M.D.",Tooele,4,0.196963539,0,Utah,4,10.97393814
278,Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome,Completed,No Results Available,Biological: TNX-832|Drug: Placebo,"Safety assessed by number of adverse events, and changes in vital signs, ECGs, laboratory, coagulation and pulmonary function parameters.|Composite of pharmacokinetics","18 Years and older   (Adult, Older Adult)",Phase 1,18,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,8-Feb,"University of Miami, Miami, Florida, United States",https://ClinicalTrials.gov/show/NCT01438853,,25.71727245,-80.27870688,"University of Miami, Miami",University of Miami,"Hing Wong, PhD",Miami-Dade,593,0.221949927,1,Florida,593,18.69846416
279,Wide Scale Monitoring for Acute Respiratory Infection Using a Mobile-Based Study Platform,Completed,No Results Available,,Incidence of inﬂuenza-like illness (ILI) and COVID-like illness (CLI) in a study participant.|Incidence of COVID-like illness (CLI) in a study participant.|Disease Prevalence,"18 Years and older   (Adult, Older Adult)",,16000,Observational,Observational Model: Cohort|Time Perspective: Prospective,8-Dec-21,"Boston Children's Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04663776,,42.33716075,-71.10568624,"Boston Children's Hospital, Boston",Boston Children's Hospital,,Suffolk,281,0.317766372,3,Massachusetts,447,48.32005745
280,Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome,Completed,No Results Available,Drug: ALT-836|Drug: Placebo,"Safety profile of the study drug|Number of ventilator-free days at Day 28|Mortality at Day 7, 14, 21, 28 and 60|Length of hospitalization at Day 28|Length of ICU stay at Day 28|Number of Non-pulmonary organ failure free days at Day 28|Changes in physiological variables of lung injury|Changes in disease severity and lung injury scores|Effects of the study drug and the etiology of the disease (i.e. pulmonary or extra-pulmonary origin)|Pharmacokinetics & Pharmacodynamics|Immunogenicity","18 Years and older   (Adult, Older Adult)",Phase 2,150,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",13-Jan,"Los Angeles County and USC Medical Center, Los Angeles, California, United States",https://ClinicalTrials.gov/show/NCT00879606,,34.0580449,-118.2073831,"Los Angeles County and USC Medical Center, Los Angeles",Los Angeles County and USC Medical Center,"Hing C Wong, PhD",Los Angeles,2126,0.184174979,1,California,2126,7.020362911
281,Careful Ventilation in Acute Respiratory Distress Syndrome (COVID-19 and Non-COVID-19),Recruiting,No Results Available,Other: Respiratory Mechanics|Other: Standard Ventilation Strategy,"All-cause 60-day mortality|Duration of ventilation|Duration of ICU and hospital stay|Number of patients with organ dysfunction|Number of patients with barotrauma|Mortality at ICU discharge, 28 days, and hospital discharge","18 Years and older   (Adult, Older Adult)",Not Applicable,740,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,24-Nov,"New York University Grossman School of Medicine, New York, New York, United States",https://ClinicalTrials.gov/show/NCT03963622,,40.742133,-73.9738511,"New York University Grossman School of Medicine, New York",New York University Grossman School of Medicine,"Laurent Brochard, MD",New York,761,,0,New York,761,
282,"Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19","Active, not recruiting",No Results Available,Biological: PLX-PAD|Biological: Placebo,Number of ventilator free days|All-cause mortality|Duration of mechanical ventilation,"40 Years to 80 Years   (Adult, Older Adult)",Phase 2,66,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",23-Feb,"University of California Irvine, Irvine, California, United States",https://ClinicalTrials.gov/show/NCT04389450,,33.6431901,-117.8401649,"University of California Irvine, Irvine",University of California Irvine,,Orange,0,0.178217076,1,California,651,5.178480972
283,Plasma Adsorption in Patients With Confirmed COVID-19,Completed,No Results Available,Device: Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol),All-cause mortality|Change in Sequential Organ Failure Assessment [SOFA] scores,"18 Years and older   (Adult, Older Adult)",Not Applicable,107,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1-Apr-22,"University of Arkansas for Medical Sciences (UAMS), Little Rock, Arkansas, United States",https://ClinicalTrials.gov/show/NCT04358003,,34.7490846,-92.3204416,"University of Arkansas for Medical Sciences (UAMS), Little Rock",University of Arkansas for Medical Sciences (UAMS),,Pulaski,8,0.432534222,0,Arkansas,209,83.8004656
284,A Phase II Randomized Trial of Fish Oil in Patients With Acute Lung Injury (ALI),Completed,Has Results,Drug: Fish oil (eicosapentaenoic acid and docosahexanoic acid),Change in Bronchoalveolar Lavage Fluid (BALF) Interleukin (IL)-8|Change in BALF Leukotriene B4|Change in BALF Interleukin-6|Change in BALF Monocyte Chemotactic Protein-1|Change in BALF Neutrophil Count|Static Lung Compliance|Oxygenation|Change in Plasma Interleukin-8|Change in Plasma Leukotriene B4|Change in Plasma Interleukin-6|Change in Plasma Surfactant Protein D|Change in Plasma vonWillebrand Factor|Worst Multiple Organ Dysfunction Score (MODS) During First 28 Days After Study Enrollment|Ventilator-free Days During First 28 Days After Study Enrollment|ICU-free Days During First 28 Days After Study Enrollment|Hospital Length of Stay|Hospital Mortality|60-day Mortality,"18 Years and older   (Adult, Older Adult)",Phase 2,90,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",9-Aug,"St. Alphonsus Medical Center, Boise, Idaho, United States",https://ClinicalTrials.gov/show/NCT00351533,,43.5543486,-116.5700199,"St. Alphonsus Medical Center, Boise",St. Alphonsus Medical Center,"Renee D. Stapleton, MD, MSc",Canyon,41,0.169450296,1,Idaho,41,2.468236487
285,Post Acute Sequelae of COVID-19,Recruiting,No Results Available,Other: Cohort study,Natural history of recovery from COVID-19|Natural history of patients who do not recover from COVID-19,"18 Years and older   (Adult, Older Adult)",,500,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,27-May,"Vanderbilt_University MC, Nashville, Tennessee, United States",https://ClinicalTrials.gov/show/NCT04964115,,36.1447034,-86.8026551,"Vanderbilt_University MC, Nashville",Vanderbilt_University MC,"Carla M Sevin, MD",Davidson,614,0.384689218,0,Tennessee,614,69.00921291
286,Ventilation and Perfusion in the Respiratory System,Enrolling by invitation,No Results Available,Device: Electrical Impedance tomography|Other: Lung mechanics and gas exchange,Distribution of ventilation|Lung mechanics|Oxygenation|Blood Gas Partial Pressure of Carbon Dioxide (PaCO2) (mmHg)|Blood Gas pH,"18 Years and older   (Adult, Older Adult)",,20,Observational,Observational Model: Case-Only|Time Perspective: Prospective,24-Jul,"University of California San Diego Health, La Jolla, California, United States",https://ClinicalTrials.gov/show/NCT05081895,,32.85150015,-117.181876,"University of California San Diego Health, La Jolla",University of California San Diego Health,"Alex Pearce, MD",CAL Fire San Diego Unit,,,2,California,570,
287,Reevaluation Of Systemic Early Neuromuscular Blockade,Completed,Has Results,Drug: Cisatracurium Besylate,Hospital Mortality to Day 90|Mean Ventilator Free Days to Day 28|Mean Organ Failure Free Days to Day 28|ICU Free Days to Day 28|Mean Hospital Free Days to Days 28|Katz Activities of Daily Living (ADL)/Lawton Instrumental Activities Of Daily Living Scale (IADL)|EuroQol (EQ-5D-5L): Health Related Quality of Life|PTSS-14: Post-traumatic Stress-like Symptoms Scores >/= 45|MoCA-Blind: Montreal Cognitive Assessment,"18 Years and older   (Adult, Older Adult)",Phase 3,1008,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,4-Apr-19,"UCSF Fresno, Fresno, California, United States",https://ClinicalTrials.gov/show/NCT02509078,,36.7435693,-119.7822114,"UCSF Fresno, Fresno",UCSF Fresno,"David A. Schoenfeld, PhD",Fresno,164,0.193083545,2,California,164,9.774440449
288,Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.,Recruiting,No Results Available,Drug: AV-001 Injection|Drug: AV-001 Placebo Injection,Safety and tolerability of multiple doses of IV administrations of AV-001 Injection compared with AV-001 placebo Injection in hospitalized patients with pneumonia due to COVID-19 and/or other respiratory infections.|Efficacy of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection in patients hospitalized with pneumonia due to COVID-19 and/or other respiratory infections|Efficacy of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection in patients hospitalized with pneumonia due to COVID-19 and/or other respiratory infections.,"18 Years and older   (Adult, Older Adult)",Phase 2,120,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",23-May,"University Medical Center of Southern Nevada, Las Vegas, Nevada, United States",https://ClinicalTrials.gov/show/NCT05123755,,36.1603396,-115.1675578,"University Medical Center of Southern Nevada, Las Vegas",University Medical Center of Southern Nevada,,Clark,0,0.2179564,0,Nevada,535,17.46386782
289,Losartan for Patients With COVID-19 Not Requiring Hospitalization,Completed,Has Results,Drug: Losartan|Other: Placebo,Percentage of Participants Admitted to the Hospital|Change in PROMIS Dyspnea Scale|Change in SF-12 Physical Composite Score|Change in SF-12 Mental Composite Score|Daily Maximum Temperature|Count of Participants With an Emergency Department or Clinic Presentation|Disease Severity Rating Day 15|Change in Viral Load by Nasopharyngeal Swab at Day 9|Change in Viral Load by Nasopharyngeal Swab at Day 15|Percentage of Patients Admitted to the Intensive Care Unit Within 15 Days|Need for Oxygen Therapy at 15 Days,"18 Years and older   (Adult, Older Adult)",Phase 2,117,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1-Feb-21,"Hennepin County Medical Center, Minneapolis, Minnesota, United States",https://ClinicalTrials.gov/show/NCT04311177,,44.97208635,-93.26218936,"Hennepin County Medical Center, Minneapolis",Hennepin County Medical Center,"Christopher Tignanelli, MD",Hennepin,311,0.214906439,2,Minnesota,311,16.52097431
290,"Novel Arm Restraint For Critically Ill Patients To Reduce Immobility, Sedation, Agitation and Cognitive Impairment",Completed,No Results Available,Device: Exersides,Mobility assessed by actigraphy|Sedation/Agitation|Delirium|Average cumulative dose of sedative medications|Average cumulative dose of analgesic medications|Average cumulative dose of antipsychotic medications,"18 Years and older   (Adult, Older Adult)",Not Applicable,58,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,28-Dec-21,"University of California San Diego, San Diego, California, United States",https://ClinicalTrials.gov/show/NCT04067622,,32.87924375,-117.2311247,"University of California San Diego, San Diego",University of California San Diego,"Renee Stapleton, MD, PhD",San Diego,570,0.184924401,2,California,570,7.252046248
291,Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection,Completed,Has Results,Drug: Losartan,Mechanical Ventilation|ICU Transfer|Oxygen Therapy,"18 Years and older   (Adult, Older Adult)",Phase 4,31,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,13-Jun-20,"Sharp Grossmont Hospital, La Mesa, California, United States",https://ClinicalTrials.gov/show/NCT04340557,,32.78093805,-117.0066625,"Sharp Grossmont Hospital, La Mesa",Sharp Grossmont Hospital,"Matthew Geriak, PharmD",San Diego,570,0.184924401,1,California,570,7.252046248
292,Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19,Terminated,No Results Available,Drug: USB002|Drug: Placebo,Number of participants with treatment emergent adverse events (TEAE),"18 Years and older   (Adult, Older Adult)",Phase 2,21,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",10-May-22,"The University of Arizona Health Sciences Center/ Banner Healthcare Systems Hospitals, Tucson, Arizona, United States",https://ClinicalTrials.gov/show/NCT04778059,,32.2318851,-110.9501094,"The University of Arizona Health Sciences Center/ Banner Healthcare Systems Hospitals, Tucson",The University of Arizona Health Sciences Center/ Banner Healthcare Systems Hospitals,"Sairam Parthasarathy, MD",Pima,296,0.186115489,2,Arizona,296,7.620270349
293,Breethe Abiomed Recovery regisTry (BART),"Active, not recruiting",No Results Available,Device: Breethe Oxy-1 System,Survival up to the hospital discharge,"18 Years and older   (Adult, Older Adult)",,1000,Observational,Observational Model: Cohort|Time Perspective: Retrospective,9-Dec-25,"AdventHealth Orlando, Orlando, Florida, United States",https://ClinicalTrials.gov/show/NCT05473130,,28.572767,-81.3714848,"AdventHealth Orlando, Orlando",AdventHealth Orlando,"Amin Medjamia, MD",Orange,0,0.178217076,0,Florida,388,5.178480972
294,Laryngeal Mask Airway (LMA) for Surfactant Administration in Neonates,Completed,Has Results,"Device: Nasal continuous positive airway pressure (nCPAP)|Device: Laryngeal Mask Airway (LMA) to deliver surfactant|Drug: Surfactants, Pulmonary",Need for Intubation and Mechanical Ventilation in the First Seven Days of Life.|Duration of CPAP Therapy|Duration of Oxygen Therapy|Incidence of Pulmonary Airleaks|Incidence of Severe IVH or PVL|Incidence of Chronic Lung Disease,up to 36 Hours   (Child),Not Applicable,103,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,15-Apr,"Loma Linda University Medical Center, Loma Linda, California, United States",https://ClinicalTrials.gov/show/NCT01116921,,34.04911185,-117.2634355,"Loma Linda University Medical Center, Loma Linda",Loma Linda University Medical Center,"Kari D Roberts, M.D.",San Bernardino,410,0.189699319,1,California,410,8.728209124
295,Comparison of Aerosol Delivery of Infasurf to Usual Care in Spontaneously Breathing RDS Patients,Completed,No Results Available,Drug: Aerosolized Calfactant|Device: Solarys,Intubation|Death|Bronchopulmonary Dysplasia|Severity of Acute RDS,1 Hour to 24 Hours   (Child),Phase 3,477,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,31-Jul-18,"USA Children's & Women's Hospital, Mobile, Alabama, United States",https://ClinicalTrials.gov/show/NCT03058666,,30.6975585,-88.0777515,"USA Children's & Women's Hospital, Mobile",USA Children's & Women's Hospital,"James Cummings, MD",Mobile,157,0.457822218,1,Alabama,157,91.61823355
296,"Use of Combined Prone Positioning and High-Flow Nasal Cannula, and Non-invasive Positive Pressure Ventilation to Prevent Intubation in COVID-19 Infection",Recruiting,No Results Available,Other: Body position change,Rate of intubation|Incidence of hypotension and cardiac arrhythmias and other nursing-related risks of combining prone positioning with high-flow nasal cannula and non-invasive positive pressure ventilation,"18 Years to 110 Years   (Adult, Older Adult)",Not Applicable,24,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,23-Jul,"Mayo Clinic in Rochester, Rochester, Minnesota, United States",https://ClinicalTrials.gov/show/NCT04694638,,44.0662734,-92.5260569,"Mayo Clinic in Rochester, Rochester",Mayo Clinic in Rochester,"Gustavo Cortes Puentes, MD",Olmsted,218,0.217462963,2,Minnesota,218,17.31132208
297,EPVent 2- A Phase II Study of Mechanical Ventilation Directed by Transpulmonary Pressures,Completed,No Results Available,Other: Esophageal-pressure guided mechanical ventilation|Other: High PEEP mechanical ventilation,A composite outcome of mortality and time off the ventilator at 28-days.|Ventilator free days to day 28|mortality|lengths of stay|biomarkers of lung injury|Survival|Need for rescue therapy|Activities of daily living|Self-reported health assessment|Frailty in patients age 65 and older,"16 Years and older   (Child, Adult, Older Adult)",Not Applicable,202,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,19-Oct-18,"University of California at San Diego, La Jolla, California, United States",https://ClinicalTrials.gov/show/NCT01681225,,32.8800604,-117.2340135,"University of California at San Diego, La Jolla",University of California at San Diego,"Daniel S Talmor, MD, MPH",San Diego,570,0.184924401,2,California,570,7.252046248
298,Blood Volume Assessment in COVID-19 and Bacterial Sepsis,Recruiting,No Results Available,Device: BVA-100|Device: Transpulmonary Thermodilution (TPTD)|Device: Sublingual Microcirculation,Change in Absolute Total Blood Volume|Change in Total Blood Volume Relative to Ideal Body Weight|Change in Absolute Red Blood Cell Volume|Change in Red Blood Cell Volume Relative to Ideal Body Weight|Change in Absolute Plasma Volume|Change in Plasma Volume Relative to Ideal Body Weight|Change in Transudation Rate of Albumin|Change in Heart Rate|Change in Cardiac Output|Change in Stroke Volume|Change in Systemic Vascular Resistance (SVR)|Change in Global End Diastolic Volume (GEDV) Index|Change in Intra-Thoracic Blood Volume Index (ITBVI)|Change in Extravascular Lung Water (EVLW)|Maximum Stroke Volume|Minimum Stroke Volume|Maximum Pulse Pressure|Minimum Pulse Pressure|Change in Systolic Blood Pressure|Change in Diastolic Blood Pressure|Mean Blood Pressure|Change in Central Venous Pressure (CVP)|Number of Participants with New Onset Renal Injury|Number of Participants Requiring Renal Replacement Therapy,"18 Years to 95 Years   (Adult, Older Adult)",,40,Observational,Observational Model: Cohort|Time Perspective: Prospective,1-Jan-24,"Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States",https://ClinicalTrials.gov/show/NCT04517695,,39.00186885,-77.08637195,"Uniformed Services University of the Health Sciences, Bethesda",Uniformed Services University of the Health Sciences,"Jan Bakker, MD, PhD",Montgomery,22,0.337506251,0,Maryland,150,54.42262855
299,Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA,Terminated,Has Results,Combination Product: Lucinactant for inhalation|Device: nCPAP alone,Number of Participants With Peri-Dosing Adverse Events - Initial Dose|Number of Participants With Air Leak|Number of Participants With Worsening of Respiratory Status Criteria|Bronchopulmonary Dysplasia|Number of Participants With Nasal Continuous Positive Airway Pressure (nCPAP) Failure|Death|FiO2|Number of Participants With Complications of Prematurity,26 Weeks to 28 Weeks   (Child),Phase 2,48,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,11-Aug-17,"Loma Linda University Medical Center, Loma Linda, California, United States",https://ClinicalTrials.gov/show/NCT02528318,,34.04911185,-117.2634355,"Loma Linda University Medical Center, Loma Linda",Loma Linda University Medical Center,"Steve Simonson, MD",San Bernardino,410,0.189699319,1,California,410,8.728209124
300,Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates,Completed,Has Results,Drug: Lucinactant for Inhalation|Device: nCPAP alone,Peri-Dosing Events|All Cause Mortality|Oxygen Saturation Levels|Serum Electrolytes|PCO2,29 Weeks to 34 Weeks   (Child),Phase 2,80,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,15-Nov,"University of Alabama at Birmingham, Birmingham, Alabama, United States",https://ClinicalTrials.gov/show/NCT02074059,,33.5016153,-86.80604756,"University of Alabama at Birmingham, Birmingham",University of Alabama at Birmingham,"Robert Segal, MD, FACP",Jefferson,471,0.48493457,6,Alabama,471,100
302,Effect Of Acute Inflammatory Mediators On Functional Limitations In Patients With Acute Respiratory Failure,Completed,No Results Available,Other: Early ICU rehabilitation strategies|Other: Usual Care,"Hospital length of stay, days","18 Years and older   (Adult, Older Adult)",Not Applicable,100,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,9-Aug,"Wake Forest School of Medicine, Winston-Salem, North Carolina, United States",https://ClinicalTrials.gov/show/NCT01707303,,36.0905029,-80.2665306,"Wake Forest School of Medicine, Winston-Salem",Wake Forest School of Medicine,"Peter E. Morris, MD",Forsyth,259,0.361796043,1,North Carolina,259,61.93180236
303,Activated Protein C to Treat Acute Lung Injuries,Terminated,No Results Available,Drug: Xigris,Number of ventilator-free days (measured at Day 28),"18 Years and older   (Adult, Older Adult)",Phase 2,90,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,7-Feb,"University of California San Francisco at Fresno, Fresno, California, United States",https://ClinicalTrials.gov/show/NCT00112164,,36.7436004,-119.7822595,"University of California San Francisco at Fresno, Fresno",University of California San Francisco at Fresno,Michael Matthay,Fresno,164,0.193083545,2,California,164,9.774440449
304,Variable Ventilation During Acute Respiratory Failure,Terminated,No Results Available,Device: variable ventilation|Other: Conventional ventilation,"The occurrence of adverse events in the use of variable ventilation versus conventional ventilation, including the loss of any of the following (1) hemodynamic stability, (2) respiratory stability,(3) acid-base stability, and (4) neurological stability.|Oxygenation","18 Years and older   (Adult, Older Adult)",Not Applicable,7,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility,23-Dec-16,"Boston Medical Center, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT01083277,,42.33417195,-71.07464492,"Boston Medical Center, Boston",Boston Medical Center,"George T O'Connor, MD",Suffolk,281,0.317766372,0,Massachusetts,447,48.32005745
305,Standardized Rehabilitation for Intensive Care Unit (ICU) Patients With Acute Respiratory Failure,Completed,No Results Available,Other: Standardized Rehabilitation|Other: Usual Care,To determine whether standardized rehabilitation therapy will decrease hospital length of stay.,"18 Years and older   (Adult, Older Adult)",Not Applicable,300,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,15-Jun,"Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States",https://ClinicalTrials.gov/show/NCT00976833,,36.1354887,-80.2792887,"Wake Forest University Health Sciences, Winston-Salem",Wake Forest University Health Sciences,"Peter E. Morris, MD",Forsyth,259,0.361796043,1,North Carolina,259,61.93180236
306,The Safety and Preliminary Tolerability of Lyophilized Lucinactant in Adults With Coronavirus Disease 2019 (COVID-19),Completed,No Results Available,Drug: Lucinactant,"Evaluate the safety and feasibility of Lucinactant surfactant replacement therapy (SRT) in treating COVID-19|Oxygen index (OI)|Fraction of inspired oxygen (FiO2)|Partial pressure of oxygen (PaO2)|Oxygenation from pulse oximetry (SpO2)|Partial pressure of carbon dioxide (PaCO2)|End tidal carbon dioxide (ETCO2)|Ratio of arterial oxygen concentration to fraction of inspired oxygen and/or ratio of pulse oximetric saturation to fraction of inspired oxygen (P/F and/or S/F ratios)|Plateau pressure and peak inspiratory pressure (PPLAT and PIP)|Ventilation Index (VI)|Lung compliance (CL)|Pressure-volume loops, if ventilator technology permits|Daily lung compliance (static) on ventilator|Ventilator free days|Days in the intensive care unit (ICU)|Days in the hospital|Incidence of all-cause mortality|Organ failure free days","18 Years to 75 Years   (Adult, Older Adult)",Phase 2,20,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16-Mar-22,"University California San Diego - Jacobs Medical Center, La Jolla, California, United States",https://ClinicalTrials.gov/show/NCT04389671,,32.8778127,-117.2263271,"University California San Diego - Jacobs Medical Center, La Jolla",University California San Diego - Jacobs Medical Center,"Yuh-Chin T Huang, MD, MHS",San Diego,570,0.184924401,1,California,570,7.252046248
307,Safety and Efficacy Study of the Draeger Babylog VN500 Device in HFOV Mode in VLBW Neonates,Unknown status,No Results Available,Device: Babylog VN500 in HFOV Mode,Alive and free from Grade III/IV intraventricular hemorrhage (IVH) and cystic periventricular leukomalacia (PVL)|Alveolar-arterial (A-a) Gradient change|Freedom from study-defined serious adverse events|Device failure rate|Neurodevelopment assessment|Change of partial carbon dioxide pressure (PaCO2)|Relationship between tidal volume high frequency (Vthf) set and Vthf observed|Stability of Vthf observed and carbon dioxide diffusion (DCO2) coefficient monitoring during high frequency oscillation over time|Freedom from Bronchopulmonary Dysplasia (BPD)|Length and Type of Respiratory Support|Neonatal survival,23 Weeks to 30 Weeks   (Child),Not Applicable,225,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20-Sep,"Arkansas Children's Hospital, Little Rock, Arkansas, United States",https://ClinicalTrials.gov/show/NCT02445040,,34.74084135,-92.29159166,"Arkansas Children's Hospital, Little Rock",Arkansas Children's Hospital,"Martin Keszler, MD",Pulaski,8,0.432534222,1,Arkansas,209,83.8004656
308,LIPS-A: Lung Injury Prevention Study With Aspirin,Completed,Has Results,Drug: Aspirin|Drug: Lactose powder,Number of Participants Who Developed Acute Respiratory Distress Syndrome (ARDS) Within 7 Days|Hospital Mortality|Number of Participants With ARDS or Mortality Within 7 Days|Number of Subjects With Mechanical Ventilation at Any Time During Hospitalization|Mean Number of Days Participants Were Ventilator-Free To Day 28|Number of Subjects Admitted to Intensive Care Unit (ICU)|Mean Hospital Length of Stay,"18 Years and older   (Adult, Older Adult)",Phase 2,400,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",15-Sep,"Stanford Univeristy, Stanford, California, United States",https://ClinicalTrials.gov/show/NCT01504867,,37.4274745,-122.169719,"Stanford Univeristy, Stanford",Stanford Univeristy,"Daryl Kor, MD",Santa Clara,313,0.173702036,1,California,313,3.782659215
309,PROSpect: Prone and Oscillation Pediatric Clinical Trial,Enrolling by invitation,No Results Available,Other: Either supine or prone positioning and either CMV or HFOV,Ventilator-free Days (VFD)|Nonpulmonary organ failure-free days (OFFD),"2 Weeks to 20 Years   (Child, Adult)",Not Applicable,800,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,31-Jul-26,"Children's of Alabama, Birmingham, Alabama, United States",https://ClinicalTrials.gov/show/NCT03896763,,33.50468945,-86.80563535,"Children's of Alabama, Birmingham",Children's of Alabama,"Martha AQ Curley, RN, PhD",Jefferson,471,0.48493457,0,Alabama,471,100
310,Open-Label Study of ARD-0403 in Testosterone Deficient Men,Completed,No Results Available,Drug: ARD-0403,Pharmacokinetic|Safety and tolerability,"18 Years and older   (Adult, Older Adult)",Phase 3,150,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,8-Feb,"Medical Affiliated Research Center, Inc, Huntsville, Alabama, United States",https://ClinicalTrials.gov/show/NCT00448955,,34.7252356,-86.58637,"Medical Affiliated Research Center, Inc",Medical Affiliated Research Center,,Madison,0,0.4416247,1,Alabama,100,86.61078112
311,Open-Label Study of ARD-0403 in Testosterone Deficient Men,Terminated,No Results Available,Drug: ARD-0403,Efficacy|Safety and Tolerability,"18 Years and older   (Adult, Older Adult)",Phase 3,150,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,8-Jun,"Medical Affiliated Research Center, Inc, Huntsville, Alabama, United States",https://ClinicalTrials.gov/show/NCT00562731,,34.7252356,-86.58637,"Medical Affiliated Research Center, Inc",Medical Affiliated Research Center,R Swerdloff,Madison,0,0.4416247,1,Alabama,100,86.61078112
312,Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome,Completed,No Results Available,Drug: Exosurf|Drug: Survanta,Death or bronchopulmonary dysplasia|Average fraction of inspired oxygen (FIO2)|Mean airway pressure (MAP),up to 6 Hours   (Child),Phase 2|Phase 3,617,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Jan-92,"Stanford University, Palo Alto, California, United States",https://ClinicalTrials.gov/show/NCT01203358,,37.4387861,-122.1569334,"Stanford University, Palo Alto",Stanford University,"Jeffrey D. Horbar, MD",Santa Clara,313,0.173702036,3,California,313,3.782659215
313,Efficacy and Safety of Dexmedetomidine During Non-Invasive Positive Pressure Ventilation,Completed,Has Results,Drug: Dexmedetomidine|Drug: Placebo,Tolerability of NIV as Assessed by an NIV Tolerance Score|Percent of Study Time Spent With a Riker-SAS Score Between 3 and 4 Inclusive,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,36,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",13-Feb,"Tufts Medical Center, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT00871624,,42.3494397,-71.06308468,"Tufts Medical Center, Boston",Tufts Medical Center,"Nicholas S Hill, MD",Suffolk,281,0.317766372,3,Massachusetts,447,48.32005745
314,Clinical Decision Support Tool in PARDS Pilot Study,Recruiting,No Results Available,Other: Ventilator protocol,Aim 1: Implementation Feasibility|Aim 2: Protocol Adherence,"1 Month to 18 Years   (Child, Adult)",Not Applicable,180,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,23-Jun,"Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States",https://ClinicalTrials.gov/show/NCT04068012,,41.8453812,-87.90828366,"Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago",Ann & Robert H. Lurie Children's Hospital of Chicago,"Christopher J Newth, MD",Cook,0,0.319824519,0,Illinois,1606,48.9563323
315,Strategies for Anticoagulation During Venovenous ECMO,Recruiting,No Results Available,Other: Low intensity anticoagulation|Other: Moderate Intensity Anticoagulation,Frequency of major bleeding events|Frequency of thromboembolic events|Frequency of cannula-associated deep vein thrombosis|Bleeding events per ECMO day|Thromboembolic events per ECMO day|Bleeding events from randomization to the first of death or discharge|Thromboembolic events from randomization to the first of death or discharge|Frequency of circuit or circuit component exchanges|ECMO circuit durability|Red blood cell transfusion volume per ECMO day|New Heparin Induced Thrombocytopenia diagnosis|Lowest platelet count|Highest total and indirect bilirubin values|Highest lactate dehydrogenase value|Death attributable to a major bleeding event|Death attributable to a thromboembolic event|Ventilator-free days|ICU-free days|Hospital-free days|In-hospital mortality,"18 Years and older   (Adult, Older Adult)",Not Applicable,15,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12-May-23,"Vanderbilt University Medical Center, Nashville, Tennessee, United States",https://ClinicalTrials.gov/show/NCT04997265,,36.14092375,-86.80163418,"Vanderbilt University Medical Center, Nashville",Vanderbilt University Medical Center,"Jonathan D Casey, MD, MSc",Davidson,614,0.384689218,2,Tennessee,614,69.00921291
316,Drug Study of Albuterol to Treat Acute Lung Injury,Terminated,Has Results,Drug: Albuterol Sulfate|Procedure: Mini-Bronchoalveolar Lavage (BAL)|Drug: Placebo,Number of Ventilator Free Days (VFD)|Mortality Prior to Hospital Discharge With Unassisted Breathing to Day 60|Mortality Prior to Hospital Discharge With Unassisted Breathing to Day 90|Number of ICU-free Days at 28 Days After Randomization|Number of Organ Failure-free Days at Day 28 Following Randomization|Ventilator Free Days to Day 28 in the Subset of Participants With ARDS|Hospital Mortality to Day 60 in the Subset of Participants With ARDS|Ventilator Free Days to Day 28 in the Subset of Patients With Baseline Shock|Hospital Mortality up to Day 60 in Subjects With Baseline Shock|Plasma Levels of IL-6 and IL-8 on Study Day 3,"13 Years and older   (Child, Adult, Older Adult)",Phase 2|Phase 3,282,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",8-Nov,"University of San Francisco-Fresno Medical Center, Fresno, California, United States",https://ClinicalTrials.gov/show/NCT00434993,,36.7377981,-119.7871247,"University of San Francisco-Fresno Medical Center, Fresno",University of San Francisco-Fresno Medical Center,"Michael A. Matthay, MD",Fresno,164,0.193083545,1,California,164,9.774440449
317,"A Study to Evaluate the Safety and Efficacy of Razuprotafib, a Novel Tie 2 Activator, in Hospitalized Subjects With Moderate to Severe Coronavirus Disease 2019 (COVID-19)",Terminated,No Results Available,Drug: Razuprotafib Subcutaneous Solution|Drug: Placebo Subcutaneous Solution,Proportion of subjects alive and free of respiratory failure at Day 7|Proportion of subjects alive and free of respiratory failure at Day 28|Length hospitalized and free of respiratory failure from baseline to Day 7|Length hospitalized and free of respiratory failure from baseline to Day 28|Length of hospitalization from baseline to Day 7|Length of hospitalization from baseline to Day 28|Proportion of subjects who improve by at least 2 categories on the NIAID 8-point ordinal scale from baseline to Day 7|Proportion of subjects who improve by at least 2 categories on the NIAID 8-point ordinal scale from baseline to Day 28|Proportion of subjects who worsen by at least 2 categories on the NIAID 8-point ordinal scale from baseline to Day 7|Proportion of subjects who worsen by at least 2 categories on the NIAID 8-point ordinal scale from baseline to Day 28|All-cause mortality at Day 7|All-cause mortality at Day 28|Length of ICU stay from baseline to Day 28|Number of subjects in each category of the NIAID 8-point ordinal scale at Day 7|Number of subjects in each category of the NIAID 8-point ordinal scale at Day 28|Time to return to prehospitalization oxygen requirement|Proportion of subjects who were discharged and remained free of respiratory failure prior to Day 7|Proportion of subjects who were discharged and remained free of respiratory failure prior to Day 28|Change in PaO2:FiO2 ratio from baseline to Day 7|Change in PaO2:FiO2 ratio from baseline to Day 28|Number of participants with any serious adverse event from baseline to Day 7|Number of participants with any treatment emergent adverse event from baseline to Day 28|Number of participants with any treatment emergent adverse event from baseline to Day 7|Number of participants with any serious adverse event from baseline to Day 28,"18 Years and older   (Adult, Older Adult)",Phase 2,31,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",26-Feb-21,"University of Southern California, Los Angeles, California, United States",https://ClinicalTrials.gov/show/NCT04511650,,34.0218833,-118.2858666,"University of Southern California, Los Angeles",University of Southern California,,Los Angeles,2126,0.184174979,0,California,2126,7.020362911
318,Pulmonary Function Using Non-invasive Forced Oscillometry,Recruiting,No Results Available,Device: Non-invasive forced airway oscillometry,Area under the reactance curve (AXR)|R7-20|R7|X7|R11|R19|X11|X19|Impedance R(f)|Impedance x(f)|Resonance frequency|Tidal volume|Respiratory rate|Longer-term pulmonary outcomes,1 Day to 2 Years   (Child),Not Applicable,1098,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,26-May,"University of Alabama at Birmingham, Birmingham, Alabama, United States",https://ClinicalTrials.gov/show/NCT03346343,,33.5016153,-86.80604756,"University of Alabama at Birmingham, Birmingham",University of Alabama at Birmingham,"Namasivayam Ambalavanan, MD",Jefferson,471,0.48493457,6,Alabama,471,100
320,Vitamin D to Improve Outcomes by Leveraging Early Treatment,Completed,Has Results,Drug: Vitamin D3|Drug: Placebo,"All-cause, All-location Mortality to Day 90|All-cause, All Location Mortality to Day 28|Hospital Mortality to Day 90|Alive and Home (Prior Level of Care) at Day 90|Hospital Length of Stay to Day 90|Healthcare Facility Length of Stay to Day 90|Ventilator-free Days (VFDs) to Day 28|Health-related Quality of Life by EuroQol (EQ-5D-5L)|Number of Participants Who Developed (New) ARDS to Day 7|Severity of Acute Respiratory Distress Syndrome (ARDS)|Worst Acute Kidney Injury (AKI)|New Renal Replacement Therapy (RRT)|Highest Creatinine Levels|New Vasopressor Use to Day 7|Highest Cardiovascular SOFA (Sepsis Related Organ Failure Assessment) Score|25OHD Levels at Day 3|Highest Total Calcium to Day 14|Highest Ionized Calcium to Day 14|Hypercalcemia to Day 14|Kidney Stones to Day 90|Fall-related Fractures to Day 90|Falls to Day 90","18 Years and older   (Adult, Older Adult)",Phase 3,1358,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",11-Dec-18,"UCSF Fresno, Fresno, California, United States",https://ClinicalTrials.gov/show/NCT03096314,,36.7435693,-119.7822114,"UCSF Fresno, Fresno",UCSF Fresno,"Boyd Taylor Thompson, MD",Fresno,164,0.193083545,2,California,164,9.774440449
321,A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE),Completed,Has Results,Drug: Gimsilumab|Drug: Placebo,Incidence of Mortality|Proportion of Subjects Who Are Alive and Not on Mechanical Ventilation|Number of Ventilator-free Days|Time to Hospital Discharge,"18 Years and older   (Adult, Older Adult)",Phase 2,227,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",1-Apr-21,"Banner University Medical Center, Phoenix, Arizona, United States",https://ClinicalTrials.gov/show/NCT04351243,,33.46470925,-112.05858,"Banner University Medical Center, Phoenix",Banner University Medical Center,,Maricopa,1004,0.188377743,1,Arizona,1004,8.31964474
322,Postoperative Respiratory Abnormalities,Unknown status,No Results Available,Other: Observational retrospective cohort to describe data validity; and Data reliability; and Completeness of the data,postoperative respiratory abnormalities|Length- of-Stay|Inpatient mortality overall|The incremental cost-effectiveness ratio (ICER)|30-day readmission|30-day hospital mortality|time to event,"18 Years to 90 Years   (Adult, Older Adult)",,50000,Observational,Observational Model: Cohort|Time Perspective: Retrospective,20-Oct,"Memorial Hermann Medical Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04079829,,29.7135267,-95.39627452,"Memorial Hermann Medical Center, Houston",Memorial Hermann Medical Center,"Paul G Loubser, MD",Harris,918,0.290090595,0,Texas,918,39.76410852
323,Point-of-care Lung Ultrasound (POCUS)-Integrated Study of Admitted Patients With COVID-19,Recruiting,No Results Available,Diagnostic Test: Point of Care Ultrasound,Association of POCUS changes with major clinical events|Time from POCUS worsening to clinical diagnosis.|Utilization of traditional radiography|Individual clinical outcomes,"18 Years and older   (Adult, Older Adult)",,240,Observational,Observational Model: Case-Only|Time Perspective: Prospective,22-Jun,"UCLA-Ronald Reagan, Los Angeles, California, United States",https://ClinicalTrials.gov/show/NCT05228717,,34.0664551,-118.4465189,"UCLA-Ronald Reagan, Los Angeles",UCLA-Ronald Reagan,,Los Angeles,2126,0.184174979,0,California,2126,7.020362911
324,Re-Evaluation of Systemic Early Neuromuscular Blockade and Transthoracic Ultrasound Assessment of the Diaphragm,Withdrawn,No Results Available,,Study feasibility - number of participating centers|Study feasibility - number of trained sonographers in study|Study feasibility - enrolment rate|Study feasibility - measurement acquisition rate|Diaphragm function|Changes in diaphragm thickness over time with or without neuromuscular blockade,"19 Years and older   (Adult, Older Adult)",,0,Observational,Observational Model: Cohort|Time Perspective: Prospective,1-Dec-18,"Brigham and Women's Health, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT03132896,,42.2087103,-71.1488623,"Brigham and Women's Health, Boston",Brigham and Women's Health,"Ewan C Goligher, MD, PhD",Norfolk,59,0.329363088,0,Massachusetts,59,51.90517486
325,Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury,Completed,Has Results,Drug: CERC-002|Drug: Placebo,Number of Subjects Alive and Free of Respiratory Failure|Number of Subjects Who Are Alive at Day 28,"18 Years and older   (Adult, Older Adult)",Phase 2,88,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",19-Jan-21,"Hoag Memorial Hospital, Newport Beach, California, United States",https://ClinicalTrials.gov/show/NCT04412057,,33.62344805,-117.9296051,"Hoag Memorial Hospital, Newport Beach",Hoag Memorial Hospital,"Scott White, MD",Orange,0,0.178217076,1,California,651,5.178480972
326,Maternal Hyperoxygenation for Intrapartum Fetal Heart Rate Tracing Abnormalities,Withdrawn,No Results Available,Other: Room air,Perinatal death|Respiratory distress syndrome|Low 5 minute Apgar score|Hypoxic-ischemic encephalopathy|Neonatal seizure|Meconium aspiration syndrome|Intracranial hemorrhage|Neonatal hypotension,18 Years to 55 Years   (Adult),Not Applicable,0,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30-Dec-22,"Loma Linda University Children's Hospital, Loma Linda, California, United States",https://ClinicalTrials.gov/show/NCT03996317,,34.0491211,-117.263821,"Loma Linda University Children's Hospital, Loma Linda",Loma Linda University Children's Hospital,"Ruofan Yao, MD MPH",San Bernardino,410,0.189699319,0,California,410,8.728209124
327,Electrical Impedance Imaging of Patients on Mechanical Ventilation,Completed,No Results Available,Device: Mechanical Ventilation|Device: CT Scan,Sensitivity and specificity for diagnosing lung pathology|Regional correlation with CT scan,"18 Years and older   (Adult, Older Adult)",,2,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,16-Aug,"Medical Center of the Rockies, Loveland, Colorado, United States",https://ClinicalTrials.gov/show/NCT02232841,,40.4154198,-104.9974664,"Medical Center of the Rockies, Loveland",Medical Center of the Rockies,"Jennifer L Mueller, Ph.D.",Larimer,55,0.22079639,1,Colorado,55,18.34184893
328,Peer Support for Post Intensive Care Syndrome Self-Management,Unknown status,No Results Available,Behavioral: Peer Support with Motivational Interviewing|Behavioral: Usual Care Group,Social Network Index|Center for Epidemiologic Studies Depression Scale (CES-D)|Patient Activation Measure|Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Scale|Short Form-36 (SF-36),"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,40,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,27-Jan-21,"Baylor Scott & White Health, Temple, Texas, United States",https://ClinicalTrials.gov/show/NCT03788096,,30.02777725,-97.87524479,"Baylor Scott & White Health, Temple",Baylor Scott & White Health,,Hays,42,0.28987782,0,Texas,42,39.69832927
329,Mobile Critical Care Recovery Program for Acute Respiratory Failure Survivors,Completed,No Results Available,Behavioral: Mobile Critical Care Program|Behavioral: Attention Control,Change in Self Reported Quality of Life|Change in Cognitive Assessment Score|Change in Physical Performance|Change in Depression Symptoms|Change in Anxiety Symptoms,"18 Years and older   (Adult, Older Adult)",Not Applicable,503,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",31-Oct-22,"Eskenazi Hospital, Indianapolis, Indiana, United States",https://ClinicalTrials.gov/show/NCT03053245,,39.77820945,-86.18436604,"Eskenazi Hospital, Indianapolis",Eskenazi Hospital,"Babar A Khan, MD, MS",Marion,14,0.370007758,2,Indiana,526,64.47044885
330,Predictors of Severe COVID-19 Outcomes,"Active, not recruiting",No Results Available,,Performance (discrimination / calibration) of models,"18 Years and older   (Adult, Older Adult)",,494,Observational,Observational Model: Cohort|Time Perspective: Prospective,21-Oct,"The University of Arizona, Tucson, Arizona, United States",https://ClinicalTrials.gov/show/NCT04388813,,32.2318851,-110.9501094,"The University of Arizona, Tucson",The University of Arizona,"Charlie Kim, PhD",Pima,296,0.186115489,2,Arizona,296,7.620270349
331,SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19,No longer available,No Results Available,Biological: eculizumab,,"18 Years and older   (Adult, Older Adult)",,,Expanded Access:Intermediate-size Population,,,"Cedars-Sinai Medical Center, Los Angeles, California, United States",https://ClinicalTrials.gov/show/NCT04355494,,34.0751604,-118.3810936,"Cedars-Sinai Medical Center, Los Angeles",Cedars-Sinai Medical Center,,Los Angeles,2126,0.184174979,0,California,2126,7.020362911
333,Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia,Terminated,Has Results,Biological: Ravulizumab|Other: BSC,Survival (Based On All-Cause Mortality) in Participants in the ITT Population At Day 29|Number Of Days Free Of Mechanical Ventilation At Day 29|Number of Days the Participants Were Alive and Not in ICU|Change From Baseline In Sequential Organ Failure Assessment (SOFA) At Day 29|Change From Baseline In Peripheral Capillary Oxygen Saturation/Fraction Of Inspired Oxygen (SpO2/FiO2) At Day 29|Number of Days the Participants Were Alive and Not in the Hospital|Estimated Number of Participants Alive At Up To Day 60 and At Up To Day 90|Serum Ravulizumab Concentrations Prior to Dosing on Day 1 and Day 29|Change From Baseline In Serum Free Complement Component 5 Concentrations At Day 29|Change From Baseline In Terminal Complement Complex C5b-9 At Day 29,"18 Years and older   (Adult, Older Adult)",Phase 3,202,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,8-Apr-21,"Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, United States",https://ClinicalTrials.gov/show/NCT04369469,,34.7463676,-92.3204675,"Central Arkansas Veterans Healthcare System, Little Rock",Central Arkansas Veterans Healthcare System,,Pulaski,8,0.432534222,0,Arkansas,209,83.8004656
334,STIP: Statin Trial for Influenza Patients,Terminated,Has Results,Drug: Rosuvastatin (crestor)|Drug: Placebo,"Hospital Mortality to Day 28 or if Mortality is Not Different Between Groups, Time to Achieve Resolution of Respiratory Failure (e.g., Time to Unassisted Breathing in Survivors (Including Patient's Never Requiring Mechanical Ventilation).","13 Years and older   (Child, Adult, Older Adult)",Not Applicable,7,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",11-Jul,"University of Arkansas, Little Rock, Alaska, United States",https://ClinicalTrials.gov/show/NCT00970606,,36.09352375,-94.17708979,"University of Arkansas, Little Rock",University of Arkansas,"Gordon R Bernard, M.D.",Washington,12,0.161466335,0,Arkansas,61,0
335,Maintaining Optimal HVNI Delivery Using Automatic Titration of Oxygen in Preterm Infants,Recruiting,No Results Available,Device: Automated Control|Device: Manual Control,Primary Safety Objective - Proportion of Time Outside of SpO2 Target Range|Primary Performance Objective - Proportion of Time Within SpO2 Target Range|Secondary Performance Objective 1 - Proportion of Time Within SpO2 Target Range (Weight Groups)|Secondary Performance Objective 2 - Proportion of Time Within SpO2 Target Range (Skin Pigmentation),"Child, Adult, Older Adult",Not Applicable,47,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,31-Dec-23,"Children's National Hospital & Research Institute, Washington, District of Columbia, United States",https://ClinicalTrials.gov/show/NCT05030012,,38.9273449,-77.0145221,"Children's National Hospital & Research Institute, Washington",Children's National Hospital & Research Institute,"Billie L Short, MD",,,,0,District of Columbia,314,
336,Universal Anti-Viral Vaccine for Healthy Elderly Adults,Completed,No Results Available,Drug: AlloStim,frequency of vaccine events|Proportion of subjects with positive T-cell response|Proportion of subjects able to suppress viral propagation,65 Years and older   (Older Adult),Phase 1|Phase 2,40,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,1-Apr-23,"Delray Physician Care Center, Delray Beach, Florida, United States",https://ClinicalTrials.gov/show/NCT04441047,,26.4588588,-80.0959837,"Delray Physician Care Center, Delray Beach",Delray Physician Care Center,"David Fineberg, MD",Palm Beach,401,0.220609298,1,Florida,401,18.28400956
337,Trial of Late Surfactant to Prevent BPD: A Pilot Study in Ventilated Preterm Neonates Receiving Inhaled Nitric Oxide,Completed,Has Results,Drug: Infasurf (ONY Inc.)|Drug: Sham,SP-B Content|Alive Without BPD at 36 Weeks Post Menstrual Age,7 Days to 14 Days   (Child),Phase 3,85,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",12-Dec,"Alta Bates Summit Medical Center, Berkeley, California, United States",https://ClinicalTrials.gov/show/NCT00569530,,37.8215138,-122.2631811,"Alta Bates Summit Medical Center, Berkeley",Alta Bates Summit Medical Center,"Roberta A Ballard, MD",Alameda,282,0.175524759,1,California,282,4.346152876
338,Early Surfactant to Reduce Use of Mechanical Breathing in Low Birth Weight Infants,Terminated,No Results Available,Drug: Early surfactant|Drug: Standard practice,Need for mechanical ventilation following randomization|Mean duration of mechanical ventilation|Risk morbidities associated with mechanical ventilation and/or early surfactant administration,up to 12 Hours   (Child),Phase 3,61,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2-Jul,"University of Alabama at Birmingham, Birmingham, Alabama, United States",https://ClinicalTrials.gov/show/NCT00005774,,33.5016153,-86.80604756,"University of Alabama at Birmingham, Birmingham",University of Alabama at Birmingham,"Edward F. Donovan, MD",Jefferson,471,0.48493457,6,Alabama,471,100
339,Epidemiologic Multicenter Study on Mechanical Ventilation Management in Children With Acute Lung Injury,Completed,No Results Available,,,"up to 18 Years   (Child, Adult)",,,Observational,Time Perspective: Prospective,7-Nov,"Children's Hospital Los Angeles, Los Angeles, California, United States",https://ClinicalTrials.gov/show/NCT00521625,,34.0976912,-118.2900801,"Children's Hospital Los Angeles, Los Angeles",Children's Hospital Los Angeles,"Philippe Jouvet, MD",Los Angeles,2126,0.184174979,1,California,2126,7.020362911
340,Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure,Completed,No Results Available,Drug: Aviptadil by intravenous infusion + standard of care|Drug: Normal Saline Infusion + standard of care,Resolution of Respiratory Failure (Alive and Free of Respiratory Failure)|Survival through day 60 (key secondary)|Improvement on NIAID Scale (key secondary measure)|Time to ICU discharge|Time on ventilation|Time to extubation|Time to discharge alive|Multi-organ failure free days,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2|Phase 3,196,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",22-Feb-21,"St. Jude Medical Center, Fullerton, California, United States",https://ClinicalTrials.gov/show/NCT04311697,,33.89466005,-117.9270646,"St. Jude Medical Center, Fullerton",St. Jude Medical Center,"Jonathan C Javitt, MD, MPH",Orange,0,0.178217076,1,California,651,5.178480972
341,A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury,Completed,No Results Available,Drug: Sivelestat,,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,600,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,2-Dec,"Birmingham, Alabama, United States",https://ClinicalTrials.gov/show/NCT00036062,,33.5206824,-86.8024326,"Birmingham, Alabama",Birmingham,,Jefferson,471,0.48493457,1,Alabama,471,100
342,Low-Level Laser Therapy Treatment of Lung Inflammation in Post-COVID-19 Recovery,Terminated,No Results Available,Device: LLLT Photobiomodulation,Decreased inflammation of the lungs|Subjective assessment of overall health,"18 Years and older   (Adult, Older Adult)",,5,Observational,Observational Model: Case-Only|Time Perspective: Prospective,21-Nov-22,"MD at Bedside, Berkeley, California, United States",https://ClinicalTrials.gov/show/NCT05258617,,37.8510347,-122.2526672,"MD at Bedside, Berkeley",MD at Bedside,,Alameda,282,0.175524759,0,California,282,4.346152876
343,Inhaled Sedation in COVID-19-related Acute Respiratory Distress Syndrome (ISCA): an International Research Data Study in the Recent Context of Widespread Disease Resulting From the 2019 (SARS-CoV2) Coronavirus Pandemics (COVID-19),Completed,No Results Available,Drug: Intravenous sedation|Drug: Inhaled sedation,"Number of days off the ventilator (VFD28, for ventilator-free days), taking into account death as a competing event|All-cause mortality|Ventilator-free days|ICU-free days|Duration of invasive mechanical ventilation|Duration of controlled mechanical ventilation|Physiological measures of lung function|Development of complications|Duration of vasopressor use|Duration of renal replacement therapy|Duration (in days) of any adjuvant therapies|Duration of continuous neuromuscular blockade|Type of sedation practices|Duration of sedation practices|Modalities of sedation practices","18 Years and older   (Adult, Older Adult)",,203,Observational,Observational Model: Cohort|Time Perspective: Retrospective,30-Apr-21,"Beth Israel Deaconess Medical Center, Inc., Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04383730,,42.33837185,-71.10970568,"Beth Israel Deaconess Medical Center, Inc.",Beth Israel Deaconess Medical Center,Matthieu Jabaudon,Suffolk,281,0.317766372,4,Massachusetts,447,48.32005745
344,Rescue Antenatal Steroids and Pulmonary Function Tests in Preterm Infants,Completed,Has Results,Drug: betamethasone|Drug: placebo,Measurements of Functional Residual Capacity in Preterm Infants.|Measurements of Respiratory Compliance (Crs) in Preterm Infants.|FiO2,"15 Years and older   (Child, Adult, Older Adult)",Not Applicable,85,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",9-Nov,"Oregon Health & Science University, Portland, Oregon, United States",https://ClinicalTrials.gov/show/NCT00669383,,45.4981929,-122.6864957,"Oregon Health & Science University, Portland",Oregon Health & Science University,"Cynthia McEvoy, MD",Multnomah,165,0.16653337,2,Oregon,165,1.566470661
345,Aerosolized Infasurf Treatment Protocol: Aerosolized Infasurf for Spontaneously Breathing Patients With Early RDS (AERO-03),Available,No Results Available,Combination Product: Infasurf Aero,,up to 42 Weeks   (Child),,,Expanded Access:Treatment IND/Protocol,,,"University of Mississippi Medical Center, Jackson, Mississippi, United States",https://ClinicalTrials.gov/show/NCT03582930,,32.32938955,-90.17252057,"University of Mississippi Medical Center, Jackson",University of Mississippi Medical Center,"Jim Cummings, MD",Hinds,218,0.421292324,0,Mississippi,218,80.32503995
346,ACTION ON COVID-19: A Study to Test Whether BI 764198 Helps Lung Health of People Hospitalised With COVID-19,Terminated,Has Results,Drug: BI 764198|Drug: Placebo,"Percentage of Patients Alive and Free of Mechanical Ventilation|Percentage of Patients Alive and Discharged Free of Oxygen Use|Percentage of Patients With Occurrence of Any Component of Composite: In-hospital Mortality or Intensive Care Unit (ICU) Admission or Mechanical Ventilation|Time to Clinical Improvement of at Least 2 Points (From Randomisation) on the World Health Organization Clinical Progression Scale, Discharge From the Hospital, or Considered Fit for Discharge|Number of Ventilator Free Days|Percentage of Mortality at Day 15, 29, 60 and 90","50 Years and older   (Adult, Older Adult)",Phase 2,133,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",31-May-21,"University of California Irvine, Orange, California, United States",https://ClinicalTrials.gov/show/NCT04604184,,33.6431901,-117.8401649,"University of California Irvine, Orange",University of California Irvine,,Orange,0,0.178217076,1,California,651,5.178480972
348,Observational Study of Expected ARF Recovery,Completed,No Results Available,,Quality of life measured using the World Health Organization Quality of Life-BREF instrument (WHOQOL-BREF) after hospital discharge|Patient expectation error measure using EQ-5D VAS,"18 Years and older   (Adult, Older Adult)",,180,Observational,Observational Model: Cohort|Time Perspective: Prospective,1-Dec-21,"Johns Hopkins University, Baltimore, Maryland, United States",https://ClinicalTrials.gov/show/NCT03797313,,39.33020225,-76.62185358,"Johns Hopkins University, Baltimore",Johns Hopkins University,Alison Turnbull,,,,1,Maryland,123,
349,Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study),Completed,No Results Available,Behavioral: Team approach to sedation management|Behavioral: Usual approach to sedation management,Duration of mechanical ventilation|Time to recovery of acute respiratory failure|Duration of weaning from mechanical ventilation|Occurrence of adverse events|Detection of life-threatening neurological events|Total sedative exposure|Occurrence of iatrogenic withdrawal symptoms|Pediatric ICU and hospital length of stay|Hospital costs|Study implementation costs and cost-effectiveness|In-hospital mortality|Post-discharge quality of life and emotional health,"2 Weeks to 18 Years   (Child, Adult)",Phase 3,2449,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,13-Dec,"Children's Hospital of Alabama, Birmingham, Alabama, United States",https://ClinicalTrials.gov/show/NCT00814099,,33.5055774,-86.8063806,"Children's Hospital of Alabama, Birmingham",Children's Hospital of Alabama,"Martha A.Q. Curley, RN, PhD",Jefferson,471,0.48493457,1,Alabama,471,100
350,The Budesonide in Babies (BiB) Trial,Recruiting,No Results Available,Drug: budesonide (Pulmicort nebulizing suspension).|Drug: surfactant (poractant alfa;Curosurf),Number of Participants with Physiologic BPD or death|Number of Participants with Death by 36 weeks' post-menstrual age|Number of Participants with Physiologic BPD|Grade of BPD Severity|Number of Participants with Grade 3 BPD|Number of Participants with Use of Additional Postnatal Steroids|Number of Participants with Severe Neurodevelopmental Impairment (NDI)|Number of Participants with Death by 2 years|Number of Participants with Severe NDI or death,up to 48 Hours   (Child),Phase 3,1160,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",30-Sep-27,"University of Alabama, Birmingham, Alabama, United States",https://ClinicalTrials.gov/show/NCT04545866,,33.5016153,-86.80604756,"University of Alabama, Birmingham",University of Alabama,"Namasivayam Ambalavanan, MD",Jefferson,471,0.48493457,0,Alabama,471,100
351,Fostamatinib for Hospitalized Adults With COVID-19,Completed,Has Results,Drug: Placebo|Drug: fostamatinib,Number of Participants With at Least 1 Serious Adverse Event|Number of Participants With Sustained Recoveries Defined by Ordinal Scale Score of 3 or Less|Number of Participants Who Progress to Mechanical Ventilation|Number of Participants With Cumulative Clinical Endpoint of Death|Number of Grade 3 and 4 Adverse Events Through Day 60|Participant Score on Ordinal Scale|Change in C-Reactive Protein Levels From Baseline|Change in Fibrinogen Levels From Baseline.|Change in D-Dimer Levels From Baseline|Change in Ferritin Levels From Baseline|Change in Interleukin 6 (IL6) Levels From Baseline|Median Days Participants Were Admitted to Intensive Care Unit|Relative Change in SpO2/FiO2 Ratio|Change in SOFA Score From Baseline|Median Days on Participants Received Supplemental Oxygen|The Number of Participants That Experienced Acute Renal Failure|Number of Participants That Experienced a Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE)|Change in Absolute Lymphocyte Count Levels From Baseline|Change in Absolute Neutrophil Count Levels From Baseline|Change in Platelet Count Levels From Baseline,"18 Years and older   (Adult, Older Adult)",Phase 2,59,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",30-Apr-21,"National Institutes of Health Clinical Center, Bethesda, Maryland, United States",https://ClinicalTrials.gov/show/NCT04579393,,39.0019296,-77.1044561,"National Institutes of Health Clinical Center, Bethesda",National Institutes of Health Clinical Center,"Jeffrey R Strich, M.D.",Montgomery,22,0.337506251,3,Maryland,150,54.42262855
352,Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial,Completed,Has Results,Drug: Betamethasone|Drug: Placebo,"Neonatal Composite Outcome|Number of Neonates With Severe Respiratory Complication,|Neonates Needing Immediate Resuscitation After Birth|Number of Neonates With Respiratory Distress Syndrome|Number of Neonates With Transient Tachypnea of the Newborn|Number of Infants With Neonatal Apnea|Number of Infants withChronic Lung Disease / Bronchopulmonary Dysplasia (BPD) Requiring Supplemental Oxygen|Neonates With Pneumonia|Number of Neonates Needing Surfactant Administration|Neonatal Outcome Composite|Number of Neonates With Pulmonary Air Leak|Neonatal Death After 72 Hours of Delivery|Birth Weight|Birth Weight Less Than 10th Percentile|Gestational Age at Delivery|Number of Neonates With Necrotizing Enterocolitic (NEC)|Number of Infants With Neonatal Sepsis|Number of Neonates With Intraventricular Hemorrhage|Neonatal Morbidity Composite|Number of Neonates With Hypoglycemia|Time Until First Neonatal Feeding|Neonatal Feeding Difficulty|Neonatal Hyperbilirubinemia|Number of Neonates With Hypothermia|Length of NICU or Nursery Stay|Median Length of Hospital Stay|Maternal Outcomes (Participant-based)|Hours From Randomization to Delivery|Median Length of Maternal Hospital Stay","Child, Adult, Older Adult",Phase 3,2831,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",31-Aug-22,"University of Alabama - Birmingham, Birmingham, Alabama, United States",https://ClinicalTrials.gov/show/NCT01222247,,33.5016153,-86.80604756,"University of Alabama - Birmingham, Birmingham",University of Alabama - Birmingham,"Monica Longo, MD",Jefferson,471,0.48493457,2,Alabama,471,100
353,Acetaminophen and Ascorbate in Sepsis: Targeted Therapy to Enhance Recovery,Recruiting,No Results Available,Drug: Intravenous Acetaminophen (room temperature)|Drug: Intravenous Vitamin C (refrigerated)|Drug: 5% Dextrose (room temperature)|Drug: 5% Dextrose refrigerated,Days alive and free of organ support to day 28|Ventilator-free days (VFD)|Vasopressor-free days|Renal replacement-free days|28-day hospital mortality|ICU free days|Hospital free days to discharge home|Days in ICU among survivors and non-survivors|Number of subjects with initiation of assisted ventilation|Number of subjects with initiation of renal replacement therapy|Change in organ-specific Sepsis-related Organ Failure Assessment (SOFA) scores between enrollment and study day 7|90-day hospital mortality|Number of subjects who developed ARDS|Change in serum creatinine concentration|Number of subjects with Major Adverse Kidney Events at 28 days (MAKE28)|Change in Radiographic Assessment of Lung Edema (RALE) score|90-day all-cause mortality|Renal calculi to day 90,"18 Years and older   (Adult, Older Adult)",Phase 2,900,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",23-Jul,"University of Alabama Medical Center, Birmingham, Alabama, United States",https://ClinicalTrials.gov/show/NCT04291508,,30.70695845,-88.09843052,"University of Alabama Medical Center, Birmingham",University of Alabama Medical Center,"Boyd Taylor Thompson, MD",Mobile,157,0.457822218,0,Alabama,157,91.61823355
354,Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors,Recruiting,No Results Available,Diagnostic Test: Cardiac MRI|Diagnostic Test: Echocardiogram|Diagnostic Test: 6-minute walk test|Diagnostic Test: Questionnaire,"Participants with focal fibrosis based on cardiac imaging (MRI and echocardiogram) > 3 months post-COVID-19 (coronavirus disease 2019) diagnosis, at first study visit|Participants with focal fibrosis based on cardiac imaging (MRI and echocardiogram) at 12-36 months post first study visit|Blood oxygenation of participants at > 3 months post-COVID-19 diagnosis, first study visit|Blood oxygenation of participants at 12-36 months post first study visit|Lung abnormalities in participants at > 3 months post-COVID-19 infection|Lung abnormalities in participants at 12-36 months post first study visit|Quality of life (QOL) in participants at > 3 months post-COVID-19 diagnosis, at first study visit based on clinical indices and symptoms assessed by the (Patient-Reported Outcomes Measurement Information System) PROMIS-29 questionnaire.|Quality of life (QOL) in participants at 12-36 months post first study visit based on clinical indices and symptoms assessed by the (Patient-Reported Outcomes Measurement Information System) PROMIS-29 questionnaire.|Effort tolerance as measured by a 6-minute walk test at > 3 months post-COVID-19 diagnosis, at first study visit|Effort tolerance as measured by a 6-minute walk test at 12-36 months post first study visit|Participants with edema based on cardiac imaging (MRI and echocardiogram) at > 3 months post-COVID-19 diagnosis, at first study visit|Participants with edema based on cardiac imaging (MRI and echocardiogram) at 12-36 months post first study visit|Participants with diffuse fibrosis based on cardiac imaging (MRI and echocardiogram) at > 3 months post-COVID-19 diagnosis, at first study visit|Participants with diffuse fibrosis based on cardiac imaging (MRI and echocardiogram) at 12-36 months post first study visit|Quality of life (QOL) in participants at > 3 months post-COVID-19 diagnosis, at first study visit based on clinical indices and symptoms assessed by the Minnesota Living with Heart Failure Questionnaire (MLHFQ)|Quality of life (QOL) in participants based on clinical indices and symptoms assessed by the Seattle Angina (SAQ) questionnaire at 12-36 months post first study visit","18 Years and older   (Adult, Older Adult)",,510,Observational,Observational Model: Cohort|Time Perspective: Prospective,30-Jul-26,"New York Presbyterian-Brooklyn Methodist Hospital, Brooklyn, New York, United States",https://ClinicalTrials.gov/show/NCT05164744,,40.6292962,-73.9275552,"New York Presbyterian-Brooklyn Methodist Hospital, Brooklyn",New York Presbyterian-Brooklyn Methodist Hospital,"Jiwon Kim, MD",,,,0,New York,,
355,Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure,Completed,Has Results,Drug: IV Ganciclovir|Drug: Placebo,"Serum IL-6 Level|Number of Participants With CMV Reactivation at 28 Days in Plasma|BAL Levels of IL-6|Number of Participants With Organ System Failure at 14 Days|Number of Days Alive and Not in the ICU|CMV Disease|Grade 3 AEs or Higher|SF-36 Health Survey|Incidence of CMV Reactivation >1,000 IU Per mL at Day 28 in Plasma|Incidence of CMV Reactivation at Any Level at 28 Days in Throat|Incidence of CMV Reactivation >1,000 IU Per mL at 28 Days in Throat|CMV AUC in Blood|CMV AUC in Throat|CMV Peak Viral Load in Blood|BAL Levels of IL-8|BAL Levels of TNFa|Plasma Levels of IL-6|Plasma Levels of IL-8|Plasma Levels of TNF a|Plasma Levels of Soluble ICAM-1|Peak Plasma Levels of Soluble ICAM-1|Peak Plasma Levels of TNF-a|Peak Plasma Levels of IL-10|Peak Plasma Levels of IL-8|Peak Plasma Levels of IL-6|AUC Plasma Levels of IL-6|AUC Plasma Levels of IL-8|AUC Plasma Levels of IL-10|AUC Plasma Levels of TNF-a|AUC Plasma Levels of Soluble ICAM-1|Length of Stay|Organ System Failure at 28 Days|Duration of Mechanical Ventilation as Assessed by Ventilator Free Days|Duration of Mechanical Ventilation as Assessed by Ventilator Days|Bacteremia and/or Fungemia|Mortality|Mortality at 180 Days|SF-36 Functional Assessment Physical Component|SF-36 Functional Assessment Mental Component|SF-36 Functional Assessment Mental Component on Day 1|Patients With Serious Adverse Events|Time to Neutropenia|Use of Granulocyte-colony Stimulating Factor|Renal Insufficiency|Red Blood Cell Transfusions Required Per Patients|Platelet Transfusions|Clinical Outcomes|Bacteremia and Fungemia Outcomes|Bacteremia and Fungemia Outcomes in Mechanically Ventilated Subjets|Overall Mortality|Number of Mechanical Ventilated Days|Number of Ventilator-free Days|Number of Days in the ICU|Number of ICU-free Days|Number of Days in the Hospital|Number of Hospital-free Days|Mortality Among Subjects Mechanically Ventilated From Day 7 to 14|Number of Mechanically Ventilated Days Among Subjects by Day 28|Number of Ventilator-free Days Among Subjects by Day 28|Number of Days in ICU Amongst Subjects by Day 28|Number of ICU-free Days Amongst Subjects by Day 28|Number of Hospital-free Days Among Subjects by Day 28","18 Years and older   (Adult, Older Adult)",Phase 2,160,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",28-Oct-16,"University of Colorado / National Jewish Health / Swedish Medical Center, Denver, Colorado, United States",https://ClinicalTrials.gov/show/NCT01335932,,40.007581,-105.2659417,"University of Colorado / National Jewish Health / Swedish Medical Center, Denver",University of Colorado / National Jewish Health / Swedish Medical Center,"Michael Boeckh, MD",Boulder,72,0.215784064,1,Colorado,72,16.79229152
356,Losartan for Patients With COVID-19 Requiring Hospitalization,Completed,Has Results,Drug: Losartan|Other: Placebo,Difference in Estimated (PEEP Adjusted) P/F Ratio at 7 Days|Daily Hypotensive Episodes|Proportion of Participants Requiring Vasopressors for Hypotension|Proportion of Participants Experiencing Acute Kidney Injury|Oxygen Saturation / Fractional Inhaled Oxygen (S/F)|28-Day Mortality|90-Day Mortality|ICU Admission|Number of Ventilator-Free Days|Number of Therapeutic Oxygen-Free Days|Number of Vasopressor-Free Days|Length of Hospital Stay|Disease Severity Rating|Change in Viral Load by Nasopharyngeal Swab Day 15,"18 Years and older   (Adult, Older Adult)",Phase 2,205,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1-Feb-21,"University of Florida Health Gainesville, Gainesville, Florida, United States",https://ClinicalTrials.gov/show/NCT04312009,,29.6416645,-82.3453101,"University of Florida Health Gainesville, Gainesville",University of Florida Health Gainesville,"Christopher Tignanelli, MD",Alachua,210,0.228647823,1,Florida,210,20.76911447
357,Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19,Terminated,No Results Available,Drug: ZYESAMI™ (aviptadil acetate)|Drug: Placebo|Device: Nebulized administration of ZYESAMI™ or Placebo,Progression to Respiratory Failure|Blood oxygenation|RPD Dyspnea Scale|Distance walked in six minutes,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,144,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",31-Dec-21,"St. Jude Medical Center, Fullerton, California, United States",https://ClinicalTrials.gov/show/NCT04360096,,33.89466005,-117.9270646,"St. Jude Medical Center, Fullerton",St. Jude Medical Center,"Jonathan C Javitt, MD, MPH",Orange,0,0.178217076,1,California,651,5.178480972
358,Late Permissive Hypercapnia for Intubated and Ventilated Preterm Infants,Completed,No Results Available,Other: Higher permissive hypercapnia|Other: Lower Permissive Hypercapnia,"Alive Ventilator-free Days from Randomization to 28 Days after randomization|All Causes of Death|Incidence of bronchopulmonary dysplasia ""BPD""|Open label treatment with postnatal steroids for bronchopulmonary dysplasia|Number of days alive, Continuous Positive Airway Pressure (CPAP)-free|Number of days alive, supplemental oxygen free|Neurodevelopmental Impairment|Growth Indices-Weight|Growth Indices-Head Circumference|Pulmonary Hypertension|Intracranial Hemorrhage",7 Days to 14 Days   (Child),Not Applicable,130,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,21-Apr,"UAB, Birmingham, Alabama, United States",https://ClinicalTrials.gov/show/NCT02799875,,33.5016153,-86.80604756,"UAB, Birmingham",UAB,"Colm P Travers, MB BCh BAo",Jefferson,471,0.48493457,1,Alabama,471,100
359,Inhaled Prostaglandin E1 (IPGE1) for Hypoxemic Respiratory Failure (NHRF),Terminated,Has Results,Drug: Aerosolized Normal Saline|Drug: Inhaled PGE1,Feasibility Assessed as the Number of Participants Who Were Enrolled in the Study|Change in Partial Pressure of Oxygen in the Blood (PaO2)|Change in Oxygenation Index (OI)|Need for Inhaled Nitric Oxide (INO) 72 Hours After INO|Duration of iNO Therapy|Death|Need for Extracorporeal Membrane Oxygenation (ECMO)|Duration of Mechanical Ventilation|Number of Days of Supplemental Oxygen (O2) Used|Length of Hospital Stay,up to 7 Days   (Child),Phase 2,7,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",12-Jun,"University of Alabama at Birmingham, Birmingham, Alabama, United States",https://ClinicalTrials.gov/show/NCT01467076,,33.5016153,-86.80604756,"University of Alabama at Birmingham, Birmingham",University of Alabama at Birmingham,"Beena Sood, MD",Jefferson,471,0.48493457,6,Alabama,471,100
360,"Investigation of a New, Oral Growth Hormone Secretagogue, AEZS-130 as a Growth Hormone Stimulation Test.",Completed,Has Results,Drug: AEZS-130 (formerly ARD-07)|Drug: L-ARG+GHRH,Receiver Operating Characteristic (ROC) Analysis on Peak GH (Growth Hormon) Concentrations|Peak Insulin-Like Growth Factor (IGF)-1 Concentration Following Treatment|Classification and Regression Tree (CART) Analysis of Peak Growth Hormone (GH) Following Macimorelin Administration|Number of Participants With Drug Related Adverse Events (AEs),"18 Years and older   (Adult, Older Adult)",Phase 3,101,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,11-Jul,"Celerion, Tempe, Arizona, United States",https://ClinicalTrials.gov/show/NCT00448747,,33.3788949,-111.9745272,"Celerion, Tempe",Celerion,"Beverly MK Biller, MD",Maricopa,1004,0.188377743,1,Arizona,1004,8.31964474
361,Trial II of Lung Protection With Azithromycin in the Preterm Infant,Completed,Has Results,Drug: Azithromycin|Drug: Placebo,Incidence of Bronchopulmonary Dysplasia (BPD),up to 72 Hours   (Child),Phase 2,220,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",12-Jun,"University of Kentucky Medical Center, Lexington, Kentucky, United States",https://ClinicalTrials.gov/show/NCT00319956,,38.02975155,-84.5066808,"University of Kentucky Medical Center, Lexington",University of Kentucky Medical Center,"Hubert O Ballard, MD",Fayette,3,0.479679108,3,Kentucky,260,98.37527725
362,Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias,Recruiting,No Results Available,Biological: Allogeneic Mesenchymal Stromal Cells,Clinical deterioration|Serious Adverse Events|ICU transfer|Respiratory support|Hospital mortality and length of stay|Ventilator free days|28 day mortality,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,10,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,4-May-23,"Medical University of South Carolina, Charleston, South Carolina, United States",https://ClinicalTrials.gov/show/NCT05286255,,32.7842965,-79.94714194,"Medical University of South Carolina, Charleston",Medical University of South Carolina,"Charlie Strange, MD",Charleston,221,0.347680432,0,South Carolina,221,57.56797016
363,Regional Lung Inflammation and Expansion in Mechanically Ventilated Patients - a PET/CT Study,Unknown status,No Results Available,,Regional 18F-FDG activity,"18 Years and older   (Adult, Older Adult)",,10,Observational,Observational Model: Case-Only|Time Perspective: Prospective,19-Mar,"Massachusetts General Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT01806532,,42.36286045,-71.06875297,"Massachusetts General Hospital, Boston",Massachusetts General Hospital,,Suffolk,281,0.317766372,2,Massachusetts,447,48.32005745
365,Study of Therapeutic Exercise in Acute Respiratory Failure to Improve Neuromuscular Disability Trial,Completed,No Results Available,Behavioral: Early mobilization intervention,Peak hour patient activity level|ICU mortality|ICU length of stay|Hospital length of stay|Duration of mechanical ventilation|Duration of time spent in deep sedation|Neurological function|Richmond Agitation-Sedation Scale (RASS),"18 Years and older   (Adult, Older Adult)",Not Applicable,1917,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Health Services Research",30-Jul-20,"Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT03863470,,39.94994805,-75.19410142,"Hospital of the University of Pennsylvania, Philadelphia",Hospital of the University of Pennsylvania,"William Schweickert, MD",Philadelphia,528,0.359212402,1,Pennsylvania,528,61.13307138
366,Betamethasone Dosing Interval - 12 or 24 Hours?,Completed,No Results Available,Drug: dosing of Betamethasone,"The diagnosis of RDS is defined as: PaO2 < 50 mm Hg in room air, central cyanosis in room air, or a requirement for supplemental O2 to maintain PaO2 > 50 mm Hg, along with chest xray findings consistent with RDS (per the Vermont Oxford Network)|Incidence of INH, NEC, BPD, Blindness","16 Years to 45 Years   (Child, Adult)",Not Applicable,200,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,9-Oct,"Cooper University Hospital, Camden, New Jersey, United States",https://ClinicalTrials.gov/show/NCT00453141,,39.94111525,-75.11636296,"Cooper University Hospital, Camden",Cooper University Hospital,"Meena Khandelwal, MD",Camden,0,0.371088042,1,New Jersey,199,64.80441797
368,ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19,Completed,No Results Available,Biological: Remdesivir|Drug: Remdesivir Placebo|Biological: Aviptadil|Drug: Aviptadil Placebo|Drug: Corticosteroid,"Recovery, assessed at 90 days|All-cause mortality|Time to death|Composite of time to recovery, days at home off new supplemental oxygen and time to death|Composite of alive, at home and off new supplemental oxygen|Composite of recovered, alive and not recovered, and dead|Time from randomization to recovery|Days alive outside short-term acute care hospital|Incidence of clinical organ failure or serious infections|Composite of death, clinical organ failure or serious infections|Composite of cardiovascular events and thromboembolic events|Composite of grade 3 and 4 clinical adverse events, serious adverse events (SAEs) or death|Incidence of infusion reactions|Percentage of participants for whom infusion was interrupted or stopped prior to completion for any reason|Percentage of participants for whom infusion was interrupted or stopped prior to completion due to adverse event|Composite of hospital readmissions or death|Incidence of no home use of supplemental oxygen above pre-morbid oxygen use|Time to hospital discharge from initial hospitalization|Composite of death or serious clinical COVID-19 related events|Pulmonary ordinal outcome|Composite of SAEs or death|Incidence of home use of supplemental oxygen above pre-morbid oxygen use|In category 4, 5 or 6 at Day 90 vs. in categories 1-3 at Day 90|In category 5 or 6 at Day 90 vs. in categories 1-4 at Day 90","18 Years and older   (Adult, Older Adult)",Phase 3,473,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",20-Nov-22,"Banner University Medical Center Tucson (Site 206-004), 1625 N. Campbell Avenue, Tucson, Arizona, United States",https://ClinicalTrials.gov/show/NCT04843761,,32.2429301,-110.9462013,"Banner University Medical Center Tucson (Site 206-004), 1625 N. Campbell Avenue",Banner University Medical Center Tucson (Site 206-004),"Samuel Brown, MD",Pima,296,0.186115489,1,Arizona,296,7.620270349
369,Synchronized Intermittent Mechanical Ventilation Versus Open Lung Ventilation With Spontaneous Respiration,Terminated,No Results Available,,Reduction in ventilator days|Progression to acute lung injury/acute respiratory distress syndrome (ALI/ARDS),"18 Years and older   (Adult, Older Adult)",,5,Observational,Observational Model: Other|Time Perspective: Prospective,8-Jan,"University of New Mexico Hospital, Albuquerque, New Mexico, United States",https://ClinicalTrials.gov/show/NCT00891085,,35.0884989,-106.6179208,"University of New Mexico Hospital, Albuquerque",University of New Mexico Hospital,,Bernalillo,138,0.318170019,0,New Mexico,138,48.44484467
370,Hemodynamics and Extravascular Lung Water in Acute Lung Injury,Completed,Has Results,"Drug: Diuresis (furosemide) part I|Other: Fluid Bolus (crystalloid or albumin)|Drug: Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine)|Drug: Dobutamine|Other: Concentrate all drips and nutrition|Drug: Diuresis (furosemide) part II|Procedure: Dialysis",The Primary Efficacy Variable Will be the Total Reduction in Measured Lung Water,"18 Years and older   (Adult, Older Adult)",Phase 2,33,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,11-Jan,"Kaiser Permanente Sunnyside, Clackamas, Oregon, United States",https://ClinicalTrials.gov/show/NCT00624650,,45.43121555,-122.5604126,"Kaiser Permanente Sunnyside, Clackamas",Kaiser Permanente Sunnyside,"Charles Phillips, M.D.",Clackamas,54,0.163766972,1,Oregon,54,0.711240472
371,Closure of Patent Ductus Arteriosus With Indomethacin or Ibuprofen in Extreme Low Birth Weight Infants,Completed,No Results Available,Drug: Ibuprofen,Number of infants with ductus closure|Urine output,up to 6 Months   (Child),Not Applicable,110,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12-Feb,"John H. Stroger, Jr. Hospital of Cook County, Chicago, Illinois, United States",https://ClinicalTrials.gov/show/NCT01758913,,41.8729343,-87.67380049,"John H. Stroger, Jr. Hospital of Cook County",John H. Stroger,"Tsu-Fu Yeh, MD, PhD",Cook,0,0.319824519,1,Illinois,1606,48.9563323
372,Symphony IL-6 Study in Patients at Risk of Severe Sepsis,Recruiting,No Results Available,,Concentration of IL-6 in hospitalized patients with COVID-19 and/or Influenza who require invasive mechanical ventilation|Concentration of IL-6 in hospitalized patients with COVID-19 and/or Influenza who expire during hospital stay|Concentration of IL-6 in hospitalized patients with COVID-19 and/or Influenza who develop severe or critical illness,"22 Years and older   (Adult, Older Adult)",,200,Observational,Observational Model: Cohort|Time Perspective: Prospective,21-Nov-23,"University of Michigan Medical Center, Ann Arbor, Michigan, United States",https://ClinicalTrials.gov/show/NCT05665153,,42.2836501,-83.731193,"University of Michigan Medical Center, Ann Arbor",University of Michigan Medical Center,,Washtenaw,92,0.349973993,2,Michigan,92,58.27702309
373,Description of Fluid Balance in Patients With Acute Respiratory Failure,Unknown status,No Results Available,,Mortality|Ventilator-free days|ICU-free days|Dialysis use|Sequential Organ Failure Assessment (SOFA),"18 Years and older   (Adult, Older Adult)",,50,Observational,Observational Model: Cohort|Time Perspective: Prospective,15-Dec,"University of Maryland Medical Center, Baltimore, Maryland, United States",https://ClinicalTrials.gov/show/NCT02523872,,39.28827365,-76.62439437,"University of Maryland Medical Center, Baltimore",University of Maryland Medical Center,"Carl Shanholtz, MD",,,,2,Maryland,,
374,Treatment of Critical Illness Polyneuromyopathy,Completed,Has Results,Procedure: intensive physical therapy|Procedure: control group,The Primary Outcome Variable for This Study Will be the Short Form of the Continuous Scale Physical Functional Performance Test (CS-PFP) Called the PFP-10|ICU-free Days|ICU Length of Stay|Mechanical Ventilation Duration|Hospital Free Days|Hospital Length of Stay|Discharged to Home|Institution Free Days,"18 Years and older   (Adult, Older Adult)",Not Applicable,120,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,15-Oct,"Medical Center of Aurora, Aurora, Colorado, United States",https://ClinicalTrials.gov/show/NCT01058421,,39.6911893,-104.831952,"Medical Center of Aurora, Aurora",Medical Center of Aurora,"Marc Moss, M.D.",Arapahoe,127,0.217488409,1,Colorado,127,17.3191887
375,CLBS119 for Repair of COVID-19 Induced Pulmonary Damage,Withdrawn,No Results Available,Biological: CLBS119,Adverse events|Change in oxygen saturation,"18 Years and older   (Adult, Older Adult)",Phase 1,0,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,21-May,"NYU Langone Health, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04522817,,40.7434467,-73.9722189,"NYU Langone Health, New York",NYU Langone Health,"Douglas W Losordo, MD",New York,761,,0,New York,761,
376,Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure,Withdrawn,No Results Available,Drug: Inhaled Prostaglandin E1,The ability to recruit an adequate number of patients (n = 50) in a 6-9 month period without excessive (>20%) protocol violations.|Progression to an OI greater than 25|Improvement in partial pressure of oxygen (PaO2) in the blood gas|Change in OI|Death|Need for inhaled nitric oxide or ECMO|Length of hospitalization|Duration of mechanical ventilation|Number of days of oxygen used and need for supplemental oxygen at 28 days of life|Occurrence of grade III-IV intracranial hemorrhage and cystic leukomalacia,up to 7 Days   (Child),Phase 2,0,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",8-Sep,"University of Alabama at Birmingham, Birmingham, Alabama, United States",https://ClinicalTrials.gov/show/NCT00598429,,33.5016153,-86.80604756,"University of Alabama at Birmingham, Birmingham",University of Alabama at Birmingham,"Michele C. Walsh, MD MS",Jefferson,471,0.48493457,6,Alabama,471,100
377,Predicting Lung Injury From Transfusion in Patients With Liver Disease,Terminated,No Results Available,,TRALI (consensus definition- with exception of absence of other acute lung injury risk factors)|Change in ratio of partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2)|Bleeding complications,"18 Years to 85 Years   (Adult, Older Adult)",,16,Observational,Observational Model: Cohort|Time Perspective: Prospective,16-Dec,"University of Colorado Denver, Anshutz medical campus, Aurora, Colorado, United States",https://ClinicalTrials.gov/show/NCT01756690,,39.7428324,-105.0059152,"University of Colorado Denver, Anshutz medical campus",University of Colorado Denver,,,,,0,Colorado,,
378,High Flow Nasal Cannula Versus Bubble Nasal CPAP for the Treatment of Transient Tachypnea of the Newborn in Infants ≥ 35 Weeks Gestation,Terminated,Has Results,Other: High Flow Nasal Cannula|Other: Bubble Nasal CPAP,Duration of Respiratory Support,up to 24 Hours   (Child),Not Applicable,7,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12-Apr,"Mount Sinai School of Medicine, New York, New York, United States",https://ClinicalTrials.gov/show/NCT01270581,,40.789793,-73.95325356,"Mount Sinai School of Medicine, New York",Mount Sinai School of Medicine,"Andrea Weintraub, MD",New York,761,0.317766372,1,New York,761,48.32005745
379,Fluid Management in Transient Tachypnea of the Newborn,Completed,Has Results,Other: Amount of total fluids,Duration of Respiratory Support|Duration of ICU Admission|Time to First Enteral Feed,up to 24 Hours   (Child),Not Applicable,64,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,10-Sep,"Mount Sinai School of Medicine, New York, New York, United States",https://ClinicalTrials.gov/show/NCT01225029,,40.789793,-73.95325356,"Mount Sinai School of Medicine, New York",Mount Sinai School of Medicine,"Annemarie Stroustrup, MD, MPH",New York,761,0.317766372,1,New York,761,48.32005745
380,"Prophylactic Continuous Positive Airway Pressure (CPAP) in Delivery Room, in the Prevention of Transient Tachypnea of Newborn (TTN): A Randomized Controlled Trial",Completed,No Results Available,Other: Prophylactic CPAP Administration,Measure of incidence of TTN|Need for admissions to NICU secondary to TTN|levels of plasma brain natriuretic peptide compared,2 Minutes to 30 Minutes   (Child),Not Applicable,138,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Care Provider)|Primary Purpose: Prevention,13-Apr,"New York Hospital Queens, Flushing, New York, United States",https://ClinicalTrials.gov/show/NCT01082900,,40.74726345,-73.82519383,"New York Hospital Queens, Flushing",New York Hospital Queens,"Pinchi Srinivasan, MD",,,,1,New York,129,
381,Effect of Supine or Prone Position After Caesarean Birth,Completed,No Results Available,Procedure: prone positioning|Procedure: Supine,,"Child, Adult, Older Adult",Not Applicable,65,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,9-Feb,"Jack D. Weiler Hospital of the Albert Einstein College of Medicine, Bronx, New York, United States",https://ClinicalTrials.gov/show/NCT01310153,,40.8485983,-73.8461914,"Jack D. Weiler Hospital of the Albert Einstein College of Medicine, Bronx",Jack D. Weiler Hospital of the Albert Einstein College of Medicine,"Orna Rosen, MD",,,,1,New York,129,
382,Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients With Acute Respiratory Failure and Sepsis,Recruiting,No Results Available,Drug: IV Ganciclovir,"Respiratory-support-free days in immunocompetent patients with sepsis-associated acute respiratory failure|To evaluate whether administration of ganciclovir increases ventilator-free days in immunocompetent patients with sepsis-associated acute respiratory failure.|To evaluate whether administration of ganciclovir increases total respiratory-support-free days (all RSDS, instead of last-off approach) in immunocompetent patients with sepsis- associated acute respiratory failure|To evaluate whether mortality and time to death in the 28 and 180 days is different among ganciclovir recipients relative to placebo recipients, respectively.|To evaluate whether duration of mechanical ventilation among survivors in the first 28 days is different among ganciclovir recipients relative to placebo recipients.|To evaluate whether duration of respiratory support among survivors in the first 28 days is different among ganciclovir recipients relative to placebo recipients.|To evaluate whether oxygenation is different among ganciclovir recipients relative to placebo recipients.|To evaluate whether ICU-free days in the first 28 days are different among ganciclovir recipients relative to placebo recipients.|To evaluate whether CMV DNA detection in plasma and endotracheal aspirate (ETA) by day 28 is different among ganciclovir recipients relative to placebo recipients.|To assess the number and severity of adverse events and serious adverse events in the first 28 days in both groups.","18 Years to 85 Years   (Adult, Older Adult)",Phase 3,500,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",31-Aug-27,"University of Colorado Denver, Denver, Colorado, United States",https://ClinicalTrials.gov/show/NCT04706507,,39.7428324,-105.0059152,"University of Colorado Denver, Denver",University of Colorado Denver,"Michael Boeckh, MD",,,,0,Colorado,,
383,Early Inhaled Nitric Oxide for Respiratory Failure in Newborns,Terminated,No Results Available,Drug: Inhaled Nitric Oxide|Drug: Standard iNO therapy,Death or use of extracorporeal membrane oxygenation (ECMO)|Use of iNO therapy based on the standard recommended threshold|Progression to severe respiratory failure (OI>40)|Neurodevelopmental impairment,up to 14 Days   (Child),Phase 3,302,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3-Aug,"University of Alabama at Birmingham, Birmingham, Alabama, United States",https://ClinicalTrials.gov/show/NCT00005773,,33.5016153,-86.80604756,"University of Alabama at Birmingham, Birmingham",University of Alabama at Birmingham,"G. Ganesh Konduri, MD",Jefferson,471,0.48493457,6,Alabama,471,100
384,Inhaled Nitric Oxide Study for Respiratory Failure in Newborns,Terminated,No Results Available,Drug: Inhaled nitric oxide|Drug: Placebo,"Death or initiation of ECMO|PaO2 levels, oxygenation index, and alveolar-arterial oxygen gradient|Neurodevelopmental outcome|Duration of hospital stay|Duration of assisted ventilation, air leaks, or chronic lung disease|Transfers for ECMO|Meeting ECMO criteria",up to 14 Days   (Child),Phase 3,235,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",May-98,"Stanford University, Palo Alto, California, United States",https://ClinicalTrials.gov/show/NCT00005776,,37.4387861,-122.1569334,"Stanford University, Palo Alto",Stanford University,"Richard A. Ehrenkranz, MD",Santa Clara,313,0.173702036,3,California,313,3.782659215
385,"Selenium as a Potential Treatment for Moderately-ill, Severely-ill, and Critically-ill COVID-19 Patients.",Not yet recruiting,No Results Available,Drug: Selenium (as Selenious Acid)|Other: Placebo,Mean change in the ordinal scale|Rate of hospital discharges or deaths|Clinical status using ordinal scale|Time to an improvement of one category using an ordinal scale|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Incidence of new oxygen use|Duration of new oxygen use|Incidence of new non-invasive ventilation or high flow oxygen use|Duration of new non-invasive ventilation or high flow oxygen use|Incidence of new ventilator use|Duration of new ventilator use|Discontinuation or temporary suspension of investigational therapeutics|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine (Cr)|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change from baseline in interleukin-1 (IL-1)|Change from baseline in interleukin-6 (IL-6)|Change from baseline in tumor necrosis factor alpha (TNF-α),"18 Years and older   (Adult, Older Adult)",Phase 2,100,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",15-Dec-21,"CHRISTUS Good Shepherd Medical Center, Longview, Texas, United States",https://ClinicalTrials.gov/show/NCT04869579,,32.5015887,-94.73005564,"CHRISTUS Good Shepherd Medical Center, Longview",CHRISTUS Good Shepherd Medical Center,"Mohamed S Ghoweba, MD",Gregg,66,0.304426036,0,Texas,66,44.19590103
386,Vitamin A Supplementation for Extremely-Low-Birth-Weight Infants,Completed,No Results Available,Drug: Vitamin A|Other: Sham Procedure,Chronic lung disease or death|Sepsis,24 Hours to 96 Hours   (Child),Phase 1|Phase 2,807,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention",Jul-99,"Stanford University, Palo Alto, California, United States",https://ClinicalTrials.gov/show/NCT01203488,,37.4387861,-122.1569334,"Stanford University, Palo Alto",Stanford University,"Jon E. Tyson, MD MPH",Santa Clara,313,0.173702036,3,California,313,3.782659215
387,Minimal Breathing Support and Early Steroids to Prevent Chronic Lung Disease in Extremely Premature Infants (SAVE),Terminated,No Results Available,Procedure: Minimal mechanical ventilation management|Procedure: Routine mechanical ventilation management|Drug: Dexamethasone|Drug: Placebo,Death or moderate to severe bronchopulmonary dysplasia|Death|Mechanical ventilation|Pulmonary interstitial emphysema|Pneumothorax|Open-label steroids|Reintubation|Intracranial hemorrhage (IVH) III or IV|Periventricular leukomalacia|Necrotizing enterocolitis|Duration of oxygen supplementation|Duration of ventilation|Length of hospitalization|Death or neurodevelopmental impairment|Neurodevelopmental impairment|Cerebral palsy|Bilateral blindness|Deafness|Bayley Scales of Infant Development-Revised II Psychomotor Developmental Index (PDI)|Rehospitalizations,5 Minutes to 10 Days   (Child),Phase 3,220,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2-Sep,"University of Alabama at Birmingham, Birmingham, Alabama, United States",https://ClinicalTrials.gov/show/NCT00005777,,33.5016153,-86.80604756,"University of Alabama at Birmingham, Birmingham",University of Alabama at Birmingham,"Waldemar A. Carlo, MD",Jefferson,471,0.48493457,6,Alabama,471,100
388,Factor Xa Inhibitor Versus Standard of Care Heparin in Hospitalized Patients With COVID-19 (XACT),Completed,No Results Available,Drug: Enoxaparin|Drug: Rivaroxaban,"Death or 30-day all cause mortality|Mechanical ventilation, intubation|Transfer to an ICU setting|New requirement for hemodialysis (HD) or continuous renal replacement therapy (CRRT) or extracorporeal membrane oxygenation (ECMO)|New thrombotic events|Major bleeding event|Time to recovery (defined as no limitation or minor limitation in activity level or hospitalized but require no oxygen)","18 Years to 100 Years   (Adult, Older Adult)",Phase 2,150,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,28-Jun-21,"St. David's Medical Center, Austin, Texas, United States",https://ClinicalTrials.gov/show/NCT04640181,,30.2896987,-97.72568587,"St. David's Medical Center, Austin",St. David's Medical Center,"Edward Chafizadeh, MD",Travis,294,0.280669712,1,Texas,294,36.85164851
389,Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19,"Active, not recruiting",No Results Available,Biological: CYNK-001,Phase 1: Frequency and Severity of Adverse Events (AE)|Phase 1 Futility Check for go/no decision to move to Phase 2: Rate of clinical improvement|Phase 2: Time to Clinical Improvement by Ordinal Scale for Clinical Improvement (OSCI)|Rate of Clearance of SARS-CoV-2|Time to Clearance of SARS-CoV-2|Phase 2: Frequency and Severity of Adverse Events (AE)|Overall Clinical Benefit by time to medical discharge|Overall Clinical Benefit by hospital utilization|Overall Clinical Benefit by measuring mortality rate|Impact of CYNK-001 on sequential organ failure assessment (SOFA) score|Time to Pulmonary Clearance|Rate of Pulmonary Clearance|Supplemental oxygen-free days|Proportion of patients requiring ventilation|Duration of hospitalization|Radiologic Evaluation Score|All-cause mortality rate|Time to clinical improvement by NEWS2 Score|Rate of clinical improvement by NEWS2 Score,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,86,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30-Jun-22,"UC Irvine, Irvine, California, United States",https://ClinicalTrials.gov/show/NCT04365101,,33.7367604,-117.7176289,"UC Irvine, Irvine",UC Irvine,"Corey Casper, MD MPH",Orange,0,0.178217076,0,California,651,5.178480972
390,Inhaled Nitric Oxide for Preterm Infants With Severe Respiratory Failure,Terminated,No Results Available,Drug: Inhaled nitric oxide|Drug: Placebo,Death or Bronchopulmonary Dysplasia|Intraventricular Hemorrhage Grade III and IV|Days on assisted ventilation|Length of hospitalization|Retinopathy of prematurity|Air leaks|Days on oxygen|Supplemental oxygen|Neurodevelopmental outcome,up to 120 Hours   (Child),Phase 3,420,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",6-May,"University of Alabama at Birmingham, Birmingham, Alabama, United States",https://ClinicalTrials.gov/show/NCT00016523,,33.5016153,-86.80604756,"University of Alabama at Birmingham, Birmingham",University of Alabama at Birmingham,"Krisa P. Van Meurs, MD",Jefferson,471,0.48493457,6,Alabama,471,100
391,Local Assessment of Ventilatory Management During General Anesthesia for Surgery,Completed,No Results Available,,"Post-operative pulmonary complications, possibly related to ventilation strategy|Intra-operative complications related to the ventilation strategy|Mechanical ventilation-settings during general anesthesia for surgery","18 Years and older   (Adult, Older Adult)",,10690,Observational,Observational Model: Cohort|Time Perspective: Prospective,13-Nov,"University of Colorado School of Medicine/University of Colorado Hospital, Aurora, Colorado, United States",https://ClinicalTrials.gov/show/NCT01601223,,39.7449417,-104.8359909,"University of Colorado School of Medicine/University of Colorado Hospital, Aurora",University of Colorado School of Medicine/University of Colorado Hospital,"Schultz Marcus, MD",Adams,0,0.223048163,1,Colorado,168,19.03798313
392,Physiological Effects of Continuous Negative External Pressure for Acute Hypoxemic Respiratory Failure,Not yet recruiting,No Results Available,Device: HFNC only|Device: HFNC + CNEP10|Device: HFNC + CNEP20|Device: HFNC + CNEP30,Change from baseline in SpO2/FiO2|Change from baseline in Respiratory Rate|Change from baseline in ROX Index|Change from baseline in Transcutaneous Carbon Dioxide (CO2)|Change from baseline in Minute Ventilation|Change from baseline in Tidal Volume|Change from baseline in Anteroposterior Ventilation Ratio|Change from baseline in End-Expiratory Lung Volume|Change from baseline in Heart Rate|Change from baseline in Blood Pressure|Change from baseline in Breathing Discomfort|Change from baseline in Anxiety|Change from baseline in Lightheadedness|Change from baseline in Nausea|Change from baseline in Skin Discomfort|Change from baseline in Skin Erythema,"18 Years and older   (Adult, Older Adult)",Not Applicable,20,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1-Apr-25,"Columbia University Irving Medical Center, New York, New York, United States",https://ClinicalTrials.gov/show/NCT05675345,,40.8419836,-73.94368971,"Columbia University Irving Medical Center, New York",Columbia University Irving Medical Center,"Jeremy Beitler, MD, MPH",New York,761,,0,New York,761,
393,Clazakizumab vs. Placebo - COVID-19 Infection,Unknown status,No Results Available,Drug: Clazakizumab|Drug: Placebo,Primary Endpoint|Requirement for mechanical ventilation and/or extracorporeal membrane oxygenation (ECMO)|Infusion-related reactions during 24 hours from the time of infusion|Patient survival at 28 days|Patient survival at 60 days|Requirement for open-label clazakizumab|Time in the intensive care unit (ICU)|Time in the hospital|Time to mechanical ventilation|Clinical status improvement assessed by the World Health Organization (WHO) Clinical Progression Scale at day 14|Clinical status improvement assessed by World Health Organization (WHO) Clinical Progression Scale at day 28|Change in Radiologic Assessment of Lung Edema (RALE) at day 14|Change in Radiologic Assessment of Lung Edema (RALE) at day 28,"18 Years and older   (Adult, Older Adult)",Phase 2,60,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",31-Jul-21,"Houston Methodist Hospital, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04494724,,29.7108167,-95.39926398,"Houston Methodist Hospital, Houston",Houston Methodist Hospital,"Howard Huang, MD",Harris,918,0.290090595,1,Texas,918,39.76410852
394,Nasal Noninvasive NAVA in the Very Low Birth Weight Infant,Completed,Has Results,Device: Nasal NIV-NAVA,Change in Partial Pressure of Carbon Dioxide on Capillary Blood Gas|Change in Fraction of Inspired Oxygen,7 Days to 1 Year   (Child),Not Applicable,40,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,31-Dec-18,"Children's Hospital of Iowa NICU, Iowa City, Iowa, United States",https://ClinicalTrials.gov/show/NCT01785563,,41.6573635,-91.5496586,"Children's Hospital of Iowa NICU, Iowa City",Children's Hospital of Iowa NICU,"Tarah T Colaizy, M.D., MPH",Johnson,0,0.288428937,2,Iowa,95,39.250408
395,Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation,Completed,Has Results,Drug: L-ascorbic acid,Number of Participants With Adverse Events Related to High Dose Intravenous Vitamin C (HDIVC)|Number of Participants With Serious Adverse Reactions|Number of Participants With Adverse Reactions|Ventilator-free Days|Intensive Care Unit (ICU)-Free Days|Hospital-free Days|All-cause Mortality|Change in S/F Ratio During High Dose Intravenous Vitamin C (HDIVC)|C-reactive Protein (CRP)|Lactate Dehydrogenase (LDH)|D-dimer|Lymphocyte Count|Neutrophil to Lymphocyte Ratio (NLR)|Serum Ferritin,"18 Years to 99 Years   (Adult, Older Adult)",Phase 1|Phase 2,20,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,13-Oct-20,"Hunter Holmes Mcguire Veteran Affairs Medical Center, Richmond, Virginia, United States",https://ClinicalTrials.gov/show/NCT04357782,,37.496087,-77.4663682,"Hunter Holmes Mcguire Veteran Affairs Medical Center, Richmond",Hunter Holmes Mcguire Veteran Affairs Medical Center,"Brian C Davis, MD",,,,1,Virginia,,
396,Evaluation and Further Development of an Artificial Intelligence-based Algorithm for Clinical Decision Support,Recruiting,No Results Available,Other: Artificial Intelligence-based Decision support,Relative time of same device settings of the health care provider and the IntelliLung algorithm,"18 Years and older   (Adult, Older Adult)",,318542,Observational,Observational Model: Other|Time Perspective: Retrospective,28-Feb-25,"Cleveland Clinic Foundation, Cleveland, USA, Cleveland, Ohio, United States",https://ClinicalTrials.gov/show/NCT05668637,,41.5006165,-81.6224967,"Cleveland Clinic Foundation, Cleveland",Cleveland Clinic Foundation,"Jakob Wittenstein, MD",Cuyahoga,680,0.376333276,0,Ohio,680,66.42597874
397,Study of Varespladib in Patients Hospitalized With Severe COVID-19,Terminated,No Results Available,Drug: Varespladib|Drug: Placebo,"Proportion of participants alive and free of respiratory failure at Day 28|Proportion of subjects using HFNC within the first 28 days after randomization|Time to initiation of use of HFNC within the first 28 days after randomization|Duration of use of HFNC within the first 28 days after randomization|Proportion of subjects using noninvasive respiratory support within the first 28 days after randomization|Time to initiation of noninvasive respiratory support within the first 28 days after randomization|Duration of noninvasive respiratory support within the first 28 days after randomization|Proportion of subjects using mechanical ventilation within the first 28 days after randomization|Time to initiation of subjects using mechanical ventilation within the first 28 days after randomization|Duration of use by subjects of mechanical ventilation within the first 28 days after randomization|Number of days of oxygen support through Day 28 after randomization|SpO₂ through Day 28 after randomization|Proportion of participants remaining free of mechanical ventilation or ECMO throughout the 28 days after randomization|Number of ventilator-free days through Day 28 after randomization|Number of hospitalization days through Day 28 after randomization|Clinical status as measured by the World Health Organization (WHO) 9-point ordinal scale from baseline through Day 60|Number of vasopressor-free days through Day 28 after randomization|Number of days without renal stabilization and/or replacement through Day 28 after randomization|Number of days at elevated level of care (ICU) through Day 28 after randomization|Number of healthcare encounters through Day 28 after randomization|Proportion of subjects with all-cause mortality through Day 60|Time to all-cause mortality through Day 60|Number of organ failure-free days through Day 28 after randomization|Incidence and severity of AEs, SAEs, and AEs leading to discontinuation of IP|Changes in vital signs: SpO₂|Changes in vital signs: respiratory rate|Changes in vital signs: body temperature|Changes in vital signs: heart rate|Changes in vital signs: blood pressure|Changes in levels of biomarkers: cardiac troponin|Changes in levels of biomarkers: C-reactive protein (CRP)|Changes in levels of biomarkers: D-dimer|Changes in levels of biomarkers: ferritin|Changes in clinical laboratory evaluations: chemistry|Changes in clinical laboratory evaluations: coagulation|Changes in clinical laboratory evaluations: hematology|Changes in clinical laboratory evaluations: urinalysis|Changes in 12-lead ECGs","18 Years to 80 Years   (Adult, Older Adult)",Phase 2,18,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",22-Nov-22,"Ventura Clinical Trials, Ventura, California, United States",https://ClinicalTrials.gov/show/NCT04969991,,34.2570889,-119.2211061,"Ventura Clinical Trials, Ventura",Ventura Clinical Trials,,Ventura,139,0.181918233,0,California,139,6.322691315
398,I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients,Recruiting,No Results Available,Drug: Remdesivir|Drug: Imatinib Mesylate|Drug: Dexamethasone|Drug: Cenicriviroc|Drug: Icatibant|Drug: Apremilast|Biological: dornase alfa|Drug: Celecoxib|Drug: Famotidine|Biological: IC14|Drug: Aviptadil|Biological: narsoplimab|Drug: Cyproheptadine|Drug: Cyclosporine,Identify agents that will result in substantial improvements to the clinical condition of participants with severe COVID-19|Mortality|Improvement in disease severity|Health care utilization|Frequency of serious AEs,"18 Years and older   (Adult, Older Adult)",Phase 2,1500,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1-Nov-23,"University of Alabama at Birmingham, Birmingham, Alabama, United States",https://ClinicalTrials.gov/show/NCT04488081,,33.5016153,-86.80604756,"University of Alabama at Birmingham, Birmingham",University of Alabama at Birmingham,"Carolyn Carolyn, MD",Jefferson,471,0.48493457,6,Alabama,471,100
400,Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients,Recruiting,No Results Available,Drug: Niclosamide|Drug: Placebo,Safety and Tolerability of ANA001 as measured by the incidence of treatment emergent adverse events (TEAE's) (Part 1 and Part 2)|Efficacy as measured by median time to hospital discharge (Part 2)|Efficacy as measured by median time to hospital discharge (Part 1)|Pharmacokinetics (PK) of ANA001 as measured by plasma concentrations (Part 1)|Efficacy of ANA001 as measured by mean change from baseline in the National Early Warning Score (NEWS 2) (Part 2)|Efficacy of ANA001 as measured by mean number of days on rescue therapy (Part 2),"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,436,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",22-Dec,"Helen Keller Hospital, Sheffield, Alabama, United States",https://ClinicalTrials.gov/show/NCT04603924,,34.746119,-87.70076057,"Helen Keller Hospital, Sheffield",Helen Keller Hospital,"Doug Rank, MD",Colbert,22,0.460859438,1,Alabama,22,92.55718819
402,Study to Evaluate the Safety and Efficacy of ATYR1923 In Patients With Severe Pneumonia Related to COVID-19,Completed,No Results Available,Drug: ATYR1923 1 mg/kg|Drug: ATYR1923 3 mg/kg|Drug: Placebo,"Incidence of treatment-emergent adverse events (TEAEs)|Time to hospital discharge|Time to recovery (World Health Organization [WHO] Ordinal Scale score ≤3)|Proportion of patients achieving recovery by Day 14 and Day 28|Duration of supplemental oxygen (O2) requirement|Number of days with fever (temperature >100.4ºF [38.0ºC])|Change from baseline in World Health Organization (WHO) Ordinal Scale score on Days 5, 7, 14, 28, and 60|Time to improvement from inpatient hospital admission based on at least a 1 point reduction in WHO Ordinal Scale score|All-cause mortality at Days 14, 28, and 60","18 Years to 75 Years   (Adult, Older Adult)",Phase 2,32,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",21-Dec-20,"University of Alabama at Birmingham, Birmingham, Alabama, United States",https://ClinicalTrials.gov/show/NCT04412668,,33.5016153,-86.80604756,"University of Alabama at Birmingham, Birmingham",University of Alabama at Birmingham,Gennyne Walker,Jefferson,471,0.48493457,6,Alabama,471,100
404,"A Open Label, Post Marketing Surveillance Study Following Transfusion of INTERCEPT Platelet Components",Completed,No Results Available,Other: Standard of Care,"Proportion of patients requiring treatment-emergent assisted mechanical ventilation during the study observation period.|Time from first study PC transfusion to onset of treatment-emergent assisted mechanical ventilation.|AEs occurring within 24 hours after the initiation of a study PC transfusion|TR occurring within 24 hours after the initiation of a study PC transfusion.|SAEs occurring within 7 days after each study PC transfusion|ARDS occurring within 7 days after each study PC transfusion|CSPAEs occurring within 7 days after each study PC transfusion|Mortality within 7 days after the last study PC transfusion, or until hospital discharge/discontinuation of outpatient platelet transfusion support, whichever is sooner (all deaths and deaths due to ARDS).","Child, Adult, Older Adult",,2291,Observational,Observational Model: Other|Time Perspective: Prospective,21-May,"UCLA Medical Center, Los Angeles, California, United States",https://ClinicalTrials.gov/show/NCT02549222,,34.0655633,-118.445498,"UCLA Medical Center, Los Angeles",UCLA Medical Center,"Edward L Snyder, MD",Los Angeles,2126,0.184174979,1,California,2126,7.020362911
405,Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen,Recruiting,No Results Available,Drug: Tozorakimab|Drug: Placebo,Proportion of participants who die or progress to Invasive Mechanical Ventilation (IMV) / Extracorporeal Membrane Oxygen (ECMO)|Proportion of participants who die|Number of days alive and outside of Intensive Care Unit (ICU)|Number of days alive and free of supplemental oxygen|Time to death or progression to IMV/ECMO|Time to death (all cause)|Number of days alive and free of Invasive Mechanical Ventilation (IMV) / Extracorporeal Membrane Oxygen (ECMO)|Number of days alive and ventilator free|Proportion of participants with Intensive Care Unit (ICU) admission or death|Proportion of participants alive and discharged|Time to discharge|Time to being off supplemental oxygen|World Health Organization (WHO) 10-category ordinal Clinical Progression Scale|Incidence of anti-drug antibodies|Baseline serum interleukin-33/soluble Suppression of Tumorgenicity 2 (IL-33/sST2) complex levels relative to primary endpoint,"up to 18 Years   (Child, Adult)",Phase 3,2352,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",9-May-24,"Research Site, Mobile, Alabama, United States",https://ClinicalTrials.gov/show/NCT05624450,,35.47348415,-97.50447766,"Research Site, Mobile",Research Site,,Oklahoma,300,0.302954793,0,Oklahoma,300,43.74106719
406,A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients,Terminated,No Results Available,Drug: OP-101|Drug: Placebo,"Stage I: Number of Participants with Treatment Emergent Adverse Events Graded as Assessed by CTCAE Version 4.0|Stage II: Percentage of Participants Who Were Alive (i.e., not died due to any reason) at Day 29|Stage I: Time to Improvement (2 points) in Clinical Status Assessment Using the World Health Organization 7-Point Ordinal Scale (WHO 7OS)|Stage I: Time to Resolution of Fever for at least 48 hours Without Antipyretics for Patients with Documented Fever (>=37.2 degree celsius [oral], or >=37.8 degree celsius [rectal], or >=38.0 degree celsius [tympanic])|Stage I: Time to Improvement in Oxygenation for at least 48 hours|Stage I: Change from Baseline in the World Health Organization (WHO)-7 Point Ordinal Scale|Stage I: Time to Discharge from Clinic or Hospital or to National Early Warning Score 2 (NEWS2) of <=2 and maintained for 24 hours|Stage I: Percentage of Patients Alive and not Using Supplemental Oxygen at Time of Discharge from Hospital/Clinic or Day 30|Stage I: Number of Days of Resting Respiratory Rate of more than 24 breath/min|Stage I: Number of Days with Hypoxemia|Stage I: Number of Days of Supplemental Oxygen use|Stage I: Number of Ventilator-free Days|Stage I: Number of Days in Intensive Care Unit (ICU)|Stage I: Number of Days of Hospitalization for Survivors|Stage I: Number of Participants with all cause Deaths|Stage I: Percent Change from Baseline in Proinflammatory Cytokines|Stage I: Incidence of Drug-related Serious Adverse Events (SAEs)|Stage II: Percentage of Participants Who Were Alive and free of Respiratory Failure|Stage II: Percentage of Participants Alive and Free of Invasive Mechanical Ventilation|Stage II: Percentage of Participants Alive and Discharged From the Hospital|Stage II: Percentage of Participants Alive and not Using Supplemental Oxygen at Time of Discharge from Hospital/Clinic or Day 29|Stage II: Percent Change from Baseline in Proinflammatory Biomarkers|Stage II: Number of Days in Intensive Care Unit (ICU)","18 Years and older   (Adult, Older Adult)",Phase 2,28,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",12-Aug-22,"Research Site, Loma Linda, California, United States",https://ClinicalTrials.gov/show/NCT04458298,,35.47348415,-97.50447766,"Research Site, Loma Linda",Research Site,,Oklahoma,300,0.302954793,0,Oklahoma,300,43.74106719
408,Dexamethasone Therapy in VLBW Infants at Risk of CLD,Completed,No Results Available,Drug: Dexamethasone Early|Drug: Dexamethasone Late,"Number of days from randomization to ventilator independence, defined as extubation not requiring reintubation, or extubation followed by elective reintubation for seven days or less so that the infant could undergo a surgical procedure|Death before discharge from the hospital|Duration of assisted ventilation|Duration of supplemental oxygen therapy|Duration of hospital stay|Incidence of chronic lung disease|Morbidity and mortality from respiratory causes during the first year",13 Days to 15 Days   (Child),Phase 3,371,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",Apr-94,"Stanford University, Palo Alto, California, United States",https://ClinicalTrials.gov/show/NCT00011362,,37.4387861,-122.1569334,"Stanford University, Palo Alto",Stanford University,"Lu-Ann Papile, MD",Santa Clara,313,0.173702036,3,California,313,3.782659215
409,Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine,Completed,Has Results,Drug: Hydroxychloroquine|Drug: Placebo oral tablet,Number of Participants With Clinical Infection With COVID-19 Infection|Number of Participants With COVID-19 Viral Shedding|Number of Participants With Serious Adverse Events (SAEs) or Hydroxychloroquine-Associated Events of Special Interest (EOSIs),"18 Years and older   (Adult, Older Adult)",Phase 3,1360,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",9-Jan-21,"Children's Hospital Colorado/University of Colorado Denver, Aurora, Colorado, United States",https://ClinicalTrials.gov/show/NCT04334148,,39.7417871,-104.8345896,"Children's Hospital Colorado/University of Colorado Denver, Aurora",Children's Hospital Colorado/University of Colorado Denver,"Adrian Hernandez, MD",Adams,0,0.223048163,1,Colorado,168,19.03798313